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The Role of Tumor Suppressors, SHIP and Rb, in Immune Suppressive Cells 
Michelle M. Collazo Ruiz 
ABSTRACT  
 
Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC) have 
been extensively studied in the past 30-40 years.  Their potent suppressive capacity 
shown in several pathological and clinical settings, such as cancer and transplantation, 
has made it evident that better understanding their development and function is critical.   
Specifically, Tregs play a pivotal role in preventing autoimmunity, graft-versus-
host disease (GvHD), and organ graft rejection.  We previously demonstrated that 
germline or induced SH2 domain–containing inositol 5-phosphatase (SHIP) deficiency in 
the host abrogates GvHD.  Here we show that SHIP-deficiency promotes an increase of 
FoxP3+ cells in both the CD4+CD25+ and the CD4+CD25− T cell compartments with 
increased expression of Treg-associated markers.  Importantly, SHIP-deficiency does 
not compromise Treg function.  Interestingly, like conventional Tregs, SHIP−/− 
CD4+CD25− T cells are unresponsive to allogeneic stimulators and suppress allogeneic 
responses by T cells in vitro, and can mediate reduced lethal GvHD in vivo.  Thus, SHIP 
limits the immunoregulatory capacity of CD4+ T cell, particularly in allogeneic settings.   
SHIP-deficiency expands the number of immunoregulatory cells in both the T 
lymphoid and myeloid lineages.  Here, we examined if these increases are interrelated.  
Specifically, we found that myeloid specific SHIP-deficiency leads to expansion of both 
MDSC and Treg numbers.  Conversely, T lineage specific ablation of SHIP leads to 
vii 
 
expansion of Treg numbers, but not expansion of MDSC, indicating an intrinsic role for 
SHIP in limiting Treg numbers.  Interestingly, MDSC lack SHIP expression suggesting 
that another SHIP-deficient myeloid cell promotes MDSC and Treg expansion.  Also, 
increased levels of G-CSF, a myelopoietic growth factor, in SHIP-/- mice may extrinsically 
promote MDSC expansion since we found that G-CSF is required for the expansion of 
splenic MDSC in mice with induced SHIP-deficiency.   
MDSC consist of two distinct subsets, granulocytic-MDSC (G-MDSC), and 
monocytic-MDSC (M-MDSC) that differ in morphology, phenotype, suppressive capacity 
and differentiation potential.  Importantly, M-MDSC can further differentiate into dendritic 
cells, macrophages and preferentially into G-MDSC, in the presence of tumor-derived 
factors (TDF).  The retinoblastoma gene (Rb1), a tumor suppressor gene and central 
regulator of the cell cycle and differentiation, has been shown to influence monocytic and 
neutrophilic lineage commitment and to limit myeloproliferative disease.  Here, we 
examined the role of Rb1 in the biology of MDSC subsets in tumor-bearing mice.  Firstly, 
M-MDSC expressed high levels of Rb1 which remained relatively stable in culture with 
GM-CSF.  Conversely, freshly isolated G-MDSC initially expressed undetectable levels 
of Rb1 that increased over time in culture, which correlated with increased histone 
acetylation at the Rb1 promoter.  This increased Rb1 expression and histone acetylation 
was accelerated by histone deacetylase inhibitors (HDACi) treatment, suggesting Rb1 
expression may be controlled by histone modification.  Furthermore, when treated with 
HDACi, M-MDSC did not differentiate into G-MDSC in culture, even with TDF present.  
Finally, induced Rb1 deficiency in vivo promoted an expansion of splenic 
CD11b+Ly6G+Ly6Clo cells, similar to G-MDSC in tumor-bearing mice.  Although further 
studies are required, these results strongly suggest that Rb1, like SHIP, plays a role in 
MDSC accumulation, particularly G-MDSC in cancer. 
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Chapter 1.  Background 
 
Regulation of Immune Responses  
The immune system, consisting of two arms, the adaptive and the innate; is a 
complex system of biological structures and processes that protects an organism against 
disease. Although it is seemly “dormant” while healthy and “wakes up” only during 
sickness, the immune system actually works constantly to maintain our health.  Disease 
occurs when the immune system is challenged in such a way that its steady state activity 
is compromised or it is no longer sufficient to overcome the challenge, be it a bacterial or 
viral infection, cancer or overwhelming stress.  When functioning properly, the immune 
system elicits an effective immune response strong enough to eliminate the challenge 
while not being deleterious to the host.  Then the immune system “turns off” or 
suppresses the mounted response and returns to its steady state of maintenance and 
surveillance.  Equally critical, cells of a healthy immune system can distinguish between 
foreign or altered self from self, dangerous from innocuous; and can appropriately 
dispose of the foreign, altered-self and dangerous1.   
Clinically, understanding this intricate balance attained and maintained by the 
immune system is very important, particularly when this balance is disrupted.  For 
example, when the distinction between foreign and self is not made, the immune system 
can turn itself against for example, normal self-constituents in autoimmune disease, 
harmless environmental substances in allergy2, an allogeneic fetus in pregnancy3, or 
commensal bacteria in certain inflammatory bowel diseases4.  In transplantation 
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procedures, establishing stable immunological tolerance to a solid organ or bone marrow 
(BM) transplant (BMT) is essential for successful engraftment5.  Conversely, in cancer, 
reversing immune unresponsiveness to autologous tumor cells is the main goal in 
immunotherapy6.   
Several concepts have been established to elucidate how the immune system 
acts in physiological and pathological settings.  The concept of Immunological Tolerance 
explains how the immune system protects from autoimmunity.  Furthermore, it provides 
great insight into how the immune system can be manipulated to tolerate allergens, to 
accept an allogeneic graft and to effectively eradicate cancer7-9.  Immune Surveillance 
and Immunoediting are concepts that further describe the role of the immune system in 
tumor progression10 and thus form the foundation, along with Immunological Tolerance, 
from which different cancer immmunotherapies are developed.   
  
Immunological Tolerance.  Immunological tolerance is said to occur when the 
immune system recognizes an antigen but does not attack.  Specifically, ‘self tolerance’ 
or ‘natural tolerance’ occurs when the immune system avoids mounting a response to 
self-antigens.  'Induced tolerance' occurs when the immune system attains tolerance to 
external antigens.  There are three types of immunological tolerance: central tolerance, 
peripheral tolerance and acquired tolerance7. 
Central tolerance begins with the development of T and B lymphocytes in primary 
lymphoid tissues, the thymus and BM, respectively.  Here, specialized antigen 
presenting cells (APCs) present maturing lymphocytes with a variety of self-antigens in 
complex with major histocompatibility complex (MHC) molecules.  Simply, those that 
recognize these self-antigens are deleted or eliminated, preventing them from being 
released into the periphery and developing into fully immune competent self-reactive 
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cells11.  This selection process occurs primarily during fetal life, but persists throughout 
life as immature lymphocytes are produced12, 13.   
More specifically, in the thymus, T cells go through a selection process that 
includes both positive and negative selection, based on the affinity of their receptor 
(TCR) to the presented self-antigen.  TCRs must have sufficient affinity for self-MHC 
molecules in order for the T cell to be positively selected and thus allowed to mature and 
released into the periphery.  T cells with insufficient affinity are forced to undergo 
apoptosis, or cell death.  T cells whose TCR has very high affinity to self-MHC molecules 
are negatively selected, also undergoing apoptosis.  Throughout this process, some T 
cells are instead recruited to further differentiate into Tregs14.  B cell tolerance occurs in 
the BM where B cells either undergo several rounds of receptor editing or clonal 
deletion, which only occurs when receptor editing has been unsuccessful.  Similar to T 
cell tolerance, self-reactive B cells are eliminated according to their ability to recognize 
autoantigens15.   
Once released into the periphery, the mature T and B cells then undergo 
peripheral tolerance.  For instance, self-reactive T cells that were not eliminated during 
selection in the thymus are suppressed by Tregs in the periphery16.  Additionally, without 
appropriate co-stimulatory signals or with co-inhibitory signals, lymphocytes that 
encounter antigen presented by peripheral APCs become hyporesponsive or anergic17.  
When an antigen is at a concentration that is too low to activate the encountering T cell, 
the insufficient stimulation instead leads to cell death.  In immune privileged sites, such 
as the testes, potentially self-reactive lymphocytes are not activated.  Finally, anatomical 
barriers, like the blood-brain barrier, can separate self-reactive lymphocytes from the 
antigen18, 19.   
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The immune system can also adapt and become non-responsive to external 
antigens that would otherwise induce a cell-mediated or humoral immune response, a 
process called acquired or induced tolerance.  A natural example of this is during 
pregnancy, where the maternal immune system must acquire tolerance to the fetus and 
the placenta20.  Acquired or induced tolerance can also be readily achieved by 
administering intravenously, sublingually or orally; very large doses of antigen, or doses 
less than that required for effective immune stimulation21, 22.  Promoting immune 
suppression, by using immunosuppressive drugs or by the preferential expansion of 
immunosuppressive cells, for example, can also facilitate tolerance induction.  This is of 
clinical importance, for example in organ or BMT, where the allogeneic organ or BM 
must be accepted by the host.  If the host is not induced properly to acquire graft 
tolerance, the graft will be rejected23, 24.  In addition, inflammatory bowel diseases, such 
as Crohn's disease, ulcerative colitis and irritable bowel syndrome, are partly, if not 
primarily, due to the failure of orally induced tolerance25.   
In change, acquired tolerance, which also occurs in cancer, is a significant barrier 
in the effectiveness of cancer immunotherapy. Specifically, tolerance induced against 
tumor antigens has been clearly shown to thwart effective anti-tumor immune 
responses26. Furthermore, this tumor-specific T cell anergy is induced early in the course 
of tumor progression27. Interestingly, in vivo activation of APCs using antibodies against 
CD40 preserved the responsiveness of tumor-specific T cells in tumor-bearing host and 
promoted the regression of established tumors in mice17. 
 
Immune Surveillance and Immunoediting.  To prevent cancer, the immune 
system employs three main functions.  First, it clears or suppresses viral infections and 
in so doing, protects against virus-induced tumors.  The immune system also removes 
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pathogens and resolves inflammation promptly thereby preventing a tumor-promoting 
inflammatory environment from being established.  Lastly, it can eliminate tumor cells in 
various tissues to prevent them from establishing malignancy28.  This process, referred 
to as cancer immune surveillance, is primarily driven by tumor-specific antigens (TSAs) 
expressed on tumor cells that are recognized by immune effector cells, which in turn 
mediate the destruction of these tumor cells10.  Despite this, cancer can still develop, 
thus evading immune surveillance.  Several studies have provided evidence and insight 
into why cancer develops in spite of an intact functioning immune system that is 
constantly employing immune surveillance.  In summary, what these studies have shown 
is that while the immune system eliminates transformed cells, it is also applying a 
selective pressure where tumor cell variants with less immunogenicity, enabled by their 
genetic instability, can prevail29.  This notion forms the basis behind the concept cancer 
immunoediting, a mechanism that justifies how the immune system can both prevent 
and promote tumor formation and progression.   
 Cancer immunoediting is a dynamic process that occurs in three sequential 
phases: elimination, equilibrium and escape; the flow of which can be influenced by 
several external factors such as environmental stress, aging and immunotherapeutic 
intervention.  Elimination is essentially a modernized version of cancer immune 
surveillance.  As explained above, during this phase, the innate and adaptive immune 
systems work together to detect and destroy transformed cells that have overridden 
intrinsic tumor suppressor mechanisms, before they can form a clinically apparent 
tumor28.  Although the precise interplay and sequence have not been clearly defined, 
studies have clearly shown that immune molecules such as perforin, interferon-α/β (IFN-
α/β), IFN-γ, TRAIL, NKG2D30, and interleukin-12 (IL-12); and immune cells such as 
natural killer (NK) cells, T cells, macrophages (MΦ) and dendritic cells (DCs), among 
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others, participate in this phase.  If successful, the process may end with the elimination 
phase, leaving the host cancer free28.   
Due to the genetic instability of transformed cells, a variant with less 
immunogenicity may emerge and remain untouched, denoting the beginning of the 
equilibrium phase.  During this phase, the tumor remains functionally “dormant”, its 
outgrowth kept in check by mechanisms employed specifically by the adaptive immune 
system, known to require such components as T cells31, 32, IL-12, and IFN-γ33.  Although 
“dormant”, during this stage the transformed cells are undergoing an immune selective 
process mediated by the constantly interacting immune system that “edits” the tumor’s 
immunogenicity, hence the term immunoediting.  The immunoediting process may end 
here with the outgrowth of clinically detectable cancers restrained for a lifetime34.   
The constant immunoediting of genetically unstable tumor cells may eventually 
allow for the selection of tumor cell variants that are capable of entering the escape 
phase.  In order to do so, the tumor cell variant may acquire one or more of the following 
qualities: (1) become undetectable by adaptive immunity by losing expression of TSAs 
or by developing defective antigen-processing or presentation machinery; (2) acquire 
resistance to cytotoxicity induced by immune effector functions mediated, for example, 
by inducing anti-apoptotic mechanisms and hyper-activation of pro-oncogenic 
transcription factors35; (3) induce an immunosuppressive microenvironment within the 
tumor by producing immunosuppressive cytokines, such as vascular endothelial growth 
factor (VEGF), transforming growth factor β (TGFβ) and indoleamine 2,3-dioxygenase 
(IDO), among others, and by recruiting regulatory immune cells, such as Tregs and 
myeloid-derived suppressor cells (MDSC) that in turn also mediate immune 
suppression36.  Although there are several other immune cells capable of suppressing 
immune responses, this dissertation will focus on Tregs and MDSC. 
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Immune Cells that Suppress Immune Responses 
 
Regulatory T cells (Tregs).  With their initial discovery in the 1970’s, Tregs have 
been extensively studied in several immune contexts prevailing as critically important in 
active immune regulation.  The discovery of Tregs, their development, mechanisms of 
suppressive function, their involvement in pathological conditions and clinical 
implications are discussed below.   
 
Discovery of Tregs.  Gershon and Kondo, in 1970, observed that T cells can 
both enhance and dampen an immune response, and that this dampening was mediated 
by a T cell population distinct from helper T cells37, coined the name suppressor T cells.  
Several studies that followed described various types of suppressor T cells according to 
antigen specificity, secretion of suppressive factors, phenotype and suppressive 
mechanism38.  Though, by the late 1980’s, several factors came together causing 
researcher to avoid describing “suppressor T cells” in the context of immunological 
suppression or inhibition.  These factors were, but not limited to, the scrutiny of the 
mouse MHC gene complex39, failure in finding markers that reliably distinguished 
suppressor T cells from other T cells, ambiguity in the molecular basis of suppression, 
difficulty of preparing antigen-specific suppressor T cell clones to perform more detailed 
studies, and lack of clinical evidence for suppressor T cells as the primary cause of any 
immunological disease40.  Most of these studies were focused on analyzing tolerance or 
suppression experimentally induced towards a particular exogenous antigen.  Though 
not successful in clearly defining the suppressor T cell population whose sole purpose 
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was to down-regulate immune responses, these experiments did lead to the discovery 
and characterization of various immunosuppressive cytokines, such as IL-1041 and 
TGFβ 42.  Immune suppression mediated by T cells was then being attributed to T cells 
that could be induced to secrete these immunosuppressive cytokines.  This gave rise to 
the accepted existence of Tr1 cells that secrete IL1043, and Th3 cells that secrete TGF-
β44, both of which were cells propagated via antigenic stimulation of naïve T cells.  
These cells are now known as induced Tregs (iTregs)45.   
In 1969, Nishizuka and Sakakura took a different approach to investigating T cell 
suppression and instead examined how autoimmune diseases can occur and be 
inhibited.  This route clearly elucidated that the immune system did indeed harbor a 
specialized thymocyte population capable of suppressing autoimmunity46.  They found 
that neonatal thymectomy of normal mice performed between the second and fourth day 
after birth resulted in manifestations of autoimmunity, specifically destruction of the 
ovaries and inflammatory tissue damage in other organs47.  Similar studies performed on 
adult rats produced comparable results, including autoimmune thyroiditis48 and type1 
diabetes49.  Furthermore, the autoimmune disease could be transferred by adoptively 
transferring CD4+ T cells from a mouse suffering of an autoimmune disease to a T cell 
deficient mouse.  The transferred CD4+ T cells functioned as helper T cells and effector 
T cells that mediate immune destruction50.  Importantly, transfer of syngeneic CD4+ T 
cells and CD4+CD8- mature thymocytes to mice than underwent a thymectomy 
prevented the onset of autoimmune diseases51.  These and other experiments clearly 
showed that the normal thymus continuously produces a CD4+ T cell population, now 
known as natural Tregs (nTregs) that protects the host from autoimmunity.  In addition, it 
was clear that in the periphery of normal mice, there co-exist two types of CD4+ T cells, 
one that can mediate autoimmunity and the other that can dominantly suppress them52.   
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The studies that followed were in search of reliably distinguishing between these 
two cell populations and clearly identifying the CD4+ T cell population responsible for 
preventing autoimmunity, particularly by the expression of surface markers.  Initially, it 
was shown that this population existed within the CD5high, CD45RBlow CD4+ T cell 
population52, 53.  In 1995, Sakaguchi et al further discerned that cells expressing the 
CD25 molecule (high-affinity IL-2 receptor a-chain) within the CD5high, CD45RBlow CD4+ 
T cell population more specifically represented the subset of T cells with suppressive 
capacity, which comprise about 5-10% of peripheral CD4+ T cells54.  These cells are now 
well-known as Tregs.  CD25 signaling is in fact required for Treg function.  IL-2, CD25 
and CD122 (the IL-2R β-chain) -deficient mice spontaneously developed severe 
autoimmunity and have considerably reduced Treg numbers55.   
Finally, several years later, FoxP3, an X-linked transcription factor belonging to 
the fork-head family, was identified as the gene responsible for causing severe 
autoimmune and inflammatory disease in Scurfy mice56 and in IPEX patients57, 58.  
Researchers then turned to examining FoxP3 and its possible relationship to Tregs, 
which was confirmed in 2003 when FoxP3 was described as a major regulator of Treg 
development and function59.  In fact, retroviral transduction of FoxP3 confers normal 
CD25-CD4+ T cells with Treg-like phenotype and function, such as suppressive capacity 
and hypoproliferation, reduced IL-2 production and increased expression of CD25 and 
other Treg associated molecules, such as glucocorticoid-induced tumor necrosis factor 
receptor–related protein (GITR) and cytotoxic lymphocyte antigen 4 (CTLA-4)59, 60.  It 
was now obvious that Tregs are vital regulators of immune responses and self-tolerance.   
  
Development of Tregs.  There are two types of CD4+ Tregs, “natural” Tregs 
(nTregs) and induced Tregs (iTregs), which differ primarily in where they develop.  
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nTregs develop in the thymus and undergo positive and negative selection, while iTregs 
develop in the periphery from conventional CD4+ T cells that have been stimulated with 
antigen under various conditions.  Together, they must achieve a fine balance between 
maintaining peripheral tolerance by suppressing autoimmunity, while controlling 
responses against foreign pathogens45.   
 nTregs arise from progenitor cells in the BM and undergo their lineage 
commitment and maturation in the thymus, from which they migrate from into the 
periphery as early as after 3 days of life61.  Like other T cells, Tregs are selected by 
peptides presented by thymic APCs, such as DCs, medullary thymic epithelial cells 
(TEC) or cortical TEC in the thymus14.  Although not fully understood, it is known that 
their development is influenced by affinity between TCR and antigen, the location and 
context within the thymus were antigen is encountered, and cytokines and co-stimulatory 
molecules45.   
 The signal strength received from the APCs that present self peptides is given by 
the degree of affinity or avidity between the TCR and MHC:peptide complexes, which in 
turn dictates the T cell selection process, as mentioned earlier14.  nTregs seem to differ 
in the TCR affinity/signal strength required for positive selection in the thymus compared 
to conventional T cells62.  Additionally, Tregs may require a specific composition of self 
peptide and amount of signal to promote their development since they do not develop in 
mice expressing a single TCR63.  Recently, the TCR of hundreds of conventional T cells 
and nTregs were sequenced.  This data suggests that nTregs actually express a 
polyclonal TCR repertoire comparable to conventional T cells, in contrast to what was 
alleged before, that nTregs preferably recognize self-antigen64, 65.  This allows for an 
alternative theory.  nTregs may have a lower activation threshold that conventional T 
cells.  In other words, Tregs may have a differential ability to propagate a signal that 
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mediates a functional outcome versus conventional T cells45.  Accordingly, human Tregs 
have been shown to be responsive to TCR stimulation at 10- to 100- fold lower antigen 
concentrations than that required to activate conventional T cells66.  Furthermore, it has 
been proposed that T cells are committed to the Treg lineage before they encounter self 
peptide67 and that even a weak TCR:self peptide-MHC interaction is sufficient to 
promote survival during thymic selection68, 69.   
 Where the antigen is encountered, the niche within the thymus seems to also 
influence the thymocyte selection process.  When quantitatively changing the level of 
thymic expression of a specific T cell epitope, there was increasing deletion of 
conventional T cells with increasing expression of the thymic epitope while no change in 
the absolute number of nTregs69.  Control of peptide repertoire expressed in the thymus, 
which is controlled primarily by the autoimmune regulator gene (Aire) also affects T cell 
development70, 71.  Some studies have suggested that Aire-expressing stromal cells may 
enhance FoxP3 expression in CD4+ thymocytes and thus may play a role in nTreg 
thymic development72.  Though, other studies show that in the absence of Aire, nTreg 
frequency and function stay the same with a slight alteration in TCR specificity73.  Thus, 
the critical importance of Aire in Treg development and function is controversial and 
remains to be resolved.   
Signals mediated by co-stimulatory molecules and cytokines are not only 
important for nTreg thymic development but also for peripheral maintenance.  When 
deficient in co-stimulatory molecules, CD2874, CD80/86 (B7)75, CD4076 and IL-2Rβ77, 
mice exhibited reduced numbers of nTregs with defective suppressive ability.  The 
cytokines, IL-2 and to a lesser extent TGFβ, are also of critical importance78, 79.  Both in 
the thymus and in the periphery, Tregs express high levels of CD25 but do not 
themselves produce IL-2, thus being dependent on paracrine IL-2 for survival and 
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growth78.  The existence of a CD25high precursor population that is poised to express 
FoxP3 upon IL-2 or IL-15 stimulation and thus becoming nTregs, has been suggested80.  
Although nTreg development seemed unaltered in TGFβ receptor dominant negative 
mice, sustained TGFβ was recently shown to be required for maintenance of FoxP3 
expression and suppressive capacity of peripheral nTregs both in vitro and in vivo79.   
As mentioned before, IL-10 induced type 1 Tregs (Tr1)43, and TGFβ induced T 
helper 3 cells (Th3)81 are the two main subsets of iTregs.  Not only do they differ from 
nTregs in their point of origin, but also in how antigen exposure and specific factors 
expressed in different settings dictate their differentiation and contribution to the overall 
immune response82, 83.  While differentiation of Tr1 and Th3 cells are promoted by 
different cytokines, IL-10 and TGFβ, respectively, they exert similar suppressive ability 
by secreting the same cytokine that drives their own existence.  Depending on the 
experimental conditions, they have been shown to also secrete other cytokines.  nTregs 
and iTregs have overlapping suppressive mechanisms and share a similar phenotype 
with activated T cells, such as CD25, CTLA-4, GITR, CD26L and CD45RBlo 
expression84, 85.  FoxP3 expression is seen in Th3 cells upon activation and TGFβ 
stimulation, though not seen in Tr1 cells86.  Cytokines IL-4 and IL-13, which signal 
through the IL-4Rα chain, have also been shown to induce FoxP3 expression in naïve T 
cells87. 
While nTreg development is dictated primarily by self antigen in the thymus, 
iTreg development is promoted by exogenous antigen that sub-optimally engages the 
TCR in the periphery88, usually in an inflammatory setting with anti-inflammatory 
cytokines.  Though, it still has not been excluded that the TCR repertoire of iTregs may 
include TCRs with high affinity for self-antigen.  Additionally, different to nTregs, iTregs 
do not require CD28 co-stimulation for development and suppressive function both in 
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vitro and in vivo89, 90.  In fact, co-stimulation may hinder iTreg development in vitro91.  
Other factors that contribute to iTreg generation includes route of exposure to antigen, 
tissue specific factors and APCs.  For example, exposure to antigen intranasal or orally 
preferentially promotes iTreg generation92.  APCs such as gut-associated DCs93, and 
tumor-associated DCs 94, MΦ associated with the lamina propria95, monocyte-derived 
DCs, like plasmacytoid DCs (pDCs)96 are all particularly efficient at generating iTregs.  
Finally, Tregs can induce their own generation, a process called “infectious tolerance97.  
For example, T cells from tolerized mice retain their tolerant state when transferred to 
another mouse, a process later shown to be maintained by Tregs who promoted iTreg 
generation from the suppressed T cells98.  When placed in a co-culture with nTregs, 
naïve CD4+ T cells were converted to iTreg with suppressive capacity dependent on IL-
1099 and TGFβ100.  Though, it must be noted that both subsets of iTregs can be 
generated in mice completely lacking nTregs, suggesting that they are indeed 
developmentally distinct98, 101.   
Recently, a third population of iTregs has been described, termed iTr35.  
Treatment with IL-35 alone induced the conversion of naïve human or murine T cells to 
iTr35, a process that was augmented by low dose IL-10.  Like Tr1 and Th3 cells, iTr35 
cells mediate suppression by secreting the cytokine that promotes its generation, IL-35.  
These cells do not express nor require FoxP3 and exhibit stable suppressive capacity in 
several in vivo models.  Compared to control T cells, IL-35 treated T cells did not exhibit 
an increased expression of CD25 nor CTLA-4, surface molecule previously described as 
mediators of nTreg suppression102.  This demonstrates that these cells are indeed a 
completely different suppressive T cell population.   
It is also important to note that recent studies have started to clearly elucidate 
another developmental property of Tregs, namely that in the periphery, they exhibit 
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significant plasticity.  For example, a reciprocal relationship has been described between 
Th17 cells and Tregs103.  As mentioned, TGFβ promotes iTreg development from naïve 
CD4+ T cells, but in the presence of IL-6 and IL-21, this process is inhibited and instead 
this cytokine combination promotes the development of Th17 cells104, 105.  In fact, in the 
presence of IL-6 and high levels of TGFβ, activated Tregs undergo conversion into Th17 
cells106, 107.  On the other hand, when retinoic acid (RA) is present, Th17 differentiation is 
inhibited and Treg induction is promoted, most likely due to increased TGFβ signaling 
and inhibited IL-6 signaling108.  Finally, other studies have also explored the ability of 
Tregs to convert to other Th cells, such as Th1 and Th2 cells.  Although contradictory 
results have been reported, Tregs have been shown to produce high levels of INFγ, a 
Th1 associated cytokine, when treated with large amounts of exogenous IL-2 and under 
Th1-polarizing conditions in vitro109, 110.  No evidence has been reported of Tregs 
converting to Th2 cells, and thus this remains unknown.   
 
Suppressive Mechanisms of Tregs.  Tregs were discovered because of their 
ability to actively mediate dominant immune suppression and peripheral tolerance in 
pathological and physiological conditions.  Tregs are capable of inhibiting several stages 
of target cell activity, namely, proliferation, differentiation and effector function, such as 
cytolytic activity, cytokine secretion and antibody production111.  They do so by 
employing several mechanisms which can be divided into three categories: cell-cell 
contact, soluble suppressive factors, and competition112.  Importantly, one mechanism is 
not more important that another and their use has been described in combination with 
each other, which seems to be context or disease dependent. 
 Mechanisms employed in cell-cell contact-dependent suppression mediated by 
Tregs are perhaps the most controversial since reproducibility of experimental results is 
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inconsistent in different settings.  In addition, in vitro data does not directly translate to 
the in vivo setting.  The suppressive ability of Tregs on naïve T cells is lost when co-
cultured using an in vitro transwell system, which is consistent with the finding that 
membrane-bound TFG-β contributes to suppression113.  Other cell surface molecules 
expressed by Tregs, such as cytolysis molecules Fas114 and Granzyme B115, LAG3116, 
cytotoxic T-lymphocyte antigen 4 (CTLA-4)117 and glucocorticoid-induced tumor necrosis 
factor receptor family–related gene (GITR)118 have been implicated in their suppressive 
ability.  Specifically, LAG3 interacts with MHC class II molecules on APC rendering them 
less capable of subsequently activating T cells119.  By engaging CD80/CD86 ligands on 
target cells, CTLA-4 transmits ‘outside-in’ suppressive signals to activated T cells and to 
DCs120.  In DCs, this signal activates indoleamine 2,3-dioxygenase, an 
immunoregulatory tryptophan catabolizing enzyme121, 122.  Lastly, Tregs are also capable 
of regulating cyclic adenosine monophosphate levels in target cells which has been 
shown to inhibit proliferation, differentiation and cytokine production123.  Evidence 
suggests that Tregs may do so by directly delivering cAMP to the target cell via gap 
junctions124 or by indirectly increasing the production of adenosine by surface bound 
ectonucleotidases CD73 and CD39125.  Adenosine then binds to the adenosine A2A 
receptor and causes an intracellular increase of cAMP126.  How increased cAMP levels 
leads to suppression is not fully understood.  A recent study has demonstrated that 
Treg-mediated increase in cAMP intracellular levels facilitates the nuclear accumulation 
of inducible cAMP early repressor (ICER) and suppression of nuclear factor of activated 
T cell c1 (NFATc1) and IL-2 production127.    
Soluble suppressive factors employed by Tregs include mediators such as IL-10, 
TGFβ, IL-35 and adenosine.  Because of their ability to promote iTreg development, IL-
10 and TGFβ are indisputably important suppressive mediators.  Though, their 
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contribution to nTreg function is still debatable since Treg function has been largely 
accepted to be contact-dependent128.  In vitro data has shown that use of neutralizing 
antibodies or of T cells unresponsive to IL-10 and TGFβ does not affect Treg 
suppressive capacity, suggesting that these cytokines are not important for Treg 
function129.  Though, this is not the case in vivo.  IL-10 or TGFβ alone or in combination 
with each other has been shown to be essential for the suppression mediated by Tregs 
in several pathological conditions, including allergy130, 131 and autoimmunity132, 
diabetes133, irritable bowel disease134, and cancer135, 136.  Furthermore, several studies 
have found that IL-10 or TGFβ production by the Tregs themselves is not required for 
the observed Treg induced suppression137, 138.   
The primary biological effect of IL-10 is seen on APCs, namely DCs and MΦ by 
affecting antigen presentation, differentiation and maturation.  Specifically, MHC class II 
expression and costimulatory molecule upregulation is inhibited by IL-10.  These effects 
in turn prevent APCs from producing Th1- and Th2-associated cytokines.  IL-10 also 
inhibits MΦ and DCs from producing proinflammatory cytokines, such as IL-1, IL-6 and 
IL-12, chemokines of both the CC and CXC type and matrix metalloproteases139.  
Finally, IL-10 also affects naïve CD4+ T cells directly by inhibiting CD28 signaling140.   
TGFβ suppresses immune responses by regulating cells of both the adaptive and 
innate immune system and does so by either inhibiting the function of inflammatory cells 
or as mentioned, by generating iTregs141.  TGFβ, which can be both membrane bound or 
secreted, was first described to suppress T cell and B-cell proliferation142, 143.  It does so 
by inhibiting the production of IL-2, a cytokine necessary for the survival and activation of 
T cell, NK cell and other types of immune cells142, 144.  Additionally, it suppresses CD4+ T 
cell effector function and thus differentiation into Th1 and Th2 effector cells145.  TGFβ 
can also regulate CD8+ T cell proliferation and effector functions, such as expression of 
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IFNγ and perforin and granule exocytosis146.  Finally, in NK cells, TGFβ negatively 
regulates INFγ production thereby indirectly controlling the induction of Th1 
differentiation from CD4+ T cells147.   
IL-35, formed by the pairing of the IL-27 β-chain and IL-12α, was recently found 
to contribute significantly to Treg suppression.  Unlike IL-10 and TGFβ, IL-35 is required 
both in vitro and in vivo.  IL-35 expression is increased in Tregs and seems to be a 
downstream target of FoxP3148.  In fact, ectopic expression of IL-35 in T cells confers 
suppressive ability149.  Though, it is still unclear which cell types are responsive and 
whether IL-35 is specifically expressed only by Tregs.  As mentioned earlier, IL35 also 
promotes the generation of a third and novel iTreg subset, iTr35.   
The last category of suppressive mechanisms employed by Tregs is competition 
or alteration of growth factors, such as cytokines and costimulatory molecules on APCs.  
Tregs express high levels of CD25, the high affinity receptor for IL-2, but do not 
themselves produce IL-2.  Thus, Tregs have an advantage to consume IL-2 over naïve T 
cells, which express CD25 only after activation111.  By consuming IL-2, Tregs are able to 
promote cytokine deprivation-induced apoptosis in the surrounding target cells150 and 
exploit it for the induction of IL-10 production151.  This was shown to be dependent on 
Bcl-2 interacting mediator of cell death (BIM).  Importantly, preactivated IL-2 deficient T 
cells, which similar to Tregs, expressed high levels of CD25 but do not produce IL-2, 
were able to suppress proliferation and induce apoptosis in wild-type (WT) responder 
cells, though not as efficiently as Tregs.  Additionally, IL-2-deficient responder cells still 
underwent apoptosis when cocultured with WT Tregs.  Thus, Tregs may be consuming 
growth cytokines other than IL-2 since they do express components of other receptors 
specific for IL-4, IL-7 and IL-15150.   
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Tregs also express CTLA-4 which specifically interacts with the costimulatory 
ligands CD80/CD86 on APC.  Thus, they may be able to compete with conventional T 
cells for these costimulatory molecules and/or modulate APC costimulatory function.  
Once binding to CD80/CD86, CLTA-4 indeed sends an intracellular inhibitory signal to 
DCs thereby dampening their ability to strongly activate T cells120.  T cell activation and 
proliferation also requires a reducing microenvironment and a supply of cysteine which is 
used to synthesize glutathione (GSH), an antioxidant essential for DNA synthesis.  DCs 
are the main shapers of this redoxing microenvironment and producers of cysteine152.  A 
recent study showed that Tregs mediate suppression by interfering with the extracellular 
redox potential, a process that is CTLA-4 dependent, antigen dependent but nonspecific, 
and cell-cell contact dependent.  Specifically, they showed that Tregs modulate DC and 
effector T cell metabolism of GSH and competitively consume extracellular cysteine, 
thereby depriving effector T cells of it153.   
As it can be appreciated, Tregs have several suppressive mechanisms at their 
disposal.  The importance of each mechanism and their differential use individually or in 
combination depends on the microenvironment and the immune pathology being 
suppressed. 
 
Tregs in Pathological Conditions and Clinical Implications.  Much of the 
experiments yielding the most clinically relevant and informative data on Tregs have 
been performed in vivo where immune responses are either deregulated, such as in 
tissue-specific autoimmunity; or overly regulated as seen in cancer and as desired in 
transplantation procedures.  The examples, GvHD, inflammatory bowel disease (IBD) 
and cancer, discussed here after, are of most relevance to the studies presented further 
in this dissertation.   
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Patients that suffer from a blood cancer, anemia or a severe immunodeficiency 
syndrome are candidates for a BMT to replace their damaged or destroyed BM with 
healthy BM.  Even if there is a good match between the donor and the host, seen usually 
among close family members, the host still runs the risk of succumbing to GvHD.  This is 
the most common complication of allogeneic BMT and can be fatal154.  GvHD is 
instigated primarily by conventional donor T cells found in the BM graft that perceive the 
host as "foreign" and launch an attack against host organs.  Specifically, host APCs 
present major and/or minor histocompatibility antigens to host-reactive donor T cells, 
which in turn become activated and expanded.  These activated donor T cells then 
infiltrate and destroy target tissues, primarily the gut, liver and skin155.  When depleting 
BMT of donor T cells, the host is effectively protected from GvHD but also loses the 
beneficial effects mediated by donor T cell, such as graft-versus-hematopoiesis or -
leukemia/-lymphoma effects, the last being the main therapeutic purpose in allogeneic 
BMT156.  Furthermore, the BMT preparative regimen may also cause damage to the host 
thymic epithelium, compromising its ability to negatively select autoreactive T cells.  
These autoreactive T cells may also then participate in allogeneic GvHD, particularly in 
the autoimmune manifestations of chronic GvHD23.   
 Because of their functional properties, anergy, suppression and dominant 
regulation of self tolerance, many have examined Tregs and their affect on host-reactive 
effector T cells after allogeneic BMT in mouse models157.  One such study showed donor 
Tregs alone do not induce GvHD when transplanted in a completely MHC mismatched 
host158.  When adoptively transferred at a high ratio (1:1) with conventional donor T cells, 
they provide protection from GvHD, which was partly mediated by Treg derived IL-10159 
and the capacity of Tregs to home effectively to lymph nodes (LNs)160.  Similar to how 
host APCs activate donor T cells that mediate GvHD, host APCs and their presentation 
20 
 
of alloantigen also promote the induction of protection against GvHD by donor Tregs161.  
Importantly, these donor Tregs did not restrain conventional T cells from mediating graft- 
versus-leukemia-effect158. 
 After being described as a lineage-defining transcription factor specific to nTregs, 
FoxP3 has been used as a reliable marker for Treg identification.  As mentioned before, 
conventional T cells can be induced to express FoxP3 and acquire in vitro suppressive 
capability by TCR stimulation and TGFβ exposure162.  This makes the in vitro generation 
of potentially therapeutic iTregs very feasible, though their in vivo efficacy is 
debatable163.  Using FoxP3-reporter mice, Koenecke et al elegantly showed that while 
suppressive in vitro, allospecific iTregs were not able to prevent recipient animals from 
succumbing to GvHD, contrary to that seen with polyclonal nTregs.  They found that 
when re-isolated from the pro-inflammatory setting characteristic to GvHD, this 
transferred iTreg population, but not nTregs, had rapidly lost their expression of FoxP3 
and suppressive activity164.  This, though negative results, points to the importance and 
requirement of a stable and sufficiently strong FoxP3 expression to maintain the Treg 
phenotype.  It has been shown that FoxP3 expression in nTregs is controlled by 
epigenetic modifications, where nTregs exhibit complete demethylation, while 
conventional T cells and iTregs exhibit full methylation at conserved CpG-rich noncoding 
regions of the FoxP3 locus165.  Thus, further studies that combine the use of in vitro 
FoxP3 induction and chromatin modifications that result in sustained FoxP3 expression 
are required to conceivably generate Treg products that are therapeutic in GvHD as well 
as in other diseases.   
IBD, which includes Crohn’s disease and ulcerative colitis, is characterized by 
chronic inflammation aberrantly orchestrated against the normal bacterial flora of the 
gastrointestinal tract.  In order to understand the cause and process behind IBD, several 
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different murine models have been utilized45.  For example, the T cell-induced colitis 
model is a well established system allowing researchers to analyze the role Tregs play in 
controlling IBD.  Specifically, when transferred into an immune deficient mouse, a small 
number of CD4+CD45RBhi T cells differentiate into Th1 cells and mediate colitis in about 
4-6 weeks.  This process can be prevented by co-transferring Tregs, and even reversed 
by transferring Tregs after the onset of colitis166.  Most studies have made clear that IL-
10 is a key cytokine used by Tregs in protecting from IBD.  Further, although IL-10 
derived from other cell types alleviates the symptoms to a degree, it is the Treg-derived 
IL-10 that effectively suppresses local inflammation137.  This coincides with the finding 
that IL-10-producing Tregs are particularly enriched in the colonic lamina propria and 
secondary lymphoid organs in IBD167.  Similarly in humans, intestinal CD4+ T cells from 
Crohn’s disease patients are defective in producing IL-10168.  In addition to IL-10, other 
cytokines such as TGFβ169, and more recently IL-35149, have also been implicated in 
Treg mediated protection of IBD.  Additionally, expression of specific chemokine 
receptors, such as CCR7170, and of L-selectin (CD62L)171 was found to be critical for 
Treg activity at inflammation sites characteristic to IBD.   
 As mentioned earlier, once cancer successfully progresses through to the 
escape phase of the immune editing theory, an immunosuppressive environment is 
established, in which Tregs contribute greatly to.  Tregs have been shown to actively 
suppress anti-tumor specific T cells172, 173 from mounting a successful immune response 
against the growing tumor.  In addition, Tregs inhibit NK cells174, B cells175 and other 
immune cells.  Tregs are found in increased numbers in the tumor microenvironment of 
patients with melanoma176, lymphoma177, breast178, gastric179 and lung cancer180, among 
others; which has been correlated, in some cases, with poor prognosis181.  Using mouse 
tumor models, several investigators have shown that the depletion of Tregs, for example 
22 
 
by use of anti-CD25 antibody, is permissive to an anti-tumor response182, 183.  
Furthermore, local depletion of Tregs specifically inside the tumor promoted a shift in the 
cytokine milieu, elimination of well-established aggressive tumors and long-term 
antitumor memory184. The mechanisms that have been described to be employed by 
Tregs in cancer are those that have already been mentioned.  In short, use of 
suppressive cytokines such as TGFβ135 and IL-10136, modulation and suppression of 
APC function185, and granzyme B-dependent cytolysis115 have all been described to be 
used by Tregs to control the tumor-specific immune response.  Interestingly, use of 
cytolysis by Tregs has only been described in the tumor microenvironment, representing 
a potentially disease-specific mechanism45.   
 It must be noted that controversy exists as to whether the presence of tumor-
infiltrating Tregs is an indicator of prognosis in human cancer.  Some reports have 
shown that increased Treg numbers correlates with poor prognosis181, 186 while others 
have shown the opposite187-189.  An obstacle to discerning what is in fact true is the 
detection method used in these studies.  Specifically, the expression of FoxP3 was used 
to determine Treg numbers.  This is not an accurate representation of human Tregs 
since conventional human T cells have been shown to transiently express FoxP3 upon 
activation190.   
 Also, the applicability and feasibility of targeting Tregs in cancer has not been 
clear-cut and straightforward.  Specifically, while depletion of Tregs has been shown to 
promote a better anti-tumor immune response, very few reports have shown that this 
ultimately resulted in tumor regression191.  Furthermore, when depleting Tregs, their 
numbers have been shown to quickly rise again from T cells converting to Tregs192.  In 
addition, the approach used to deplete Tregs also ends up depleting anti-tumor T 
effector cells193.  Moreover, before considering Treg depletion as a treatment for human 
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cancer, the distinction between solid cancers and cancers of hematopoietic origin should 
be made.  Given that Tregs inhibit lymphocyte function175, Tregs may retard the 
progression of some hematopoietic cancers, particularly those involving B and T cell 
lineages.  Thus, when designing immunotherapeutic approaches that involve Treg 
depletion, improvement of anti-tumor T cell responses must be weighed against the 
direct suppression of cancer cells mediated by Tregs194.   
 
Myeloid Derived Suppressor Cells (MDSC).  The discovery of MDSC in the 
1980’s instigated a field of study that has continued to become more complex and very 
exciting.  Because of their heterogeneity and their varying presence in several 
pathological conditions, deciphering the biology of MDSC is instrumental for 
understanding and treating several diseases.  The discovery, development and 
heterogeneity of MDSC, as well as their suppressive mechanisms, involvement in 
pathological conditions and clinical implications are discussed below. 
 
Discovery of MDSC.  The first description of MDSC could be dated back to the 
early 1980’s in studies examining the effects of cancer on the immune system.  One 
particular study showed that mice transplanted with mammary carcinoma exhibited 
abnormal hematopoiesis resulting in an expansion of a population of cells devoid of T 
and B-cell surface antigens in the spleen (SPL) and BM.  These “null” cells seemed to 
further differentiate to neutrophilic granulocytes with an undefined function.  This study 
suggested that the tumor influenced the primary lymphoid organs resulting in 
granulocytopoiesis and marked changes in lymphocyte populations195.  Young et al later 
made similar observations in mice bearing a metastatic variant of Lewis Lung carcinoma 
LLC-C3 that stimulated an increase in the frequency of monocytes in the peripheral 
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blood, SPL and BM.  They took it one step further by functionally characterizing these 
cells, at least those isolated from the BM, as being suppressive to T-lymphocyte 
blastogenesis.  In addition, their experiments suggested that there was a colony 
stimulating factor secreted by the LLC-C3 that promoted the generation of these 
suppressor cells with immature monocytes-macrophage characteristics196.  A few years 
later, it was found that treatment of tumor-bearing mice with a monoclonal antibody 
against granulocytes inhibited the growth of cancer197 and even promoted tumor 
rejection mediated by CD8+ T cells198.  Although not fully understood, several other 
studies supported the observation that tumor progression correlated with increased 
immune suppression.  Furthermore, this suppression was mediated by a tumor-derived 
factor that promoted an increase in a suppressive immature myeloid population199, which 
was sometimes referred to as natural suppressors, suppressor MΦ or macrophage 
precursors, among many other names.  Fu et al, who also observed the correlation 
between immune suppressive MΦ and tumor progression, provided compelling data 
suggesting that GM-CSF specifically, released by the tumor, mediated immune 
suppression by promoting the expansion of these MΦ200. Shortly after, the same lab 
identified two mechanisms employed by these MΦ to suppress immune responses in 
tumor-bearing mice, PGE2 production and cell-cell contact, which was MHC-
independent201. During this same time, similar cells were also described to control 
immune responses associated with infectious diseases like Trypanosoma202 and 
Salmonella203.  Eventually, Bronte et al described a suppressive population co-
expressing the cluster of differentiation molecule 11b (CD11b), also known as integrin 
alpha M, and the granulocyte receptor-1 (Gr1) that accumulates following a potent 
primary immune response to a highly effective immunization strategy204.  The co-
expression of Gr1 and CD11b, a seemingly immature myeloid phenotype, and 
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suppressive capacity soon became the most reliable markers used to study MDSC, a 
name coined several years later in 2007 to eliminate confusion205.  It must be noted that 
this definition remains very broad and thus includes a variety of cells that fit this criteria 
yet differ in anatomical compartmentalization, expression of other surface markers, 
differentiation state, suppressive mechanism, and pathological condition with its 
corresponding microenvironmental stimuli which promote their accumulation.  Thus 
another characteristic of these cells is their extensive heterogeneity.  Although the 
identity of this population has been most extensively studied in cancer, it is greatly 
appreciated that MDSC also play a role in other inflammatory diseases such as chronic 
infection, autoimmunity and trauma, among other pathological conditions206.   
 
Development of MDSC.  MDSC are comprised of a variety of myeloid precursor 
cells at different stages of differentiation that may and do give rise to granulocytes, 
monocytes, MΦ, and dendritic cells.  Thus, in order to understand the development of 
MDSC in pathological conditions, the normal development of myeloid cells should be 
reviewed.  It is widely accepted that in the BM, hematopoietic stem cells give rise to a 
common myeloid progenitor/precursor which further differentiates into a 
macrophage/dendritic cell precursor (MDP).  MDPs represent an intermediate 
differentiation stage from which both monocytes and DCs arise and then go into 
systemic circulation where they can enter the tissues and further differentiate into DCs 
and MΦ.  MDPs may also generate immature and mature polymorphonuclear cells, thus 
possibly being part of a broader granulocyte-monocyte progenitor population.   
This is a very simplified schematic that is still not fully elucidated and that is 
further complicated by the fact that these cell types can be further divided into either 
distinct subsets or functional states depending on several factors.  After leaving the BM, 
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the localization, microenvironment and interaction with other cells greatly affect the 
terminal differentiation, function and activation fate of these newly arriving cells.  For 
example, MDPs can give rise to “resident” or “inflammatory” monocytes, plasmacytoid or 
classical DCs, and “classically” or “alternatively” activated MΦ, which are all different 
phenotypically and functionally206.  Inflammation and cancer create further complexity 
due to the secretion of a vast array of cytokines, chemokines, and growth factors such 
as prostaglandins, vascular endothelial growth factor (VEGF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), stem cell factor (SCF), macrophage colony-
stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), MMP-9, 
CCL2, CXCL5/12, IL-1β, IL-6, , TGFβ , IL-10, IL-12, and IL-13207.  These secreted 
factors then activate several signaling pathways that ultimately deregulate the main 
transcription factors involved in myelopoiesis, resulting in the observed accumulation of 
MDSC.  It has been hypothesized that the accumulation of MDSC requires at least two 
signals.  One signal is mediated by growth factors and cytokines that promote their 
development and expansion.  The other signal mediated by pro-inflammatory molecules 
that dictate their activation, which translates into their suppressive ability208.  Although 
not limited to these, some of the extensively studied signaling pathways that become 
activated during MDSC development involve members of signal transducer and activator 
of transcription (STATs) family, NF-κB, cyclooxygenase 2 (Cox-2) and prostaglandin E2 
(PGE2). These are discussed below.  Important to the studies presented in the following 
chapters, SHIP signaling also plays a role in the development of MDSC and is discussed 
separately in the subsection titled “SHIP in Myeloid Cells”. 
Many of the above mentioned cytokines signal through the JAK (Janus tyrosine 
kinase)/STAT pathway.  Particularly, STAT3, which is controlled by JAK2, has been 
shown to be hyperactivate in the presence of tumor-derived factors and in turn be critical 
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for the expansion209, suppressive capacity of MDSC, and to their contribution to 
angiogenesis210.  STAT3 signaling in myeloid cells prevents cells apoptosis and 
differentiation, and promotes cell proliferation by controlling the expression of Bcl-xL, c-
myc, cyclin D1 and survivin211.  MDSC suppressive activity is abolished in vitro by 
STAT3 inhibition.  Targeting STAT3 signaling in vivo using the multi-targeting tyrosine 
kinase inhibitor, sunitinib, inhibited the expansion of MDSC in tumor-bearing mice212.   
There are many pathways downstream of STAT3 that may also regulate MDSC 
expansion and suppression.  For example, the calcium-binding pro-inflammatory 
proteins S100A9 and S100A8 are upregulated upon STAT3 activation in hematopoietic 
progenitor cells (HPC).  Further, HPCs with overexpressed S100A9 were impaired in 
their ability to differentiate into DC and instead differentiate into MDSC in vitro.  Similarly, 
overexpression of S100A9 in mice exhibited defective DC and macrophage 
differentiation and accumulation of MDSC in tumor-free mice.  Consistently, in tumor-
bearing mice rendered S100A9 deficient, MDSC splenic expansion was blocked213.  
MDSC have also been shown to secrete high levels of S100A8 and S100A9 which 
accumulate systemically thereby promoting their own accumulation.  Signaling triggered 
by S100A9 and S100A8 activates the NF-κB pathway in MDSC.  It is proposed that 
S100A9, dimerized with S100A8, promotes NADPH oxidase (Nox2) formation, which in 
turn produces ROS in myeloid cells, a known inhibitor of myeloid cell differentiation214.  
In addition, it was found that activated STAT3 upregulated Nox2 levels directly by 
promoting the transcription of p47phox and gp91phox, its subunits215.   
STAT3 has also been shown to regulate the expression and DNA binding activity 
of the transcription factor CCAAT-enhancer-binding protein beta (C/EBPβ) whose 
expression is induced by tumor secreted cytokines like GM-CSF, G-CSF and IL-6216.  
C/EBPβ, which is vital in emergency granulopoiesis, was found to be critical for the 
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differentiation of myeloid precursors to functional MDSC.  Additionally, adoptive transfer 
of tumor-specific CD8+ T cells mounted an effective response against the established 
tumor only in mice with C/EBPβ-deficiency in the myeloid compartment217. 
Several other signaling pathways involving STAT3 activity have been identified 
critical to MDSC accumulation and function.  In short, STAT3 controls the expression of 
acute-phase proteins, which in turn play a role in MDSC mobilization and survival.  Heat-
shock protein 72 (Hsp72) induces MDSC function by activating STAT3 in an IL-6, TLR2, 
and myeloid differentiation primary response gene 88 (MyD88)-dependent manner.  
Finally, STAT3-induced down-regulation of PKCβII, which is required for DC 
differentiation from myeloid progenitor cells, may in turn promote the preferred 
differentiation and accumulation of MDSC in tumor-bearing mice218. 
 Other STATs also play a role in MDSC accumulation and function.  STAT1, 
which is activated by INFγ or IL-1β, regulates iNOS (inducible nitric oxide synthase) and 
arginase-1 (Arg-1) activity.  Because of this, STAT1-deficient MDSC are not 
suppressive.  Further, blocking secretion of INFγ in either T cells or MDSC also 
abrogated MDSC mediated suppression219.  STAT5 also plays a role in MDSC 
accumulation particularly in the presence of GM-CSF, which is abundant in the tumor 
microenvironment.  MDSC accumulation was prevented by sunitinib specifically in the 
SPL of tumor-bearing mice.  But, within tumors, MDSC were resistant to sunitinib due to 
the abundance of GM-CSF, which activates STAT5 while inhibiting STAT3220.  Finally, 
similar to STAT3, activation of STAT6, which results from IL-4 or IL-13 engagement of 
the receptor CD124, also dictates MDSC suppressive function.  CD124 activation was 
shown to upregulate Arg-1 activity221, 222 and TGFβ223 production in MDSC.  In addition, 
MDSC expansion after traumatic stress was dependent on STAT6 signaling224. 
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 As mentioned briefly above, NF-κB signaling influences MDSC mediated 
suppression and expansion.  In myeloid cells, NK-κB activation occurs downstream of 
signaling initiated at the toll-like receptor 4 (TLR4), among other TLR family members, 
and transmitted through MyD88.  Consistently, MDSC accumulate in infections, trauma 
and sepsis225.  Particularly, in the presence of IFNγ, LPS, a bacterial endotoxin that 
engages TLR4, promoted the expansion of splenic MDSC in vivo and impeded DC 
differentiation from BM cells in vitro226.  Another study showed that dust mite-induced 
airway eosinophilia and T-helper 2 (Th2) cytokine production was hindered by high dose 
LPS in mice.  Furthermore, the development of lung-resident MDSC was promoted by 
this LPS treatment in a TLR4 and MyD88-dependent manner.  These MDSC suppressed 
Th2 mediated allergic airway inflammation227.  Consistently, in a model using tumor 
exosomes, MDSC from Mydd88-/- mice, different to WT counterparts, did not suppress T 
cell activity or cytokine release, and did not accumulate in the lung228.   
IL-1β, which also signals through the NF-κB pathway, activates MDSC and thus 
plays a role in MDSC development.  For example, overexpression of IL-1β specifically in 
the stomach of transgenic mice caused spontaneous gastric inflammation and led to 
cancer.  This is accompanied with the accumulation of MDSC in the stomach, all of 
which was inhibited by an IL-1β receptor antagonist229.  Importantly, studies examining 
the role of NF-κB have shown that NF-κB signaling mainly dictates MDSC activation and 
acquisition of suppressive capacity more so than promoting MDSC accumulation.   
The activity of prostaglandin E2 (PGE2), its receptor E-prostanoid 4, Cox-2, and 
Arg-1 are all interrelated and have been implicated in MDSC development.  During 
PGE2 synthesis, Cox-2, expressed by many cell types, particularly tumor cells and 
MDSC, catalyzes the conversion of arachidonic acid to prostaglandin G2 that is further 
modified to PGE2 by PGE synthase.  PGE2, a well known tumor-derived factor, then 
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engages its receptor, E-prostanoid 4, expressed on MDSC, and induces the expression 
and activity of Arg-1230.  Furthermore, the use of Cox-2 inhibitors was shown to block the 
expression of Arg-1, prevent the accumulation of MDSC and elicit a lymphocyte-
mediated antitumor response in a 3LL Lewis Lung carcinoma mouse model231.  In a 
study using tumor exosomes that induced the accumulation of MDSC, the use of 
antibodies against PGE2 and TGFβ attenuated MDSC-mediated promotion of tumor 
progression by preventing MDSC induction232.  These and many other studies have 
clearly shown that Cox-2 and PGE2 comprise a critical signaling pathway dictating both 
MDSC differentiation and function.    
   
Heterogeneity of MDSC.  In accordance with the variety of factors produced by 
tumors and infectious agents that promote the development of these cells; MDSC, as 
defined by suppressive capacity and co-expression of Gr1 and CD11b, are extensively 
heterogeneous morphologically, phenotypically and functionally.  The confusion brought 
on by this heterogeneity has led researchers to further dissect MDSC into subsets 
according to their morphology, phenotype and suppressive capacity. 
Initially, it was proposed that a more potent suppressive subset could be 
distinguished among MDSC by analyzing the expression of specific surface markers, 
specifically the M-CSF receptor (CD115), the IL-4 receptor (IL-4R) α chain (CD124), 
CD40, CD80 and CD49d.  One such study using a mouse colon carcinoma model 
showed that CD115+ MDSC were significantly more potent at suppressing antigen-
specific T cell stimulation and inducing Treg development compared to CD115- MDSC233.  
Using a colon carcinoma mouse model, Gallina et al showed that expression of CD124 
was required for MDSC-mediated suppression of alloreactive CTL generation in vitro.  
Furthermore, they showed that adoptively transferred tumor-specific CD8+ T cells were 
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able to prevent tumor growth in myeloid-specific CD124 knockout tumor-bearing mice, 
while not so in WT tumor-bearing mice219.  Another study using a mouse ovarian 
carcinoma, described the requirement of CD80 expression on MDSC to suppress 
antigen-specific immunity mediated by CD4+CD25+ Tregs and CD152 signaling234.  The 
studies performed by Pan et al suggested that the expression of CD40, an immune 
stimulatory receptor, on CD115+ MDSC was essential for their capacity to directly induce 
T cell tolerance and tumor-specific Treg expansion235.  Finally, CD49d expression 
discovered using gene-expression analysis, subdivided MDSC into two distinct 
populations.  CD49d+ MDSC were mainly monocytic, while CD49d- MDSC were 
granulocytic.  The CD49d+ MDSC subset was more potent at suppressing T cell 
proliferation in an NO-dependent manner compared to the CD49d- subset236.  Although 
these markers are indeed expressed by MDSC, further studies on other tumor models 
showed that these markers were actually more tumor model specific than universal 
markers defining the most immunosuppressive population among MDSC.  Importantly, it 
is clear that MDSC consists of both monocytic cells, M-MDSC and granulocytic cells, G-
MDSC. 
 Because MDSC express varying levels of Gr1, some researchers have 
suggested that the immune suppression capabilities of MDSC could be determined by 
Gr1 expression level.  Specifically, when isolated from tumor-bearing mice, CD11b+Gr1int 
MDSC, comprised mainly of M-MDSC and myeloid precursors, were potently 
suppressive of CD8+ T cell effector functions.  On the other hand, CD11b+ Gr1high MDSC 
comprised mainly of G-MDSC, exhibited moderate suppression only in particular tumor 
models which required them to be present in high numbers.  In addition, the 
CD11b+Gr1int MDSC could further differentiate into CD11c and F4/80 expressing cells 
while the CD11b+Gr1high cells could not237, 238.   
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The antibody most commonly used to examine Gr1 expression, RB6-8C5, 
recognizes Ly6G, which is present on neutrophils, and Ly6C, which is present on 
neutrophils, dendritic cells and subpopulations of lymphocytes and monocytes239.  Using 
antibodies that distinguish between these surface proteins allowed for the clear 
distinction of two subsets within MDSC in tumor-bearing mice238, CD11b+ Ly6G+Ly6Clo 
and CD11b+ Ly6G-Ly6Chigh.  After morphological analysis, it was clear that the 
CD11b+Ly6G+Ly6Clo MDSC were granulocytic, corresponding to G-MDSC or the Gr1high 
cells.  The CD11b+Ly6G-Ly6Chigh were monocytic corresponding to M-MDSC or the Gr1int 
cells described above240, 241.  These two major subsets differ also in the nature of their 
immune suppression, which is discussed in more detail in the next section.  Briefly, G-
MDSC suppress in an antigen-specific manner, which is mediated by their expression of 
Arg-1, high levels of ROS production and direct cell-cell contact with T cells.  M-MDSC 
effectively suppress in a nonspecific manner, independent of cell-cell contact, by 
upregulating the expression of both iNOS and Arg-1, and by producing various 
suppressive cytokines240, 242.  When examined on a per cell basis, some studies suggest 
that M-MDSC are more potent suppressors than G-MDSC243.  Though, in most tumor 
mouse models, G-MDSC are significantly more abundant than M-MDSC in peripheral 
lymphoid organs241.  Importantly, within the tumor, the ratio of G-MDSC to M-MDSC is 
much lower than that in the periphery, thus possibly shaping a distinct 
immunosuppressive environment within the tumor site.  In addition, these two subsets 
differ in their proliferative potential, where M-MDSC are highly proliferative compared to 
G-MDSC, which are not as proliferative244. 
It must be noted that MDSC heterogeneity, as described by analyzing 
morphology, suppressive mechanism, proliferation and compartmental accumulation, is 
not restricted to these two major subsets.  Intermediate groups of cells at different 
33 
 
stages of differentiation that possess varying phenotypes most likely exist.  Other MDSC 
subsets not mentioned here have been described and more subsets will most probably 
be identified in the future.   
 
Suppressive Mechanisms of MDSC.  Several immunosuppressive mechanisms 
employed by MDSC have been described.  It must be kept in mind that these 
mechanisms are very likely influenced by the specific microenvironment in which MDSC 
develop, by tumor characteristics and by the activation level of the lymphocytes being 
suppressed245.  In summary, MDSC suppressive activity has been associated with L-
arginine metabolism, production of reactive oxygen species (ROS) including 
peroxynitrites, induction of Tregs, sequestration of cysteine and downregulation of L-
selectin on T cells207, 246, 247.  These mechanisms are discussed below in more detail.  
Importantly, many of these mechanisms have not only been described in cancer but also 
in chronic inflammation, experimental autoimmune encephalomyelitis and infection207.  In 
addition to suppressing T cell activity, MDSC also inhibit the innate immune response by 
affecting MΦ, NK cells and NKT cells activity246. 
 L-arginine is a substrate for two enzymes highly expressed by MDSC: iNOS, 
which produces NO, and Arg-1, which uses L-arginine to produce urea and L-ornithine.  
Both M-MDSC and G-MDSC express high levels of Arg-1 while M-MDSC also express 
iNOS.  The increased expression of these enzymes leads to enhanced L-arginine 
metabolism.  MDSC can either import excess L-arginine from their environment through 
their CAT-2B transporter, as seen in murine MSDS, or release Arg-1 into circulation, as 
seen with human MDSC, specifically from renal cell carcinoma patients248. Regardless, 
either method depletes the amount of L-arginine available for T cells, which require L-
arginine for protein synthesis.  L-arginine deprivation inhibits T cell proliferation by 
34 
 
decreasing the expression of the CD3ζ chain249, and the expression of cell cycle 
regulators cyclin D3 and cyclin-dependent kinase (CDK) 4250.  Furthermore, NO has 
been shown to downregulate the activation of JAK3 and STAT5 required for IL-2 
mediated T cell proliferation251.  NO also inhibits the expression of MHC class II on a 
variety of cells207, 252. 
Increased ROS production, which is characteristic of G-MDSC and their 
increased Arg-1 activity, has been extensively described as a major mediator of MDSC 
suppression in cancer patients and tumor-bearing mice.  In fact, in vitro inhibition of ROS 
production blocks the suppressive capacity of MDSC isolated from cancer patients and 
mice211, 212.  ROS production, which requires STAT3 and NADPH activation, is induced 
by several known tumor-derived factors such as TGFβ, IL-10 and GM-CSF253.  In 
addition, engagement of integrins expressed on MDSC upon interacting with T cells, has 
been shown to enhance ROS production by MDSC254.  ROS has been shown to affect T 
cell activity in several ways.  One study showed that increased ROS, particularly 
hydrogen peroxide, produced by MDSC inhibited cytokine production by T cells in 
vitro255.  Another study showed that ROS production was responsible for MDSC-
mediated suppression of antigen specific CD8+ T cell responses256. 
Peroxynitrite (ONOO-), a powerful oxidant produced when superoxide (O2-) 
reacts with nitric oxide (NO), causes the nitration and nitrosylation of amino acids 
cystine, methionine, tryptophan and tryosine257.  Peroxynitrite found in high levels has 
been associated with tumor progression in several cancers257-259 and with T cell 
unresponsiveness.  For example, unresponsive CD8+ T with high levels of nitrotyrosine 
were found within human prostate adenocarcinomas.  The use of Arg-1 and iNOS 
inhibitors decreased tyrosine nitration in T cells and restored their anti-tumor activity260.  
Recently, it was more clearly elucidated that peroxynitrite produced by MDSC when in 
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direct contact with T cells, nitrated the TCR and CD8 molecules on the T cell.  This 
altered the T cell’s ability to bind to antigen/MHC complexes, and thus become activated 
upon antigen recognition.  This phenomenon is antigen-specific, since the T cells were 
still responsive to nonspecific stimuli261.   
MDSC can also promote the development of Tregs, which requires the presence 
of IFNγ and IL-10, and the activation of tumor-specific T cells233.  Contradictory studies 
have been presented regarding the requirement of TGFβ production by MDSC in 
promoting Treg development, suggesting that different MDSC subsets use diverse 
mechanisms to induce Tregs223, 233.  Furthermore, other studies have argued against the 
idea that MDSC promote Treg development240, thus requiring further studies to 
demonstrate this definitively.  Regardless, MDSC and Tregs seem to be involved in a 
common immunoregulatory network.   
Similar to L-arginine, cysteine is required by all cells for protein synthesis.  
Specifically, T cells require cysteine for activation and subsequent proliferation and 
differentiation.  Though, they are not capable of importing cystine, the oxidized form of 
cysteine, or of producing cysteine themselves.  Thus, T cells rely on exogenous sources 
of cysteine, which they import through the ASC neutral amino acid transporter246.  
Exogenous cysteine is supplied by APCs, such as DCs and MΦ, particularly during 
antigen presentation262.  Recent studies have clearly demonstrated that MDSC, which 
also need cysteine, deplete their environment of cystine, disrupt the extracellular 
production of cysteine by thioredoxin, and do not export surplus cysteine as APCs do.  
Because MDSC are present during antigen presentation, they deplete the local 
microenvironment of cysteine and thereby inhibit T cell activation and proliferation263. 
Finally, MDSC prevent naïve T cell from homing to sites where they would 
otherwise undergo activation by mediating the down-regulation of L-selectin (CD62L) 
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surface expression on T cells.  L-selectin facilitates leukocyte extravasation from the 
blood to LNs and inflammatory sites such as tumor microenvironments, where they 
encounter antigen and become activated246.  Naïve T cells normally have an L-
selectinhigh phenotype.  Conversely, in tumor-bearing mice and cancer patients, T cells 
have lower levels of L-selectin expression, which is inversely correlated to MDSC level 
and tumor burden.  In fact, when co-cultured with MDSC, T cells acquire an L-selectinlow 
phenotype.  MDSC directly down-regulate L-selectin expression because they 
constitutively express ADAM17, a disintegrin and metalloproteinase domain 17 that 
mediates the proteolytic cleavage and shedding of the L-selectin ectodomain by T 
cells264.   
MDSC also affect cells of the innate immune system, such as MΦ, NK cells, and 
NKT cells.  MΦ can be activated “classically” and differentiate into so-called M1 MΦ, 
which promote an anti-tumor response; or “alternatively” and differentiate into so-called 
M2 MΦ, which enhance tumor development.  When in contact with MDSC, which 
produce IL-10, MΦ acquire the M2 phenotype and decrease their production of IL-12222, 
265.  M2 MΦ also release IL-10, exert selective immunosuppressive activity, and inhibit T-
cell proliferation.  In addition, Ilkovitch et al demonstrated that in the liver, MDSC 
accumulate and interact with Kupffer cells, which are liver-residing specialized MΦ.  This 
interaction upregulates the expression of PD-L1, a negative T cell costimulatory 
molecule, on Kupffer cells, which contributes to immunosuppression in tumor-bearing 
mice266.  
The effect of MDSC on NK cells varies.  One study showed that MDSC inhibited 
NK cell cytotoxicity and perforin production, which required cell-cell contact267.  In 
contrast, another study showed that a specific subset of MDSC expressing RAE-1, the 
ligand for the activating receptor NKG2D, promoted NK cell activity, particularly INFγ 
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production.  Furthermore, these activated NK cells could eliminate MDSC when they 
were co-cultured in vitro or adoptively transferred in vivo268.   
The relationship between NKT cells and MDSC also varies depending on the 
NKT cell type in question.  Type 1 or invariant NKT cells inhibited MDSC suppressive 
activity in a CD1d- and CD40- dependent manner269.  In change, type II NKT cells 
produce IL-13270 which has been shown to promote M2 macrophage and MDSC 
accumulation222.   
 
MDSC in Pathological Conditions and Clinical Implications.  MDSC have 
been most extensively studied, particularly in cancer.  As mentioned before, MDSC also 
play a role in other inflammatory diseases such as chronic infection, autoimmunity and 
trauma, among other pathological conditions206.  Similar to Tregs, the more that is 
understood about the development and function of MDSC, the more effective it will be to 
target them, which is critical in cancer, or to exploit their suppressive ability as desired in 
transplantation procedures.  The involvement of MDSC specifically in GvHD, IBD and 
cancer are of most importance to the studies presented further in this dissertation.  Since 
their involvement in cancer has already been discussed above, what follows is what is 
known about their involvement in GvHD and IBD. 
 As mentioned before, GvHD is a significant hurdle that limits the use of BMTs as 
an effective treatment for diseases mediated by pathological immune function such as 
cancer, anemia or severe immunodeficiency syndrome.  Similar to Tregs, MDSC 
suppressive function can be exploited to prevent GvHD.  One such study examined the 
role of MDSC in preventing GvHD while preserving the GVL reactivity of donor 
lymphocyte infusions (DLI) in a murine model using a minor histocompatibility antigen- 
mismatched BMT.  If the DLI was administered immediately after the BMT, the mice 
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would succumb to GvHD; but if 3 weeks passed before administering the DLI, GvHD did 
not occur while preserving GVL.  The researchers suggested that this was mediated by 
MDSC that underwent a transient expansion peaking at 3 weeks after radiation and 
BMT, and whose suppressive function was dependent on INFγ and mediated by NO 
production271.  Morecki et al showed that MDSC generated in and enriched from mice 
treated with CpG+IFA were capable of preventing GvHD when co-transferred with naive 
T cells272.  Recently, another group, using G-CSF and GM-CSF, was able to generate 
MDSC in vitro.  The suppressive activity of these MDSC was mediated by Arg-1 
expression and enhanced by IL-13.  These IL-13 enhanced MDSC protected mice from 
GvHD while also preserving the GVL effect of donor T cells.  Furthermore, use of 
pegylated Arg-1 alone also resulted in significant GvHD reduction273. 
 The role of MDSC in IBD and colitis has not been extensively studied, though the 
few existing studies clearly demonstrate that they may indeed play a role.  One study 
used an antigen-specific mouse model of IBD mediated by CD8+ T cell.  While VILLIN-
HA mice receiving a single transfer of HA-specific CD8+ T cells exhibited weight lose and 
intestinal inflammation, mice that received repetitive transfer of splenocytes from CL4-
TCR mice showed almost no signs of enterocolitis or weight loss.  The repeated transfer 
of splenocytes caused an increase of MDSC in the SPL and intestine that produced high 
levels of NO and expressed functional Arg-1.  Though, their suppression of CD8+ T cell 
proliferation was dependent on NO production and not on Arg-1 activity.  Furthermore, 
when co-injected with CL4-TCR splenocytes, MDSC isolated from mice with 3 transfers 
protected recipient mice from developing enterocolitis274.   
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The Role of Tumor Suppressor, SHIP, in Regulating the Immune System 
 
Discovery of SHIP.  Src homology (SH) 2 domain containing 5’ inositol 
phosphatase 1 (SHIP), a 145kDa protein, was first described in hematopoietic cell lines 
where stimulation with erythropoietin (Epo) induced its phosphorylation at a tyrosine 
residue and its subsequent association with Shc275.  A few years later, in 1996, five 
research groups independently cloned SHIP by gene trapping276 and by its binding to the 
SH3 domain of growth factor receptor-bound protein 2 (Grb2)277, to the protein-tyrosine 
binding (PTB) domain of SH2-containing sequence protein (Shc)277-279 and to the IgG Fc 
receptor, FcγRIIB280.  Once identified, SHIP was been found to hydrolyze the 5’ 
phosphate group in inositol-1,3,4,5–tetrakisphosphate (IP4) and in phosphatidylinositol-
3,4,5-phosphate (PIP3)279.  IP4, a soluble phosphoinositide, regulates store-operated 
Ca2+ channels in lymphocytes281.  In modulating PIP3 levels, SHIP regulates the activity 
of signaling molecules, such as Tec kinases, Akt and PLCγ, downstream of 
phosphoinositide 3-kinase (PI3K), which in turn modulates several cellular pathways that 
drive proliferation, differentiation, apoptosis and migration282.  Because the expression of 
SHIP is shared by most hematopoietic cells277-279, 283, its role in modulating immune 
function and hematopoiesis has been extensively studied.  The structure of SHIP, the 
factors that influence its activity and its role in T cells and myeloid cells specifically are 
reviewed below. 
  
SHIP Structure and Functional Domains.  In addition to the enzymatic domain, 
the 5’ inositol phosphatase located at its core, SHIP’s contains other regions, such as an 
SH2 domain in its animo terminus, and several NPXY and polyproline rich motifs in its 
carboxyl terminus, that mediate its interaction with a variety of other signaling molecules.   
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SH2 Domain.  The SH2 domain allows SHIP to bind to phosphorylated tyrosine 
residues on activation or inhibitory motifs found on the intracellular tails of several 
receptors such as FcγRIIB on B cells280, Ly49 receptors on NK cells284, and the IgE 
receptor, FcɛRI on mast cells285.  In addition, the SH2 domain allows SHIP to interact 
with Shp-2286, 287, an SH2 domain containing tyrosine phosphatase, Lyn288, a member of 
the Src family of protein tyrosine kinase, and Shc289, the SH2 domain containing 
transforming protein 1, when tyrosine residues within them are phosphorylated.  
Importantly, as a result of these interactions, SHIP becomes localized near the 
membrane and acquires enhanced function290.  The phosphorylated tyrosine residue 
through which SHIP interacts with Shc is the same docking site for Grb2.  Thus, when 
SHIP interacts with Shc via its SH2 domain, it prevents Grb2 from interacting with Shc 
and subsequently, from recruiting other protein complexes that activate the Ras and 
downstream mitogen-activated protein kinase (MAPK) pathways283.  Similarly, the SH2 
domain confers SHIP with a masking function pivotal in its ability to modulate other 
signaling pathways291.   
  
5’ Inositol Phosphatase.  SHIP’s enzymatic domain is pivotal to its ability to 
affect cell signaling.  In order for it to recognize its substrates, the 5’ inositol phosphatase 
requires a phosphate group, PO4, positioned at the D3 location of the inositol ring.  This 
limits its enzymatic activity to the following phosphoinositides, PIP3 and IP4, which are 
converted to PI(3,4)P2 and I(1,3,4)P3, respectively, by SHIP279.  PI3K is responsible for 
the production of PIP3 from PI(4,5)P2292 and inositol 1,4,5-trisphosphate 3-kinases 
(IP3K) is responsible for the production of IP4 from I(1,4,5)P3293.   
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By decreasing PIP3 levels in the cell, SHIP can limit the activation of pathways 
downstream of PI3K, such as AKT, also known as Protein Kinase B (PKB)294.  
Specifically, AKT translocates to the site of PIP3 production, primarily at the plasma 
membrane, via its pleckstrin homology (PH) domain295.  Here, it becomes activated by 
being phosphorylated at Threonine 308 and Serine 473296, 297.  Activated AKT has been 
shown to phosphorylate and thereby inactivate pro-apoptotic proteins, such as BAD, 
which ultimately resulted in the inhibition of the intrinsic pro-apoptotic pathway298.  Thus, 
SHIP activity indirectly leads to decreased proliferation and survival signaling.  In 
addition, PI(3,4)P2 has been shown to trigger qualitatively different PI3K effector 
pathways than those promoted solely by PIP3.  In cells, PI(3,4)P2 has been suggested to 
serve as a secondary messenger resulting in the activation of AP1 and AKT299-301.  Thus, 
it can be said that in certain contexts, SHIP may amplify PI3K signals.   
PIP3 levels dictate the progression of several other signaling pathways.  For 
example, bruton tyrosine kinase (Btk), a Tec family kinase, is another downstream target 
whose membrane localization and activation is inhibited by decreased levels of PIP3.  
This results in decreased levels of PLCγ and a subsequent block in the influx of 
extracellular calcium.  In addition, PLCγ generates the IP3K substrate, I(1,4,5)P3 from 
PI(4,5)P2.  Thus, by indirectly causing a decrease in the IP3K substrate, SHIP limits the 
production of its own substrate, IP4, by IP3K302.  Finally, decreased PIP3 levels have 
also been found to down-regulate gene transcription in myeloid cells mediated by the 
NF-κB pathway303.   
Importantly, recent studies have shown that SHIP’s enzymatic activity can be 
allosterically regulated.  Specifically, SHIP contains a C2 domain which enables it to 
associate with its product PI(3,4)P2.  This association was found to increase SHIP’s 
catalytic activity304.  In addition, cAMP-responsive PKA mediated phosphorylation of 
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SHIP on serine can also enhance SHIP’s enzymatic activity305.  Thus, availability of its 
own product and phosphorylation by PKAs, and perhaps other kinase, may determine 
the potential magnitude of SHIP’s enzymatic activity. 
 
NPXY and PxxP Motifs.  At the carboxyl terminus, SHIP has several NPXY 
motifs where NPXY represents the amino acids, arginine (N), proline (P), any amino acid 
(X), and tyrosine (Y).  When SHIP becomes activated, these motifs are phosphorylated 
at the tyrosine residue forming a binding site for proteins containing PTB domains, such 
as Shc, Dok1 and Dok2289, 306, 307.  The p85 subunit of PI3K can also bind directly to 
these NPXY motifs, suggesting another mode in which SHIP may control PI3K 
signaling308, 309.  Although, studies suggest that the phosphorylation of NPXY motifs does 
not seem to be required for the function of the 5’ inositol phosphatase310.  Finally, 
polyproline rich regions found within the carboxyl terminus, allow for SH3 domain 
containing proteins to interact with SHIP311.    
 
Factors that Dictate SHIP Signaling.  SHIP expression and recruitment, in 
addition to allosteric control, already discussed above, are all important factors dictating 
SHIP’s involvement in cell signaling.  Although expressed in all hematopoietic cells279, 
312, SHIP is differentially expressed in certain cell types313.  In fact, its expression seems 
to contribute to the varying functional activities of cell subsets within specific lineages, 
such as within myeloid and NK cells314, 315.  SHIP expression at the protein level can be 
controlled at multiple levels.  For example, SMAD family transcription factors can induce 
its transcription316, microRNA species317 can target it posttranscriptionally, and 
ubiquitination and subsequent degradation can occur posttranslationally318.  SHIP can 
also be truncated posttranslationally at the C-terminus, which would prevent its 
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recruitment by proteins that bind to its polyproline rich regions319.  In addition, there is an 
intronic promoter within the SHIP gene that allows for the transcription of an 110kDa 
isoform, namely s-SHIP, found to be specifically expressed by stem cells, such as 
hematopoietic stem cells (HSC).  This isoform lacks more than 200 amino acids at the 
amino terminus, thus missing the SH2 domain312. 
Recruitment of SHIP from the cytosol to the plasma membrane where signaling 
occurs, also determines SHIP’s contribution in cell signaling.  PI3K activity and the 
production of PIP3 occur primarily at the plasma membrane.  Phee et al showed that 
when and where SHIP gets recruited to the membrane dictates the extent of its 
phosphatase effects.  Specifically, membrane localization of SHIP, but not 
phosphorylation or receptor tyrosine engagement of SHIP, resulted in a significant 
reduction in the levels of cellular PIP3290.  As mentioned earlier, SHIP contains functional 
elements, SH2 domains, NPXY motif and polyproline rich regions, that facilitate its 
recruitment291.  Adapter proteins such as Shc, Grb2 and Dok3, and scaffold proteins 
such as Gab1 and Gab2 have been found to associate with these structural elements 
and recruit SHIP to sites of cell signaling279, 312, 320-323.  Specifically, SHIP has been 
shown to be recruited directly or by these adaptor and scaffold proteins to the 
intracellular tail of various growth factor receptors and immunological receptors such as 
Fc receptors280, the B cell receptor, T cell receptor, Ly 49 receptors, KLRG1, DAP10, 
DAP12, and 2B4324-330.  Many of these associations require tyrosine phosphorylation / 
activation of SHIP, which as mentioned, was first discovered to occur as a consequence 
of Epo stimulation275.  In fact, phosphorylation of SHIP is promoted following stimulation 
with other various cytokines including GM-CSF, G-CSF, Flt3-L, IL-3, IL-4, IL-2 and 
stromal cell derived factor-1 (SDF-1), among others279, 289, 331-335.  Finally, SHIP’s 
recruitment may also serve to compete with the recruitment of other key signaling 
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proteins, as seen in NK cells where SHIP prevented the recruitment of SHP1 to 2B4336.  
Furthermore, SHIP was also found to prevent the recruitment of PI3K to DAP10 and 
DAP12 on immune receptors330.   
 
Murine Models of SHIP-Deficiency.  Several SHIP-deficient mouse models 
have been engineered that differ in the specific portion of the protein being deleted337, 338, 
and in where, meaning specific tissue or cell type339, 340, or when, as accomplished in 
inducible models341, SHIP-deficiency is achieved.  These mouse models have helped 
elucidate the role SHIP plays in hematopoiesis.  Mice with germline SHIP-deficiency are 
viable337.  Though, many abnormalities manifest as the mice develop, including hyper-
responsive degranulation in mast cells342, a reduction in CD8+ T cells337, a disrupted NK 
cell repertoire325 and myeloproliferation343, 344, which results in the expansion of the 
myeloid compartment in the BM and peripheral lymphoid organs.  The myeloid cells in 
the periphery have also been found to be immunosuppressive345, similar to MDSC found 
in tumor-bearing mice.  This, in combination with the disrupted NK cell repertoire, 
provides the SHIP-deficient mouse with protection against GvHD and with the ability to 
accept a BMT from a completely allogeneic donor325, 341, 345.  Though, if allowed to 
progress, this myeloproliferation has detrimental consequences that lead to 
consolidation of the lung due to macrophage infiltration and ultimately to death at 6-10 
weeks of age337.   
 Several mouse models of SHIP-deficiency were used in the studies presented 
here.  Specifically, two different germline models, one inducible model and two different 
cell lineage, namely T cell346 and myeloid cell347, specific models of SHIP-deficiency 
were used.  All models employed site-specific recombinase technology to mediate the 
functional deletion of SHIP325.  Specifically, short DNA sequences called loxP sites are 
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inserted to flank, also termed as flox, the targeted nucleotide sequence.  LoxP sites are 
recognized by Cre recombinase, which mediates the excision of the intervening DNA 
and recombination of the remaining DNA348.  In one of the germline SHIP-deficient 
models indicated throughout as SHIP-/-, the promoter and first exon of the SHIP gene 
were floxed325, while in the other germline model indicated as SHIPΔIP/ΔIP, the exons 
encoding the enzymatic domain were floxed340.  Embryonic stem cells that had the 
floxed gene properly integrated, namely SHIPflox/flox ES cells, were transiently transfected 
to express Cre recombinase thus resulting in the deletion of the floxed genomic 
sequence.  These ES cells were then used to generate chimeric mice, which were then 
backcrossed to achieve germline transmission of SHIP-deficiency in the entire mouse325.   
In addition, SHIPflox/flox ES cells were used to generate mice that would allow for 
the targeted deletion of SHIP induced at any given time during development or in a given 
cell type, specifically T cells339 and myeloid cells347, depending on the promoter used to 
drive the expression of Cre recombinase.  In order to achieve the inducible model of 
SHIP deletion, SHIPflox/flox mice were crossed with MxCre transgenic mice, which have 
the Mx1 promoter driving Cre recombinase expression, thus generating the 
MxCreSHIPflox/flox mouse341.  The Mx1 promoter, usually inactive in healthy mice, 
becomes active in virtually all cells, notably in hematopoietic cells, upon elevated levels 
of interferon (INF).  This can be induced by administering polyinosinic-polycytidylic acid 
(polyI/C) injections.  In other words, upon polyI/C injections, interferon levels increase 
activating the Mx1 promoter and expression of Cre recombinase that then excises the 
floxed sequence349, resulting in the deletion of SHIP.  In order to achieve T cell specific 
SHIP deletion, SHIPflox/flox mice were crossed with LckCre transgenic mice to generate 
LckCreSHIPflox/flox mice.  In these mice, the expression of Cre recombinase is controlled 
by the Lck promoter, which is active from the earlier stages of T cell development346.  
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The myeloid specific SHIP-deficiency mouse model was generated similarly by using 
instead the LysCre transgenic mice347.  The Lys (M lysozyme) promoter is exclusively 
active in cells of the myeloid lineage such as monocytes/MΦ and neutrophils. 
 
SHIP and the Hematopoietic Compartment.  As can be appreciated in the 
overall phenotype of SHIP-deficient mouse model, SHIP plays a significant role in the 
development and function of the hematopoietic compartment.  Further detailed studies 
have shown that SHIP contributes significantly to cell signaling within virtually every 
hematopoietic cell including HSC, B cells, NK cells, T cells, myeloid cells, neutrophils, 
basophils, mast cells and eosinophils291.  Important to the work presented here is SHIP’s 
role in T cells and myeloid cells, as discussed specifically below.   
 
SHIP in T Cells.  The initial studies of SHIP in T cells demonstrated that upon 
TCR engagement, SHIP becomes phosphorylated and associated with Shc289.  Further 
studies using leukemic T cell lines and PBLs provided evidence that SHIP contributes to 
the metabolism of PIP3 and thus can limit the activity of effectors downstream of PI3K350.  
SHIP was also found to interact with Tec, a member of the Tec family of protein-tyrosine 
kinases.  Tec localizes to the membrane by the PI3K product, PIP3, and mediates PLCγ 
activation upon TCR engagement.  By interacting with Tec, SHIP functionally inactivates 
Tec by dephosphorylating local PIP3 and thereby preventing its recruitment to the 
membrane351.  Another study showed that SHIP is recruited to the killer cell lectin-like 
receptor G1 (KLRG1) expressed on specific subset of T cells and NK cells.  Importantly, 
KLRG1 engagement was found to inhibit sub-optimal TCR signaling, which required its 
association with SHIP as well as SHP2327.  Finally, upon TCR stimulation, SHIP has also 
been shown to associate with a multimolecular complex including downstream of kinase 
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1 (Dok1), Dok2, Grb2 and linker for activation of T cells (LAT), a membrane signaling 
scaffold protein.  Notably, SHIP was required for the recruitment of Dok2 to this complex, 
which is critical in attenuating early TCR signals324.  These in vitro studies suggest that 
SHIP could alter signals emanating from the TCR that may ultimately affect the 
development and function of T cells.   
In vivo studies have provided further insight into SHIP’s role in T cell signaling.  
Importantly, in SHIP-deficient mice, both germline and T cell specific, autoimmunity or 
neoplasm involving the T cell compartment have not been observed.  In fact, the 
frequency of T cells is normal or reduced in these SHIP-deficient mice325, 340, 344.  
Furthermore, T cells isolated from the periphery of SHIP-deficient mice displayed 
reduced antigen specific IFN-γ production352, thus pointing to defective, not hyperactive, 
TCR signaling in SHIP-deficient T cells.  Also, reduced levels of SHIP expression is not 
commonly observed in cancer T cell lines, with the exception of Jurkat cells350 as well as 
most T-ALL cancer cases353.  Other cancer T cell lines exhibit phosphorylated SHIP, 
indicating its active participation in cell signaling350.   
Although it is not yet clear what role SHIP plays in modulating TCR signaling, it 
has become evident, by using mouse models of SHIP-deficiency, that SHIP plays a 
prominent role in the function, differentiation and accumulation of T cell subsets.  Studies 
using T cell specific SHIP-deficient mice showed a direct role for SHIP in TH1, TH2, and 
CD8+ T cell functions.  Specifically, based on cytokine production and response to 
infection, TH2 responses were compromised while TH1 responses were normal or slightly 
enhanced.  Intriguingly, the cytolytic response by CD8+ T cells was more potent, possibly 
due to enhanced TH1 support promoted by T cell specific SHIP-deficiency339.  As shown 
by Kashiwada et al, SHIP-deficient mice exhibited an increased frequency of Tregs in 
peripheral tissues with normal in vitro suppressive capacity354.  Subsequently, in vitro 
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studies performed by Locke et al suggest that SHIP skews T cell differentiation towards 
TH17 cells versus Tregs355.  The studies herein further examine the role of SHIP in the 
accumulation and suppressive function of Tregs.   
 
SHIP in Myeloid Cells.  SHIP also plays a critical role in regulating the myeloid 
compartment as simply demonstrated by the significant expansion of myeloid cells in the 
SPL, LN and BM of SHIP-deficient mice.  Although this myeloproliferative syndrome 
does not develop into myeloid leukemia, it is thought to be significantly responsible for 
the consolidation of the lungs in SHIP-deficient mice344.  This myeloid expansion is 
thought to be initiated by microenvironment cells, such as osteoblasts, that produce 
excessive amounts of myelopoietic growth factors, such as G-CSF.  Consistently, 
osteoblasts exhibit defective maturation and G-CSF serum levels are increased by 400-
500% in SHIP-deficient mice356.   
 Several groups examining SHIP’s role in modulating the myeloid compartment 
have found conflicting evidence showing that SHIP can promote and repress effector 
functions.  For example, one study found that SHIP represses phagocytosis initiated by 
the Fcγ receptor and complement receptor signaling357, while another study found that 
SHIP can promote phagosome maturation via PIP2 production301.  SHIP has also been 
described as limiting the production of inflammatory cytokines and superoxide in 
oxidative burst358.  Conversely, SHIP’s product has been shown to promote oxidative 
burst by increasing early NADPH oxidase activity, which results in the generation of 
ROS359.  This contradictory data has been obtained from studies performed primarily ex 
vivo on myeloid cells from SHIP-deficient mice.  Thus, further in vivo studies may 
provide more definitive answers, especially if utilizing myeloid specific SHIP-deficient 
mice291.   
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Importantly, both in vitro and in vivo data has been obtained showing that SHIP 
promotes the effector function of osteoclasts, which are mature tissue MΦ that mediate 
bone remodeling by engulfing bone forming osteoblasts.  Consequently, SHIP-deficient 
mice are osteoporetic338.  In addition, the use of myeloid specific SHIP-deficient mice 
has clearly shown that SHIP is required for the development of marginal zone MΦ in 
vivo340.  Finally, in vivo data has shown that SHIP, whose upregulation is induced by 
LPS, is critical for endotoxin tolerance mediated by MΦ and their production of TGFβ314.  
Furthermore, SHIP expression in MΦ is also induced by TGFβ in a SMAD-4 
independent manner, which along with endotoxin-mediated SHIP induction, can further 
amplify SHIP signaling during intense immune responses291, 360. 
Most important to the studies discussed herein is SHIP’s role in limiting the 
accumulation of immunosuppressive myeloid cells, which will also be referred to as 
MDSC from here on.  As mentioned before, these MDSC are thought to largely 
contribute to the ability of SHIP-deficient mouse to accept an allogeneic BMT while being 
protected from GvHD325, 341, 345.  The mechanism by which this MDSC accumulation 
occurs is still not fully understood.  This is further investigated in the studies described in 
the following chapters.    
 
 
 
The Role of Tumor Suppressor, Rb, in Regulating the Immune System 
 
Discovery of Rb.  The retinoblastoma gene (Rb1), one of the first genes 
identified as a tumor suppressor gene361, was initially described as the human genetic 
locus that predisposes to retinoblastoma362, a name first coined by Verhoeff et al in 1926 
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and adopted by the American Ophthalmological Society to denote the malignant 
childhood ocular tumor363.  As early as 1973, the existence of regulatory genes was 
proposed, now known as tumor suppressor genes, which were responsible for actively 
inhibiting transforming genes (potential oncogenes) that when active, promote cell 
growth.  Thus, when the regulatory gene was inactivated, suppression was released and 
subsequent cellular transformation could ensue364.  Rb1 was proposed and later 
validated to be such a regulatory gene.  Furthermore, the onset of retinoblastoma 
required the inactivation of both Rb1 alleles, first described by the Knudson’s two-hit 
hypothesis365, 366.  This hypothesis also explained the difference between the hereditary 
and non-hereditary forms of retinoblastoma where the inheritance of a germline mutation 
in one of the Rb1 alleles dictated the severity of the disease.  Specifically, children that 
are affected by unifocal retinoblastoma do not carry an Rb1 germline mutation, meaning 
that they do not inherit this mutation from one of their parents.  On the other hand, 
children with multifocal and bilateral retinoblastoma did inherit a germline mutation in 
one of the Rb1 alleles361.  In addition, children with Rb1 germline mutations are 
predominantly afflicted with retinoblastoma at a very early age and are predisposed to 
develop osteosarcoma, melanoma or soft tissue sarcoma later in life367, 368.   
Once discovered to reside on chromosome 13q 14369, further investigation into 
the function and activity of Rb1 gene revealed that it was expressed in most tissues and 
underwent inactivation by loss of heterozygosity in many other cancers370.  In fact, the 
majority of studied human cancers, including breast371, bladder372, prostate373 and small 
cell lung carcinoma374, exhibit Rb1 inactivation either directly with mutations in the Rb1 
locus or indirectly with mutations affecting other proteins that regulate Rb1 cellular 
function.   
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Rb Structure and Functional Domains.  The retinoblastoma gene encodes a 
phosphoprotein involved in numerous cellular processes, such as differentiation, 
apoptosis, cell cycle progression and as appreciated recently, DNA repair and cell cycle 
checkpoints375.  Although cells contain two copies of the Rb1 gene, only one normal 
copy is needed to accomplish its function376, 377.  The human Rb1 locus spans about 200 
kilobases (kb) of genomic DNA, consisting of 27 exons from which a 4.8 kb mRNA 
species is transcribed378.  The translated product in humans is a 928-amino acid (aa) 
protein; while in mice, Rb1 is 921 aa long with 91% homology to human Rb1379.  The 
Rb1 protein consists of three distinct regions: the N-terminus, the central A/B “pocket” 
made of an A and B domain separated by a spacer, and the C-terminus.  The Rb1 gene 
is a member of the Rb gene family along with two other members, p107 and Rb2/p130.  
All Rb gene family members are collectively known as ‘pocket proteins’ because they all 
share resemblance in the A/B pocket domain.  Although in some instances, they play 
somewhat compensatory roles in the cell, they do differ in several aspects375.   
In order for Rb family members to associate with most of its binding partners, it is 
critical that the A/B pocket be structurally intact380.  Numerous cellular and viral proteins 
harbor an LXCXE motif that allows them to bind to an LXCXE binding site within the A/B 
pocket.  The LXCXE motif (where the L is leucine, C is cysteine, E is glutamine and X is 
any amino acid) was initially described in viral oncoproteins as critical for their interaction 
with Rb1381.  Examples of Rb1-binding viral oncoproteins are the SV40 large-T 
antigen382, the adenovirus EIA protein383, and the human papilloma virus E7 protein384.  
The most documented activity of Rb family proteins is their interaction and repression of 
E2F family of transcription factors which contributes to Rb –mediated control over cell 
cycle progression and survival.  Though E2F proteins do not possess any LXCXE 
domains, their interaction with Rb family proteins is also dependent on the A/B pocket 
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along with a portion of the C-terminus385.  Other Rb-binding partners known to interact 
with Rb family proteins via the LXCXE binding site within the pocket domain are D-type 
cyclins386, histone deacetylases (HDAC)-1, -2 and -3 recruited by the Rb-binding protein 
(RBP1)387, 388, BRG1 of the human SWI/SNF chromatic-remodeling complexes389, the 
polycomb group (PcG) protein HPC2390, the histone methyltransferase Suv39H1391, and 
the CtIP/CtBP transcriptional corepressor complex392, among others.  Some of these 
binding partners, such as the D-type cyclins and HDACs, also require a portion of the C-
terminus to form a stable complex393.  Importantly, Rb family proteins bind E2F proteins 
and several other binding partners concurrently since the binding sites are distinct from 
each other.  In fact, transcriptional repression of E2F target genes requires this 
simultaneous interaction with E2F and the other Rb-binding partners just mentioned394.   
As mentioned, Rb1/p105, p107 and Rb2/p130 are all part of the Rb gene family.  
Rb2/p130 and p107 share 50% amino-acid homology, thus being more related to each 
other than they are to Rb1, which shares 30-35% homology.  Functionally important, the 
length of the C-terminus differs among Rb family members.  The C-terminus contains 
the nuclear localization signal (NLS) which controls the transport of Rb into the nucleus 
from the cytoplasm and also works as a carrier for E2F proteins.  As mentioned, the C-
terminus is also required for the binding of HDAC1 and cyclin/cdk complexes394.  
Although many studies show that these proteins serve partially compensatory roles in 
several instances, the use of murine models deficient in one or more of the Rb gene 
family members has exhibited different phenotypes demonstrating that this functional 
redundancy is not absolute.  Their expression differs with cell status, specifically if 
quiescent, differentiated or proliferating.  Their binding ability to E2F family members and 
to cyclin/cdk complexes, which fluctuates throughout the cell cycle, also differs.  Analysis 
of cells deficient in the RB gene family members demonstrated that Rb and p107/p130 
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regulate different E2F target proteins.  Specifically, p107/p130 deficiency promoted the 
deregulation of a much larger set of E2F target genes compared to Rb1.  DNA 
microarray analysis has provided evidence suggesting that Rb1 regulates genes 
encoding DNA replication and cell cycle regulatory proteins, while p107/p130 regulate 
genes encoding proteins involved in cell growth and maintenance of the extracellular 
matrix and its signaling activities395.  In addition, the Rb family members differ in their 
ability to elicit cell cycle arrest in specific cell types.  Finally, they differ in their specific 
involvement in regulating differentiation and apoptosis, which also seems to depend on 
cell type375.  Importantly, the literature reviewed below pertains specifically to Rb1 and 
not the other family members, unless otherwise noted specifically.   
 
Regulation of Rb Expression and Activation.  Various mechanisms and 
proteins have been described to regulate Rb1 expression at the transcriptional level.  
Firstly, several transcription factors, such as p16INK4A, BRCA1, ICBP90, and YY1 have 
been found to regulate Rb1 transcription.  One group showed that Rb1 mRNA levels 
were much higher in cell lines that lacked p16INK4A expression.  The reestablishment of 
p16INK4A expression using an adenovirus vector resulted in a significant reduction in Rb 
mRNA levels396.  BRCA1 also inhibits the expression of Rb1 and Rb family proteins.  
Interestingly, in order to mediate this transcriptional regulation of Rb, BRCA1 requires a 
functional LXCXE motif, allowing it to be in complex with Rb.  Thus, Rb regulates its own 
transcription in this context397.  ICBP90 (inverted CCAAT box binding protein of 90kDa), 
a transcriptional regulator of the topoisomerase II alpha gene, is also a negative 
regulator of Rb expression398.  When overexpressed in lung fibroblasts, ICBP90 was 
found to down-regulate Rb mRNA levels with an increase in S and G2/M-phase cells 
fractions.  ICBP90 was shown to bind to the Rb gene promoter when methylated399.  
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Finally, YY1, a polycomb group protein and transcription factor associated with both 
positive and negative transcriptional regulation as well as initiation of transcription, has 
been shown to act as a repressor of Rb expression during myogenesis.  Specifically, 
YY1 is present on the Rb promoter with GABP, a GA-binding transcription factor.  Upon 
signals to differentiate, YY1 leaves the Rb promoter, while GABP along with the cofactor 
HCF-1, a chromatin associated heterodimeric complex, stays and activates Rb 
expression400.  The Rb promoter also contains binding sites for two nuclear 
transcriptional factors, ATF and SP1, that regulate Rb expression and have been found 
to be mutated in hereditary retinoblastoma401, 402.   
Additionally, several studies suggest that Rb itself, Rb family members and other 
upstream member of the Rb pathway autoregulate Rb transcription.  For example, the 
Rb promoter has an E2F binding site that when methylated, has been shown to recruit 
repressor complexes and down-regulate Rb transcription403.  Furthermore, when 
overexpressed, E2F1 can activate Rb expression in some contexts404.  Also, in cells that 
exhibit functional inactivation of Rb by phosphorylation, researchers have observed 
increased levels of Rb protein405.  Another study showed that overexpression of Rb in 
P19 cells resulted in repression of an Rb reporter406.  Because p107 and p130 also 
interact with E2F proteins, they may also regulate the Rb promoter.  In fact, loss of p107 
in mouse embryos has been shown to lead to an increase in Rb expression, although 
the exact mechanism is unclear407.  More recently, Burkhart et al showed in various 
murine organs and tissues that Rb transcription is indeed regulated in vivo by members 
of the Rb and E2F families.  Interestingly, they found that unlike other classical gene 
targets of E2F, Rb expression was not always upregulated during cell cycle 
progression408.   
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Regulation of Rb activation is achieved posttranslationally in a cell-cycle 
dependent manner where gradual phosphorylation, mediated primarily by cdks370, 
inactivates it.  The hypophosphorylated Rb form is active, capable of binding E2F and 
thereby preventing cell cycle entry.  Specifically, D-type cyclins coupled with cdk4 or 
cdk6 have been shown to phosphorylate Rb during early G1 phase.  In late G1 phase, 
cyclin E and A in complex with cdk2 further phosphorylate and thereby inactivate Rb409, 
leading to the disassociation of E2F factors.  Rb remains hyperphosphorylated until late 
mitosis410.  Phosphorylation, which can be reversed, occurs both on the A/B pocket and 
on the C-terminus394.  In some instances, phosphorylation can expose a proteolytic 
cleavage site within Rb that can ultimately lead to its degradation411.  Rb has also been 
shown to undergo other post-translational modifications, such as acetylation412, 
sumoylation413, ubiquitination414 and methylation415 in response to varying cell signals.  
These modifications alter the protein levels of Rb, as well as its ability to interact with its 
binding proteins. 
 
Rb Signaling Pathways.  As mentioned above, Rb1 plays a role in several 
cellular processes, such as regulating cell cycle entry, promoting and maintaining 
differentiation, protecting from cell death and maintaining genomic integrity.   
 
Rb and the Cell Cycle.  The cell cycle is a tightly orchestrated process in which 
cyclin/cdk complexes play distinct roles during each phase by phosphorylating specific 
target proteins in a coordinated manner that allows for cell cycle progression.  
Importantly, cyclin expression and cdk activity fluctuates throughout the cell cycle.  
Specifically, cyclins D and E mediate progression through G1/S phases, while cyclins A 
and B mediate progression through the S/G2/M phases.  The expression of cyclin D is 
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rapidly induced by mitogens.  With sustained mitogenic stimuli, cyclin D/cdk activity 
persists through the first and subsequent cycles.  Cyclin E protein levels peak at the 
G1/S transition followed by an increase in cyclin A protein levels in S phase.  At the 
G2/M boundary, cyclin B protein levels increase, thereby activating its partner, cdk1394.   
Normally, upon mitogenic stimuli, a cell decides to proceed through and complete 
the cell cycle only during a specific phase of its cycle known as the ‘‘restriction point’’, 
which is between early G1 phase and G1/S phase.  Once past this ‘‘restriction point’’, 
cells become committed to DNA synthesis and subsequent cell division.  Many studies 
have demonstrated that Rb1 functions as the ‘restriction point’ switch416.  Specifically, 
one study showed that purified unphosphorylated Rb1 protein microinjected into cells 
during early G1 phase, caused reversible G1 arrest.  When injected during late G1 
phase of early S phase, Rb1 protein had no impact417.  In resting G0 cells, the actively 
growth-suppressing hypophosphorylated Rb1 is predominate, capable of repressing E2F 
transcriptional activity.  Rb proteins repress gene transcription by directly binding to the 
transactivation domain of E2F or by binding to the promoter of these regulated genes in 
complex with E2F and other proteins such as HDAC, SWI/SNK factors, polycomb group 
proteins or methyltransferases.  As mentioned above, when the cell progresses through 
G1 phase, Rb1 is increasingly phosphorylated by cyclin/cdk complexes thereby no 
longer capable of binding to E2F and repressing the transcription of E2F target gene 
necessary for S phase progression394.   
There are six E2F family members that can be divided into two classes: 
activators (E2F1, E2F2, E2F3) and repressors (E2F4 and E2F5) of transcription416.  
E2F6 has been found to behave as a transcriptional repressor in an Rb-independent 
manner.  Thus, it is considered independent and lacks several functional domains, such 
as the Rb-binding domain and the trans-activation domain418.  Rb1 binds preferentially to 
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activator-E2Fs, while p130 binds to repressor-E2Fs and p107 only binds to E2F4, 
preferentially419.  These proteins complexes exhibit precise expression patterns 
throughout the cell cycle with the Rb1/E2F complex being present in G1 phase, the 
p130/E2F complex being most evident in quiescent cells and the p107/E2F complex 
being detected in both G1 and S phase416.   
Rb proteins can also regulate transcriptional repression and cell cycle 
progression through E2F independent mechanisms.  For example, Rb1 mutants not 
capable of binding E2F promoted the formation of promyelocytic leukemia (PML) nuclear 
bodies which led to transcriptional repression and was associated with entry into 
senescence, particularly in Soas-2 cells420.  In addition, hLin-9 was also shown to 
cooperate with Rb1 to induce senescence is Soas-2 cells and promote Rb1-dependent 
transcriptional activation regardless of its ability to bind E2F421.  Rb1 has also been 
shown to mediate cell cycle arrest by increasing the expression and stabilization of the 
cdk inhibitor (CKI) p27.  By using timed Rb1 expression experiments, researchers found 
that the effects of E2F repression lagged behind the onset of G1 cell cycle arrest.  
Instead, p27 was found to accumulate much faster.  Furthermore, disruption of p27 
function or expression prevented Rb1 from causing G1 arrest.  Non-E2F binding Rb1 
mutants were capable of increasing p27 expression and stability.  Importantly, these Rb1 
mutants were also equally capable of causing G1 cell cycle arrest as WT Rb1422.    
Finally, more recent studies have demonstrated that control of cell cycle 
progression mediate by Rb1 is not limited to the ‘restriction point’ between early G1 
phase and G1/S phase.  For example, Rb family members have been shown to also 
regulate the earlier transition from G0 to G1423.  During G0, hypophosphorylated Rb1 
promotes low levels of RNA, characteristic of the G0 state, by inhibiting the expression 
of ribosomal and transfer RNA394.  Exit of G0 and increase in RNA content is mediated 
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by the cyclin C/cdk3 complex that, in turn, phosphorylates Rb1.  Consistently, cyclin C 
expression precedes that of cyclin D424.  Another example comes from Mukherjee et al 
which demonstrated that Rb1 also functions to prohibit cell cycle progression during late 
G1.  This process requires treatment with TGFβ, a potent inhibitor of cell proliferation, 
during late G1 (presumably past the ‘restriction point’) and does not involve inhibition of 
cyclin/cdk complexes.  Instead, Rb1 mediates TGFβ arrest by directly targeting the 
activity of the minichromosome maintenance (MCM) helicase and thereby inhibiting the 
activation of the prereplication complex and initiation of DNA replication (the G1/S 
transition)425. 
  
Rb and Differentiation.  Embryos deficient in Rb1 die between gestation days 
13 and 15 making it evident that Rb1 plays a role in development and differentiation426.  
Put simply, Rb proteins remove specific blocks set at certain stages of development to 
ensure the proper timing of differentiation.  The role of Rb proteins in differentiation has 
been found to be highly dependent on tissue type while involving cell specific factors.  A 
role for Rb proteins in development and differentiation has been established in several 
tissue types, including neuronal tissue, skeletal muscle, adipose tissue, and retina.  Rb 
proteins also a role in the development of cells of the hematopoietic compartment, which 
is discussed further in its own subsection416.   
Rb knockout mice display defects in differentiation of neuronal cells and 
erythrocytes.  These defects are, in part, promoted by the unrestricted activity of the 
inhibitor of differentiation Id2, a target of Rb that is required to maintain the proper 
sequencing in differentiation and that positively regulates cell cycle progression427.  Rb 
interacts with and sequesters Id2, thereby preventing its activity428.  This is supported by 
the fact that Id2 deficiency rescues Rb knockout embryos from these defects, prolonging 
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their life span395.  Rb deficiency causes abnormal mitosis and apoptosis in the 
intermediate zones of developing neural tubes, and decreased expression of several 
neuronal markers.  It can be concluded that Rb is critical following commitment to a 
neuronal fate416.  Interestingly, extraembryonic tissues of the placenta exhibit extensive 
apoptosis making it possible that the defects seen in Rb -/- embryos could be due to 
functions external to the developing embryo.  In fact, the presence of a normal placenta 
allows Rb-/- embryos to reach full term, at which time they instead die from severe 
skeletomuscular issues429.  Recently, a mouse model with conditional Rb deficiency 
specifically in the cerebrum demonstrated the Rb does play a cell-autonomous role in 
neuronal migration430. 
RB mRNA and protein levels have been found to increase during muscular 
differentiation431.  Rb has been found to enhance the activity of MyoD, a transcription 
factor important in suppressing cell cycle progression and in promoting differentiation in 
muscles.  In fact, the transcription of certain myogenic genes promoted by MyoD also 
requires functional Rb432.  Also, Rb inactivation inhibits myoblast and myotube 
differentiation in culture.  Further studies have been able to tease apart the molecular 
mechanism underlying the exact role Rb plays during myogenesis.  Specifically, studies 
performed by Delehouzee et al led them to propose a model where transcription factors 
GABP, YY1, and HCF-1, described above, all work in concert to promote the 
upregulation of Rb expression at day 2 of myogenesis400.  Using mouse models where 
Rb is deleted before or after myogenic differentiation support this model.  If Rb is deleted 
in myoblasts as achieved with Myf5CreRbflox/flox mice, the mice die at birth exhibiting 
extensive apoptosis and the absence of myofibers.  In contrast, MCKCreRbflox/flox mice 
that have Rb deleted in differentiated fibers were viable with normal muscle 
development.  Thus, in muscles, Rb is vital for the initiation and progression, but not for 
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the maintenance, of the differentiated state433.  Different results are obtained when 
looking at Rb conditionally deleted in hair cells, demonstrating that the exact role and 
requirement of Rb during differentiation is dependent on cell or tissue type434.   
There are two major cell types with distinct functions that arise from adipocyte 
precursor cells; namely, white adipose, which stores energy, and brown adipose, which 
releases energy via thermogenesis416.  In adipogenesis, the Rb family members have 
been found to play opposing roles.  Rb1-deficient MEFs do not convert into adipocytes 
upon proper treatment with inducers known to be adipogenic, thus having defective 
differentiation potential435.  With PPAR-gamma ligand treatment, Rb1-deficient MEFs 
preferentially differentiated into white adipocytes436.  Though, when Rb1 is deleted in 
adult primary preadipocytes, their differentiation into white adipocytes is inhibited437.  
Conversely, MEFs deficient in p130 or p107 have an increased potential for 
differentiation438.  Furthermore, in p107 deficient mice, a replacement of white adipose 
tissue with brown adipose tissue has been observed437.  These studies suggest that Rb 
family members mediate the determination between brown or white adipocyte 
differentiation416. 
The retina consists of several different cell types present in proper proportions to 
each other and arranged specifically to dictate the overall size of the retina and 
ultimately, the quality of vision achieved.  This functional arrangement is mediated by the 
precise coordination of cell cycle exit and cell fate specification; which when uncoupled, 
result in vision obstruction and tumor formation, as seen in retinoblastoma416.  
Specifically, Rb1 deficiency promotes ectopic cell proliferation in the retina made even 
more severe when in combination with p107 deficiency439.  Studies suggest that Rb1-
deficient retinal precursor cells are incapable of undergoing terminal differentiation and 
this is what leads to oncogenic transformation.  Though, Rb1-deficient retinal cells are 
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also prone to growth arrest and thus must escape this propensity to develop into 
retinoblastoma440.  In addition, the role that Rb1 plays is different among the cell types 
composing the retina.  For example, in proliferating retinal progenitor cells, Rb1 
mediates cell cycle exit; while in differentiating rod photoreceptors, Rb1 is necessary for 
proper maturation441.  Also, in lens progenitor cells, Rb1 was found to interact with Pax6, 
a regulatory factor critical in the formation of the lens442 and active in peripheral retinal 
progenitors at embryonic day 10.  With Pax6 deficiency during retinal development, Rb1 
becomes inactivated and thereby causing a decrease in ganglion and bipolar cells416. 
  
Rb and Apoptosis.  Aside from their ability to induce expression of genes 
associated to cell-cycle progression, the E2F family of transcription factors also controls 
the expression of pro-apoptotic genes.  In repressing E2F-target genes, Rb1 can thus, 
also block E2F-induced apoptosis443.  Although, studies have shown that this depends of 
the type of apoptotic stimuli444.  To illustrate its role in apoptosis, embryos deficient in 
Rb1 display widespread cell death in cells of the central nervous system (CNS).  This 
can be mitigated by mutations in p53 and E2F1 which allow for prenatal development 
but that do not save the fetus from dying shortly after birth due to extensive apoptosis in 
skeletal muscles445.  Dysfunctional Rb1 promotes the accumulation of p53 and 
subsequently the induction of apoptosis by p53.  Specifically, with increased E2F1 
activity, the expression of p19ARF is increased which in turn prevents MDM2, a p53 
ubiquitin ligase, from degrading p53446, 447.  In addition, E2F1 and p53 both control the 
expression of Apaf-1, a component of the apoptosome and a player in the pathway 
activating mitochondria-dependent apoptosis.  Deletion of Apaf-1448 and caspase-3449 
rescues the CNS and peripheral nervous system, respectively, from apoptosis in Rb1-
deficient embryos, thus demonstrating that apoptosis mediated by the absence of Rb1 
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requires the apoptotic machinery.  Interestingly, Rb1 contains several caspase-3 
cleavage consensus sites which enhance its degradation upon transduction of the 
apoptotic signal450.  In fact, in mice, the use of a caspase-resistant Rb1 mutant 
repressed apoptosis promoted by the type I tumor necrosis factor (TNF)-α receptor but 
not by the TNF receptor type II, whose expression is limited to the cells of the 
hematopoietic compartment451.  This provides yet another example of how Rb functions 
differently in specific tissues.  Rb1 has also been found to bind to and inhibit c-ABL, a 
tyrosine kinase452, and JNK kinase445, which are other pro-apoptotic proteins involved in 
apoptosis induced by stress. 
 
Rb and DNA Repair.  Maintaining the integrity of DNA and achieving its faithful 
replication is vital for all living organisms in order to avoid the onset of impaired cellular 
functions, apoptosis, irreversible growth arrest and cancer.  Inevitably, DNA damage is 
mediated by both exogenous and endogenous sources, such as radiation, chemicals, 
and free radicals generated during metabolism.  Lesions induced by these sources 
include oxidation, deamination, pyrimidine dimerization, depurination, single-strand 
breaks (SSB) and double strand breaks (DSB), this last one being the most harmful375.  
These lesion are known to inhibit transcription and to promote cell cycle arrest and 
apoptosis453.  Accordingly, cells have the ability to deal with DNA damage mediated by 
several repair factors and DNA-repair mechanisms specific to the several types of DNA 
lesions.  In order to employ the DNA-repair machinery, cells must initiate a response 
mechanism that includes halting cell cycle progression in order to provide time for DNA 
repair.  This occurs at specific transition points named “cell cycle checkpoints”375.  
Studies have shown that, as a response to DNA damage, phosphorylation of Rb is 
inhibited and the accumulation of hypophosphorylated Rb is promoted, thereby 
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activating the Rb pathway.  This is thought to be a downstream consequence of the 
p53/p21Cip1 pathway which becomes activated by DNA damage454.  Upon DNA damage, 
Rb has been found to be recruited to certain initiation sites of replication presumably to 
inhibit replication from continuing aberrantly455.  Studies have proposed that one of the 
ways Rb prevents replication is by disrupting the association of PCNA to chromatin456.  
In addition, the expression of several factors involved in DNA damage repair, such as 
PCNA, RPA2-3, and FEN1, among others, is influenced by Rb375.   
Rb has been implicated in the effectiveness of cell cycle checkpoints upon DNA 
damage.  In summary, Rb mediates its contribution to the DNA damage checkpoint 
response by repressing the transcription of E2F-regulated genes, by inducing cell cycle 
arrest in the various phases and by inhibiting the accumulation of DNA DSB mediated by 
E2F1457.  Specific to this last mechanism, if Rb becomes inactivated, E2F1 consequently 
becomes deregulated which promotes the induction of DNA DSB independent of Atm, 
p53, ROS, caspases, and apoptosis458.  The following paragraphs describe how Rb 
induces arrest during each phase of the cell cycle.   
Firstly, let’s consider the G1 checkpoint.  The presence of Rb in transcriptional 
repression complexes and its phosphorylation status serve as a measure for controlling 
G1 exit375.  When DNA damage occurs during G1, it has been shown that the cell cycle 
arrest that follows is mediated by the p53/p21Cip1 pathway, which requires functional Rb.  
In fact, when Rb activity is lost, cells do not engage the G1 checkpoint and do not 
undergo G1 arrest in response to DNA damage regardless of p53/p21Cip1 activation459.  
Loss of p16INK4A or overexpression of cyclin D1 or cdk4, also results in the disablement 
of this checkpoint370.   
In S phase, Rb has been found at sites of DNA replication and involved in 
causing S phase arrest when cells have encountered DNA damaging agents at high 
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doses.  Upon DNA damage during S phase, Rb is dephosphorylated followed by 
complete termination of DNA synthesis, even when cells have already achieved S phase 
DNA content460.  Furthermore, when rendered Rb-deficient, fibroblasts exposed to DNA 
damaging agents undergo hyper-replication and display hyperploidy461.  Because it is 
known to interact with SWI/SNF complexes, Rb may also regulate S phase 
progression375.   
Another checkpoint exists in the G2 phase, allowing for cell cycle arrest in 
response to DNA damage.  Although initiating the G2 phase checkpoint is independent 
of it, Rb has been shown to control the length of G2 arrest.  The duration of G2 arrest is 
critical for allowing the time for DNA repair proportionate to the extent of DNA damage.  
Similar to that seen for G1 arrest, p53/p21Cip1 mediates the accumulation of 
hypophosphorylated active Rb, which in turn maintains G2 arrest462.  In addition, G2 
arrest induced by DNA damage is accompanied with the decreased expression of genes 
required during G2 and M phase, some of which have been shown to be downregulated 
by Rb2/p130 and p107 specifically463.  Inactivation of Rb family members, of the 
p21/WAF1 pathway or of cdks prevents the cell from initiating and sustaining the G2/M 
arrest375. 
 
Murine Models of Rb Deficiency.  Rb1 homologues have been described in 
several vertebrates including sharks, chicken, cats, and mice464.  As mentioned before, 
mouse Rb shares 90% homology with human Rb and Rb deficiency in mice results in 
death in utero between embryonic days 13-15 due to defective neurogenesis and 
erythropoiesis465.  Also, low expression of Rb1 achieved with an Rb1 transgene 
engineered into Rb-/- mice delays death until birth, which is caused by defects in 
muscular differentiation466.  Mice heterogeneous at the Rb locus (Rb+/-) are viable and do 
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not develop retinoblastoma but instead exhibit tumors in the pituitary gland467.  When 
depleted in combination with p107, as seen in chimeric mice generated with Rb and 
p107 deficient ES cells, mice are prone to developing retinoblastoma439.  This suggests 
that in mice, p107 may play a compensatory role when Rb is deleted.  Furthermore, 
chimeric mice generated with Rb and p130 deficient ES cells develop lung 
neuroendocrine hyperplasia, retinoblastoma and pheochromocytoma468.  Mice deficient 
in p107 alone, particularly in a Balb/cJ background, are viable and display increased 
proliferation and apoptosis of neural progenitor cells of the CNS, thickening of long 
bones, growth impairment and myeloproliferative disease469.  Interestingly, on a Balb/cJ 
background, p130 deficiency is lethal at E11-13 with aberrant neural, muscular and 
cardiac development, while on the C57BL/6J background, mice are viable and fertile470.  
Several mouse models lacking the different pocket proteins in combination with other 
important binding partners, all exhibiting varying phenotypes, have also been generated. 
Examples are Rb1 deficiency in combination with deficiency in E2F1, -2, or -3, or Rb1 
deficiency in combination with ARF, Id2, N-ras, K-ras, Casp3 or Apaf1.  In addition, 
mouse models with similar deficiency combinations have been generated where Rb1 
deficiency is instead heterozygous.  Finally, the ability to conditionally ablate Rb1 in 
different tissues has provided greater insight into the role Rb1 plays in different cell 
types; a role which has both cell autonomous and non-cell autonomous aspects to it395.  
 Important to the studies presented here is the MxCreRb1flox/flox mouse model, 
which is functionally similar to that described above for the MxCreSHIPflox/flox mouse 
model.  In short, this model allows for the conditional deletion of Rb1 in cells responsive 
to INF, primarily cells of the hematopoietic system including HSC, upon injection of 
polyI/C, which causes an inflammatory response that includes elevated INF expression.  
Importantly, this can be achieved during adulthood, once development has occurred 
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normally349.  Importantly, In MxCreRbflox/flox mice, when stable Rb1 deletion is achieved, 
the expression of p130 and p107 does not increase in compensation for Rb loss.  
Immediately following Rb1 deletion, MxCreRb1flox/flox rendered Rb1-deficient exhibited a 
mild and stable anemia.  After 4 weeks post-deletion, MxCreRb1flox/flox mice displayed 
pan-leukocytosis with elevated levels of progenitor cells circulating in the peripheral 
blood.  Twelve weeks after deletion, a myeloproliferative-like disease could be observed 
within the BM of MxCreRb1flox/flox mice, characterized by myeloid hyperplasia (mainly 
neutrophilia) while B-lymphopoiesis and erythropoiesis were inhibited.  MxCreRb1flox/flox 
also displayed apparent changes in bone architecture and loss of trabecular bone, an 
important niche for HSCs within the BM.  Consistently, HSCs were lost from the BM with 
extensive extramedullary hematopoiesis occurring in the SPL, which increased 5.5 fold 
in weight in Rb-deleted MxCreRb1flox/flox mice compared to controls471.  The results 
obtained from the use of this mouse model as well as other cell type specific Rb deletion 
models have provided great insight to the role that Rb plays in the hematopoietic system 
which is discussed below. 
 
Rb and the Hematopoietic Compartment.  Cells of the hematopoietic 
compartment are constantly undergoing proliferation, differentiation and apoptosis. Thus, 
it is no surprise that Rb would play a role in such.  Consistently, Rb has been shown to 
interact with several hematopoietic transcription factors, such as NF-IL-6, PU1 and 
ElF1472.  As mentioned briefly earlier, a role Rb in the hematopoietic compartment was 
identified with the initial studies examining Rb-/- embryos which exhibit neural and 
hematopoietic defects, specifically in erythropoiesis395.  Use of chimeric mice provided 
further insight into the fact that Rb also had functions that were not cell-autonomous.  In 
chimeric mice, phenotypically normal peripheral blood erythrocytes were found to be Rb-
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/- while abnormal nucleated erythrocytes were WT473.  Furthermore, studies 
demonstrated that when Rb-/- embryos are supplied by a WT placenta, they survived to 
term without exhibiting the neurological and erythroid defects, suggesting that the many 
defect exhibited by Rb-/- embryos are at least partly due to inadequate placental function.  
Though, these Rb-/- pups still succumbed to death due to severe skeletal muscle 
abnormalities429.  Another more recent study showed that the abnormal erythropoiesis 
was instead mediated by defective fetal liver MΦ.  This study found that Rb opposes the 
inhibitory function of Id2, a transcription factor that regulates differentiation, and thereby 
promotes macrophage differentiation.  In Rb-/- embryos, Id2 is unrestrained in MΦ 
leading to the aberrant erythropoiesis.  In fact, Id2 inactivation in Rb-/- embryos inhibits 
this erythroid defect474.  Although these experiments only point to an extrinsic role for Rb 
in erythropoiesis, other studies have clearly demonstrated that Rb indeed plays an 
intrinsic role as well.  By acutely deleting Rb1 in vitro in erythroblasts, Spike et al showed 
that Rb1 was intrinsically required for proper erythroblast expansion and red cell 
enucleation under stress conditions.  By performing different hematopoietic 
reconstitution experiments using WT, Rb+/-, Rb-/-, or Rb-/- chimeric fetal liver as donor 
tissue, they also demonstrated a cell intrinsic role for Rb in maintaining hematopoietic 
homeostasis475.  Another study showed that Rb also intrinsically controls cell cycle exit 
required for the differentiation of early erythroblasts to late erythroblasts.  Rb deficiency 
was also found to inhibit mitochondrial biogenesis which is coupled to this differentiation 
block476.     
 In addition, Rb has been shown to be involved in the differentiation of progenitor 
cells to cells of the monocytic and neutrophilic lineages.  Specifically, in one study, 
human CD34+ progenitor cells promoted to undergo monocytic differentiation with Flt3-L 
and IL-3, exhibited a high level of hypophosphorylated Rb.  In contrast, when promoted 
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to undergo neutrophilic differentiation with G-CSF and SCF, a low level of 
hypophosphorylated Rb was observed.  Furthermore, CD34+ progenitor cells in liquid 
culture treated with antisense Rb oligonucleotides, which effectively reduced Rb 
expression, were inhibited from differentiating into monocytes, even in the presence of 
Flt3-L and IL-3, and instead preferentially differentiated into neutrophilic cells472.  
Consistently, a more recent study which described the expression levels of cell-cycle 
proteins during granulopoiesis in vivo, found that the expression of Rb and the other two 
pocket proteins was down-regulated from the myelocyte and metamyelocyte stages, 
which represent two neutrophil precursor populations, onward.  There was no detectable 
phosphorylated Rb protein and very little nonphosphorylated Rb protein expressed in 
mature polymorphonuclear neutrophils.  Similar results were obtained for p107 and p130 
expression.  Consistently, the expression of cdks and of cyclin D and A were also 
downregulated in the more mature neutrophil populations477. 
Lastly, the role of Rb in HSC self-renewal, quiescence and multilineage 
differentiation has been extensively studied.  These studies have used conditional Rb 
knockout mouse models.  In one study, whole BM from MxCreRbflox/flox mice was 
transplanted into WT congenic mice and once hematopoietic reconstitution was 
accomplished, Rb was deleted.  The ability of Rb-/- HSCs to contribute to hematopoiesis 
in the peripheral blood and multilineage differentiation was unaffected, except for a mild 
onset of anemia.  When analyzing the BM, for the most part, hematopoiesis was very 
similar between Rb-deficient and Rb-expressing cells.  Only the number of Rb-deficient 
mature B cells per femur was significantly lower.  In addition, the use of serial 
transplantation showed that HSC self-renewal is unaffected by loss of Rb.  Notably, the 
expression of the other pocket proteins, p107 and p130 is not deregulated in HSC 
lacking Rb478.  Another group examined the role Rb played in regulating the relationship 
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between HSC and their BM microenvironment.  When Rb was deleted in MxCreRbflox/flox 
mice during adulthood, the development of myeloproliferative disease was promoted, 
accompanied by hematopoiesis in extramedullary sites.  For example, the SPLs of 
MxCreRbflox/flox mice increased significantly in weight following Rb deletion due to an 
excess of megakaryocytes, erythroid cells and myeloid cells.  In addition, Rb-deleted 
MxCreRbflox/flox mice displayed extensive peripheral mobilization of stem and progenitor 
cells that also exhibited increased differentiation.  Though, these phenotypes were not 
observed when Rb-deficient HSC were in a WT microenvironment or when Rb deletion 
was myeloid-restricted.  Transplantation experiments where myeloid specific Rb-
deficient (LysCreRbflox/flox) mice were donors and MxCreRbflox/flox were recipients 
demonstrated that myeloproliferative disease developed only when Rb1 was deleted in 
myeloid-derived cells and in the microenvironment, while still being expressed in HSC.  
This study suggests that Rb1 regulates HSC homeostasis in an extrinsic manner 
involving the BM microenvironment and its interaction with myeloid cells471.  Though, this 
does not discount the possibility that the other Rb family members may be serving 
compensatory roles.  A more recent study used Rb family triple knockout (TKO) mice in 
which deletion is achieved simultaneously in adulthood.  The collective contribution of 
the Rb pocket proteins to the function and homeostasis of HSCs was examined.  TKO 
mice developed a cell-intrinsic myeloproliferative disease originating from early 
hematopoietic progenitor cells undergoing hyperproliferation and from lymphoid 
progenitors undergoing increased cell death.  TKO HSC displayed enhanced 
mobilization and could not mediate long-term reconstitution of hematopoiesis upon 
transplantation.  Interestingly, the myeloproliferative disease was prevented when a 
single WT allele of p107 was genetically reintroduced.  Using gene expression profiling, 
the researchers showed that TKO hematopoietic progenitor cells exhibited a gene 
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expression profile consistent with preferential myeloid development and decreased 
lymphoid development, as can be observed in TKO mice479.   
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Chapter 2.  Materials and Methods 
 
Mice 
SHIP−/− mice were created previously325 and maintained by intercrossing SHIP+/− 
mice (F10 to the C57BL/6J background).  The creation of SHIPΔIP/ΔIP mice is described in 
Karlsson et al340. SHIP-deficient mice and WT littermates used were between 6 and 9 
weeks of age.  Mice with germline transmission of a SHIPflox allele were previously 
created in our laboratory325 and maintained by intercrossing with SHIPflox/flox mice (F10 to 
the C57BL/6J background).  MxCre transgenic mice (Jackson Laboratory) were 
intercrossed with SHIPflox/flox mice to generate MxCreSHIPflox/flox on a C57BL/6J 
background.  MxCreSHIPflox/flox and SHIPflox/flox littermates were generated by 
intercrossing MxCreSHIPflox/flox and SHIPflox/flox mice.  LysCreSHIPflox/flox, LckCreSHIPflox/flox 
mice and SHIPflox/flox littermates were generated in a similar fashion.  Likewise, MxCre 
transgenic mice and Rb1flox/flox mice (National Cancer Institute) were intercrossed to 
generate MxCreRb1flox/flox and Rb1flox/flox littermates.  Tumor-bearing mice were 
established by injecting 500,000 EL-4 thymoma cells or MC-38 tumor cells 
subcutaneously in the right flank of 6–8 wk old C57BL/6J mice (National Cancer 
Institute).  Rag2−/−γc−/− mice on an H2d background were obtained from Hergen Spits480 
(Netherlands Cancer Institute).  Severe combined immune deficient (SCID) mice 
(C57BL/6J background) were purchased from The Jackson Laboratory.  Studies were 
performed in accordance with the guidelines and approval of the Institutional Animal 
Certification and Use Committee at the University of South Florida. 
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Conditional Deletion of SHIP or Rb1 
SHIP or Rb1 was conditionally deleted in MxCreSHIPflox/flox mice or 
MxCreRb1flox/flox mice, respectively, by intraperitoneal injection of 625μg polyinosinic-
polycytidylic acid (polyI/C; Sigma-Aldrich) on days 0, 3, and 6.  SHIPflox/flox or Rb1flox/flox 
littermates were also injected simultaneously to serve as controls.   
 
Cell Purification 
Whole splenocytes from SHIP−/−, SHIPΔIP/ΔIP, MxCreSHIPflox/flox, and respective 
littermate controls were magnetically enriched for CD3+ T cells using anti–CD3-
phycoerythrin (PE), Miltenyi anti-PE microbeads, and an Automacs (Miltenyi Biotec, 
Auburn, CA) per the manufacturer's instructions.  The positive fraction was stained for 
CD8, CD4, CD25, and viability (4′,6-diamidino-2-phenylindole dihydrochloride [DAPI]), 
then sorted for viable CD3+CD4+CD25−CD8− and CD3+CD4+CD25+CD8− T cells using a 
BD FACS (fluorescence-activated cell sorter) Aria cell sorter.  Population purity was 
more than 95% as determined by post-sort analysis.  Sorted cells were used for Western 
blot analysis, in vitro mixed leukocyte reactions (MLRs), or adoptive transfer.   
Whole splenocytes and BM (BM) cells from naïve (phosphate-buffered saline 
(PBS) treated) mice, and from MC-38 or EL-4 tumor-bearing mice (3-weeks after 
injection) were processed into a single cell suspension.  MC-38 tumors were extracted 
and digested with collagenase D (400U/ml, Roche) to process into a single cell 
suspension.  Splenic and intratumoral (MC-38) MDSC were isolated by staining the 
single cell suspensions with fluorescent antibodies against CD11b and Gr1 and with 
DAPI.  The stained cells were sorted using BD FACSAria cell sorter to isolate viable 
CD11b+Gr1+ and CD11b-Gr1- populations.  Population purity was more than 95% as 
determined by post-sort analysis.  Sorted cells were lysed and the lysates used for 
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Western blot analysis.  MDSC or G-MDSC from EL-4 tumor-bearing mice were 
magnetically isolated from SPL or BM (BM) cells by staining the single cell suspension 
with biotin conjugated antibody specific for either Gr1 (BD Biosciences) for MDSC 
isolation, or Ly6G (Miltenyi Biotec) for G-MDSC isolation.  Labeled cells were then 
subjected to magnetic isolation using Miltenyi anti-biotin microbeads, a MidiMacs 
separator and an LS column (Miltenyi Biotec) per the manufacturer's instructions.  Purity 
of the MDSC or G-MDSC population was more than 90% as determined by flow 
cytometry using an LSRII (BD Biosciences).  Isolated cells were used for Western blot 
analysis, RT-PCR analysis and in vitro culture assays.   
 
Flow Cytometry 
For phenotypic analysis and quantitation of viable T cells or MDSC, splenocytes, 
mesenteric LN cells, or thymocytes were Fc-blocked and stained using fluorescent-
conjugated antibodies.  For T cells, antibodies against the following surface markers 
were used: CD3, CD4, CD25, CD103, GITR, OX40, CD127, and CD16/32 (R&D 
Systems).  Importantly, when staining for CD16/CD32, Fc block was not used.  For 
intracellular FoxP3 expression, cells were stained as mentioned above, then 
permeabilized and fixed using the eBioscience Fixation/Permeabilization kit 
(eBioscience), and stained with anti-FoxP3 (FJK-16a).  For MDSC, antibodies against 
the following surface markers were used: CD11b, Gr1, Ly6G, and Ly6C; and DAPI was 
used for analysis of viability.  All samples were analyzed on an LSRII (BD Biosciences).  
All antibodies except CD16/32 were purchased from BD Biosciences or eBioscience.   
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In Vitro Culture  
All cell cultures were done using complete media consisting of RPMI (Cellgro) 
with 10% FBS (Atlas Biologicals) and 1% antibiotics (Invitrogen), except for MC-38 colon 
carcinoma tumor cells which were cultured in complete media with DMEM (Invitrogen), 
10% FBS and 1% antibiotics.  In MDSC cultures, the complete media was supplemented 
with 10ng/ml GM-CSF (Invitrogen) and changed every 2-3 days.  EL-4 tumor explant 
supernatant (TES) was generated by obtaining a tumor mass with no ulceration from a 
tumor-bearing mouse (6x105 EL4 cells were subcutaneously injected about 3 weeks 
prior).  The tumor was mechanically separated, incubated in collagenase D (2mg/ml in 
RPMI) for 1 hour and strained through a cell strainer to obtain a single cell suspension.  
Cells were then plated at 2 million cells per ml of complete media.  The supernatant 
media (TES) was then collected and filter sterilized after two days in culture.  When 
culturing with TES, MDSC were plated in complete media supplemented with GM-CSF, 
as mentioned above, and with TES as 20% of the final volume.  When using HDAC 
inhibitor (HDACi) treatment, the following final concentrations were used: Trichostatin A 
(TSA) was used at 20nM or 100nM (Cell Signaling Technology); valproic acid (VPA) was 
used at 1mM (Sigma-Aldrich), suberoylanilide hydroxamic acid (SAHA) was used at 3µM 
(Cayman).  The DMNTi, 5-aza-2’-deoxycytidine (AZD) was used at 1µM or 2µM (Sigma-
Aldrich).   
 
BrdU Incorporation  
To measure proliferation, the BrdU incorporation assay was performed using BD 
Pharmigen BrdU flow kit.  Simply, cells were plated for 2 days, pulsed with 10uM of BrdU 
for 4 hours before harvesting for staining of surface markers, CD11b, Ly6G, and Ly6C 
(BD Biosciences).  After 20 minutes of staining, cells were washed with staining media 
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and fixed using the provided Cytofix/Cytoperm buffer for 30 minutes at room temperature 
(RT).  Cells were then washed and stored in freezing media (10% dimethylsulfoxide, 
DMSO, in FBS) until further use.  Once cells were thawed, they were washed again and 
incubated in the Cytofix/Cytoperm buffer for 5 minutes.  Cells were treated with DNase 
for 1 hour at 37°C to expose incorporated BrdU, washed then stained with fluorescent 
anti-BrdU antibody for 20 minutes at RT.  After washing, DAPI at 1µg/ml (Invitrogen) was 
added to stain the DNA for DNA content and cell cycle analysis.  Samples were run on 
an LSRII (BD Biosciences) and analyzed on FlowJo software. 
 
Mixed Leukocyte Reaction 
A total of 1x105 cells/well irradiated (2000rad) Balb/cJ splenocytes (stimulators) 
were plated in quadruplicate with 1x105/well WT or SHIP-deficient 
CD3+CD4+CD25−CD8− T cells (responders) in 96-well U-bottom plates (Corning Life 
Sciences) containing RPMI 1640 complete media.  After 3 days of culture, proliferation 
of responder T cells was determined by quantifying overnight incorporation of [3H] 
thymidine (1.0μCi per well; MP Biomedicals).  Results were expressed as the mean 
counts per minute (cpm) of quadruplicate wells plus or minus SEM (standard error).  To 
assess suppressive ability, WT CD3+CD4+CD25+CD8− Tregs, SHIP-deficient 
CD3+CD4+CD25+CD8− Tregs, or SHIP-deficient CD3+CD4+CD25−CD8− T cells were 
added at the indicated ratios to each MLR well containing 1x105 irradiated BALB/C 
splenocytes and 1x105 WT CD3+CD4+CD25−CD8− responder T cells.   
 
Western Blotting 
Protein lysates were prepared from magnetically isolated or FACS–sorted cells 
by resuspending cell pellet in a modified TNE lysis buffer (50mM Tris-HCl, 1% Nonidet 
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P-40, 150mM NaCl, 1mM ethylenediaminetetraacetic acid, 1mM phenylmethylsulfonyl 
fluoride, 1mM NaOV, 1mM NaF, and protease inhibitors) and incubating for 30 minutes 
on ice.  For SHIP and FoxP3 protein analysis, equal cell equivalents were resolved on a 
4% to 12% Bis-Tris gel (Invitrogen) and transferred to a Hybond-ECL nitrocellulose 
membrane (GE Healthcare).  Blots were blocked with Odyssey blocking buffer (LI-COR 
Biosciences), probed with antibodies against SHIP1 (P1C1, 1:200) or FoxP3 (eBio7979, 
1:500) and β-Actin (C-11, 1:500) followed by a fluorochrome-tagged secondary.  Probed 
blots were developed on a LI-COR Odyssey imager to quantitate and normalize SHIP 
levels or FoxP3 levels to β-Actin, displayed as arbitrary fluorescence units (AFU).  For 
Rb1 and E2F detection, 50ng of protein were run on an 8% SDS page gel at 90V for 25 
minutes.  Voltage was increase to 120V once loading buffer passed the stacking buffer 
and proteins were run until 25kD protein ladder ran off the gel.  Samples in the gel were 
transferred to a methanol pre-activated PVDF (Millipore) membrane at 20V overnight at 
4°C.  Membrane was blocked with 5% Milk PBS-T (1% Tween-20 in PBS) for 2 hours at 
RT with agitation.  Membrane was then incubated with the primary antibody in 5% milk 
PBS-T.  For Rb1 detection, membrane was incubated with the primary antibody (BD 
Biosciences) overnight at 4°C.  For Actin (Santa Cruz Biotechnologies) and E2F (Santa 
Cruz Biotechnologies) detection, membrane was incubated with the primary antibody for 
2 hours at RT with agitation.  This was followed by probing with a secondary antibody 
conjugated to HRP (Santa Cruz Biotechnologies).  Protein levels were detected using 
Pierce ECL Plus Western Blotting Substrate (Thermo Scientific) and autoradiography 
film (Midwest Scientific). 
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Quantitative Real-Time PCR (qRT-PCR) 
RNA extraction was performed using Trizol (Invitrogen) and Qiagen RNeasy 
columns.  Simply, Trizol was added to the cell pellet and incubated at RT while vortexing 
frequently.  Chloroform (1/5 of Trizol amount) (Fisher Scientific) was added and mixed 
well.  The sample was centrifuged at 12,000xg for 15 minutes at 4°C to separate 
phases.  The top layer was mixed equal parts with 70% ethanol and transferred to an 
RNeasy Mini spin column.  The rest was performed according to manufacturer’s 
instructions, including DNase I (Qiagen) treatment to remove traces of DNA.  0.5μg of 
total RNA was used to synthesize 20ul of cDNA using the High-Capacity Reverse 
Transcription kit (Applied Biosystems), following manufacturer’s protocol.  RT-PCR was 
performed with 2μl cDNA, 10µl of 2X TaqMan gene expression master mix and TaqMan 
primers specific for one of the following target genes, Rb1 (Mm00485586_m1), β-Actin 
(Mm00607939_s1), and 18S (4319413E) (Applied Biosystems).  Standard curve 
(absolute quantitation) assays were done for each gene using the Applied Biosystems 
7900HT Fast Real-Time PCR System and corresponding software.  For each sample, 
the amount of Rb1 was normalized against the amount of control gene (β-Actin and/or 
18S) in the same sample.  Relative fold changes in target gene expression were then 
calculated among the samples being compared. 
 
Chromatin Immunoprecipitation  
 
The Acetyl-Histone H3 Immunoprecipitation (ChIP) assay kit (Millipore) 
components were used throughout.  7-10x106 freshly sorted or cultured cells that were 
harvested were washed with ice cold PBS and cross-linked immediately by incubating 
for 10 minutes with 0.4% formaldehyde (in PBS) with gentle stirring at RT.  To stop 
cross-linking, 0.125 M glycine was added and the cells in solution were incubated with 
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continued stirring for an additional 5 minutes at RT.  Cells were then washed twice with 
ice cold PBS and pelleted by centrifugation at 400xg for 10 minutes at 4°C.  The cell 
pellet was resuspended in 500µls of SDS lysis buffer (with added protease inhibitors) 
and incubated for 10 minutes on ice.  Lysates were sonicated to shear DNA to lengths 
between 200 and 1000 basepairs (bp) (confirmed by electrophoresis) using a 
BioruptorTM from Diagenode.  Making sure to keep samples ice cold, a cycle of eight 
pulses of 30 seconds with 30 seconds rest time was repeated eight times at a frequency 
of 20 KHz.  After centrifugation at 16,000xg for 10 minutes at 4°C, the supernatant was 
collected, and kept at -80°C.  An aliquot of 25µls was removed to analyze DNA 
fragmentation.  Crosslinking was reversed with NaCl treatment overnight followed by 
RNase and Proteinase K treatment to eliminate RNA and protein contamination.  The 
same amount of each sample was run on a 1% agarose gel with Ethidium Bromide to 
visualize DNA.  The average intensity of the bands was measured and used to calculate 
how much of lysate should be used among samples being compared to start 
immunoprecipitation with approximately equal amounts of DNA.  Each sample was 
aliquoted three ways to contain approximately equal amounts of DNA in 100µls of 
sonicated cell supernatant for each antibody specific immunoprecipitation, no-antibody 
immunoprecipitation and input.  The sonicated cell supernatant was then diluted 10 fold 
in ChIP Dilution Buffer (with added protease inhibitors) for a final volume of 1ml in each 
immunoprecipitation condition.  To reduce nonspecific background, samples were pre-
cleared with Salmon Sperm DNA/Protein A Agarose-50% Slurry (Catalog #16-157C) for 
one hour at 4°C with agitation.  After brief centrifugation, the collected supernatant was 
immunoprecipitated with Acetyl-Histone H3 specific antibody overnight at 4°C with 
rotation.  For the negative control, a no-antibody immunoprecipitation was performed by 
incubating the supernatant fraction with Salmon Sperm DNA/Protein A Agarose-50% 
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Slurry for one hour at 4ºC with rotation.  Antibody/histone complexes were recovered by 
adding Salmon Sperm DNA/Protein A Agarose Slurry for one hour at 4ºC with rotation.  
The protein A agarose/antibody/histone complexes were washed once with the Low Salt 
Immune Complex Wash Buffer, once with the High Salt Immune Complex Wash Buffer, 
once with LiCl Immune Complex Wash Buffer and twice with the TE Buffer.  The solution 
was incubated during each wash for 5 minutes with rotation at 4°C.  The histone 
complexes were then eluted from the antibody by adding 150µls of freshly prepared 
elution buffer (1%SDS, 0.1M NaHCO3), vortexing and incubating at RT for 15 minutes 
with rotation.  This was repeated twice and the supernatant fractions (eluate) were 
combined.  NaCl (12µls of 5M NaCl) was added to the combined eluates (300µls total) to 
reverse histone-DNA crosslinks by heating at 65ºC for 4 hours.  Reversal of cross 
linkage was also performed on the input/starting material.  6µl of 0.5M EDTA, 12µl 1M 
Tris-HCl, pH 6.5 and 1.2µl of 10mg/ml Proteinase K were added to the combined eluates 
and incubated for one hour at 45ºC.  To purify DNA, the Qiagen DNA purification kit was 
used.  RT-PCR was performed on the purified DNA using Rb1 promoter specific primers 
(forward: 5’-TACTTGGGTTCGAGTCCTCTGCCAG-‘3, reverse: 5’-
AGTTGGCCGTGTTCATGCG-‘3) on a CFX96 RT-PCR thermal cycler (Bio-Rad) and 
analyzed using Bio-Rad CFX Manager software. 
 
G-CSF Neutralization and SDF1 ELISA 
SHIP was conditionally deleted in MxCreSHIPflox/flox mice by administering an 
intraperitoneal injection of 625μg polyinosinic-polycytidylic acid (polyI/C)) (Sigma-Aldrich) 
on days 0, 3, and 6 as described in Paraiso et al.  SHIPflox/flox mice were treated similarly 
to serve as control mice.  On day 2, polyI/C treated MxCreSHIPflox/flox mice and SHIPflox/flox 
control mice were also injected subcutaneously with monoclonal anti-mouse G-CSF 
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antibody (R&D systems, 10µg/animal/day) or PBS (diluent) for one week.  Then MDSC 
and Tregs in the SPL and mesenteric LNs were quantitated by flow cytometry (as 
described above). 
 
Adoptive Transfer of T cells for Colitis and GvHD Induction 
In the syngeneic colitis model, to assess Treg function, C57BL/6J SCID hosts 
received 4x105 sorted CD3+CD4+CD25−CD8− T cells from WT C57BL/6J donors along 
with or without 7x104 sorted CD3+CD4+CD25+CD8− Tregs from WT or SHIP−/− C57BL/6J 
donors by intraperitoneal injection on day 1.  In parallel, a control group of C57BL/6J 
SCID hosts received a PBS injection.  In the allogeneic GvHD colitis model, to assess 
allogeneic T cell response, Rag2−/−γc−/− mice (on an H2d background) received 105 
sorted CD3+CD4+CD25−CD8− T cells from WT or SHIP−/− C57BL/6J donors by retro-
orbital injection.  In parallel, a control group of Rag2−/−γc−/− mice hosts received a PBS 
injection.   
 
Clinical and Histologic Examination of Colitis 
Recipient mice were weighed and monitored for colitis-associated appearance 3 
times per week.  Recipient mice were kept in a pathogen-free barrier room for 8 to 12 
weeks after cell transfer.  When premoribund (lost ≥ 10% or more of its starting body 
weight) or after 8 to 12 weeks after cell transfer, recipient mice were killed and given a 
disease activity index (DAI).  The colon was obtained from each mouse and fixed in 10% 
formalin in PBS.  Paraffin-embedded sections were cut and stained with hematoxylin 
and eosin for histologic examination and scoring.  Histology micrographs were taken 
using a Leica DMLB microscrope (N PLAN 20x/0.40, total magnification x200, at RT, 
and a SPOT Insight QE Model 42 camera with Spot Advanced acquisition software 
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(Diagnostic Instruments).  The DAI represents the sum of 2 scores: the clinical 
assessment score (CAS) and the histopathology score (HPS).  The CAS is determined 
on a scale from 0 to 4 as follows: 0 indicates no signs; 1, bristled fur; 2, bristled fur with 
hunched posture, and/or reduced activity; 3, all of the above and change in stool 
consistency (for example, soft, sticky); 4, rectal prolapse. The HPS was determined by 
grading the histologic appearance of the colon using the following criteria: grade 0 
indicates an unaffected proximal colon; grade 1 indicates mild leukocyte infiltration of the 
lamina propria (not shown); grade 2 indicates moderate leukocyte infiltration of the 
lamina propria, mild reduction of goblet cells, and mild crypt epithelial regenerative 
hyperplasia; grade 3 indicates marked leukocyte infiltration beyond the muscularis 
mucosa into a thickened submucosa, goblet cell depletion, and epithelial regenerative 
hyperplasia with atypia; and grade 4 indicates marked transmural leukocyte infiltration 
deep into a thickened submucosa and tunica muscularis with increased vascular density, 
marked goblet cell loss, and epithelial regenerative hyperplasia with atypia.  
Histopathology grading was performed in a blinded fashion by Dr. Robert Engelman.   
 
Vascularized Heart Rejection Model 
C57BL/6J, polyI/C-treated MxCreSHIPflox/flox and SHIPflox/flox mice received hearts 
from adult Balb/cJ donors.  Fourteen days after the initiation of SHIP deletion, 
vascularized heart transplantations were performed following the procedure of Corry et 
al481.  Monitoring of transplant function was assessed by daily palpation of the graft.  
Moderate rejection was detected by a sclerotic graft, final rejection by missing 
heartbeats.   
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Statistics 
In vitro experiments are representative of at least 3 independent analyses.  MLR, 
flow cytometry results, weight change, and HPS results were analyzed with the 2-tailed 
Student t test or the Mann-Whitney U test using Prism 4 software (GraphPad Software).  
Differences were considered significant at P values less than 0.05.  Comparisons of graft 
or mouse survival were done using the Kaplan-Meier log-rank test using Prism 4 
software.   
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Chapter 3.  SHIP Limits Immunoregulatory Capacity in the T Cell Compartment 
 
Note to Reader 
 The work presented in this chapter has been previously published (Collazo et al, 
2009)482 and are utilized with permission of the publisher. 
 
Introduction 
Tregs actively mediate self-tolerance and thus control autoimmunity52, 483.  Tregs 
also limit antitumor T cell responses and deleterious allogeneic T cell responses that 
cause GvHD158, 159 and solid organ allograft rejection,484 making them valuable 
therapeutic targets.  We previously found that donor and host allogeneic responses are 
compromised in SHIP-deficient hosts, which exhibit significantly reduced acute rejection 
of MHC-mismatched BM grafts and GvHD325, 341.  Thus, an immunosuppressive 
environment prevails in SHIP-deficient hosts.  We also consistently observe a profound 
expansion of MDSC in SHIP-deficient mice325, 341, 345, 485.  Because host and donor Tregs 
limit GvHD159, 486 and CD11b+Gr1+ cells, similar to SHIP−/− MDSC, expand Tregs in tumor 
and GvHD models233, 487; we considered that the Treg compartment in SHIP-deficient 
hosts may also be expanded.  In addition, SHIP-deficiency could intrinsically affect Treg 
homeostasis and function.  SHIP can oppose PI3K signaling pathways triggered by 
engagement of costimulatory and cytokine receptors critical for the suppressive function, 
survival, and expansion of Tregs, such as CD25, IL-7R, and OX40488-490. 
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Because Tregs were initially characterized as CD4+ T cells coexpressing CD25, 
most Treg studies focus on this phenotype, which is shared with activated CD4+ T 
cells54.  To distinguish between Tregs and activated T cells, molecular markers 
correlated with or obligate for Treg function have been identified, such as the 
transcription factor FoxP3, as well as surface markers CD103, GITR and OX40, among 
others.  FoxP3 functions as the master regulator in the development and suppressive 
ability of Tregs60.  CD103 expression among CD4+CD25+ Tregs distinguishes an 
effector/memory-like subset that displays an inflammation-seeking phenotype and 
exhibits greater suppressive capacity491, 492.  In addition, CD103, which binds E-cadherin, 
mediates the retention of CD103+ lymphocyte in epithelial compartments492, which are 
major sites of GvHD.  Thus, CD103+ Tregs might have a prominent role in the prevention 
against GvHD.  GITR and OX40, members of the tumor necrosis factor receptor 
superfamily of receptors, are costimulatory molecules known to play key roles in 
promoting the homeostasis, expansion, and suppressive capability of Tregs493, 494.  
Furthermore, CD4+CD25+OX40+ Tregs represent a mature population that does not 
require preactivation or stimulation to suppress antigen-specific T cell responses495. 
Analysis of CD103, GITR, and FoxP3 expression has allowed the identification of 
a Treg population among “naive” CD4+CD25− T cells.  Specifically, CD4+CD25−CD103+ T 
cells display regulatory activity in both an in vitro proliferation assay and in vivo disease 
models, such as colitis and antigen-induced arthritis491, 496.  Additionally, 
CD4+CD25−GITR+ T cells express IL-10, TGFβ , and intracellular CTLA-4, are anergic, 
suppress T cell proliferation, and can prevent wasting disease, colitis, autoimmune 
myocarditis, diabetes, and multiorgan inflammation497, 498.  Thus, when assessing the 
entire Treg compartment, one should also consider these immunoregulatory subsets 
within the so-called “naive” CD4+CD25− T cell compartment.   
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Using 3 murine genetic models of SHIP-deficiency, we show here that the 
frequency of CD4+CD25+FoxP3+ Tregs and CD4+CD25−FoxP3+ T cells is increased in 
SHIP-deficient mice.  We find that the suppressive capacity of SHIP-deficient 
CD3+CD4+CD25+ Tregs (CD25+ Tregs) is equal to that of WT CD25+ Tregs.  
Interestingly, the SHIP-deficient CD3+CD4+CD25− T cell (CD25− T cell) compartment 
displays significant immunosuppressive capacity in vitro and in vivo, possibly because of 
the increase in FoxP3+ T cells.  Furthermore, the surface expression of CD103, GITR, 
OX40, and FcγRII/III is significantly increased in SHIP-deficient CD25− and CD25+ CD4+ 
T cell compartments.  These qualitative changes possibly increase the survival and 
immunosuppressive capacity of the SHIP-deficient T cell compartment and contribute to 
the reduced host-versus-graft and graft-versus-host responses observed in SHIP-
deficient hosts.   
 
 
Results 
 
Mice with Germline SHIP-Deficiency have Increased Numbers of 
Conventional Tregs.  The expansion of Tregs in SHIP-deficient mice would be 
consistent with their relative resistance GvHD325, 341.  Thus, we examined the Treg 
compartment in peripheral lymphoid organs of mice from 2 different genetic models of 
SHIP-deficiency.  Both models are germline SHIP-deficient, one having the promoter 
and first exon of SHIP deleted (SHIP−/−) and the other having the exon encoding the 
enzymatic domain of SHIP deleted (SHIPΔIP/ΔIP).  Consistent with our hypothesis, we 
observed a significantly increased frequency and absolute number of CD25+FoxP3+ 
Tregs in the SPL and LN of both SHIP-deficient strains relative to their WT littermates 
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(Figure 1).  In neither mutant strains is the frequency of total CD3+ T cells increased in 
the SPL or LN.  In fact, the frequency of splenic CD3+ T cells is significantly decreased in 
both strains, whereas LN CD3+ T cell frequency remains unchanged (Figure 2).  
Interestingly, FoxP3 expression levels appear to be greater in splenic SHIP-deficient 
Tregs compared to their WT counterparts as determined by flow cytometry and Western 
blot analysis of sorted splenic CD25+ Tregs (Figure 3).  Thus, germline SHIP-deficiency 
promotes a preferential expansion and/or accumulation of conventional Tregs that have 
increased expression of FoxP3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Mice with germline SHIP-deficiency have an expanded CD25+ Treg 
compartment in peripheral lymphoid organs compared to WT counterparts. 
(A) Representative CD4 vs. CD25 staining after gating on CD3+ T cells for SPL and LN 
of SHIPΔIP/ΔIP and WT littermates.  (B) Percentage frequency of CD4+CD25+FoxP3+ 
Tregs after gating on CD3+ T cells, and total absolute CD3+CD4+CD25+FoxP3+ Treg 
numbers in the SPL and LN of the indicated genotype.  For SHIPΔIP/ΔIP mice: n = 12 and 
littermate control: n = 10.  For SHIP−/− mice: n = 6 and littermate controls: n = 6.  (*P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001)   
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Figure 2.  The frequency and absolute number of CD3+ T cells in mice with 
germline SHIP-deficiency compared to WT counterparts.   
Percentage frequency (A) and absolute number (B) of CD3+ T cells after gating on viable 
cells in the SPL and LN of the indicated genotype.  For SHIPΔIP∕ΔIP mice: n = 12 and 
littermate control: n = 10.  For SHIP−∕− mice: n = 6 and littermate control: n = 6.  (*P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001)   
 
 
 
 
 
Figure 3.  FoxP3 expression levels are greater in splenic SHIP-deficient Tregs 
compared to WT counterparts.   
(A) Representative FACS analysis of FoxP3 expression in CD3+CD4+CD25+ Tregs from 
the SPL of the indicated genotype.  (B) Western blot analysis of SHIP, FoxP3, and β-
Actin expression in lysates prepared from sorted CD3+CD4+CD25+ Tregs of the indicated 
genotype.  AFU values for FoxP3 expression in SHIP-/- (-/- Treg) and WT Tregs are 
displayed below the corresponding band in the bar graph.   
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We then considered whether peripheral expansion of the Treg compartment 
might be partly the result of increased thymic production of CD25+ Tregs.  To examine 
this, we assessed the thymic content of CD25+FoxP3+ Tregs in both SHIP-deficient 
strains compared with their WT littermates.  We found a significant increase in the 
frequency of thymic FoxP3+ with CD25− and CD25+ T cell compartments in both SHIP-
deficient models relative to their WT littermates (Figure 4).  However, because SHIP-
deficient mice have smaller thymuses, the absolute numbers of these FoxP3+ Tregs are 
not significantly different from their WT littermates.  Thus, increased thymic output does 
not account for the expanded peripheral Treg compartment.  On a side note, the ratio of 
CD4+CD8−, CD4+CD8+, and CD4−CD8+ T cells in the thymus of SHIP-deficient mice is 
not significantly different from that seen in WT mice (data not shown).   
 
 
 
Figure 4.  Mice with germline SHIP-deficiency have higher percentages of thymic 
CD4+FoxP3+ Tregs than WT counterparts.   
(A) Representative CD25 vs. FoxP3 staining after gating on CD4+CD8− thymic cells from 
SHIPΔIP/ΔIP or SHIP−/− and WT littermate controls.  (B) Percentage frequency of 
CD25+FoxP3+ and CD25−FoxP3+ Tregs after gating on CD4+CD8− T cells and total 
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absolute number of CD4+CD25+FoxP3+ and CD4+CD25−FoxP3+ Tregs in the thymus of 
the indicated genotype.  For SHIP ΔIP/ΔIP mice: n = 5 and littermate control: n = 5.  For 
SHIP−/− mice: n = 4 and littermate control: n = 4.  (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001) 
 
 
SHIP Regulates Treg Compartment Size during Normal Adult Physiology.  
We previously found that, when SHIP-deficiency is induced in adulthood, the MDSC 
compartment expands rather rapidly, indicating that SHIP regulates MDSC numbers in 
peripheral lymphoid tissues in response to homeostatic signals present in adult 
physiology341.  To test whether this is also the case for Tregs, we examined the T cell 
compartment in peripheral lymphoid organs in adult MxCreSHIPflox/flox mice after inducing 
SHIP-deficiency.  The results obtained are strikingly similar to that observed for germline 
SHIP-deficiency.  The frequency and absolute number of CD25+FoxP3+ Tregs are 
significantly increased in both the SPL and LN of MxCreSHIPflox/flox mice with induced 
SHIP-deficiency compared with SHIPflox/flox mice (Figure 5).  Thus, SHIP-deficiency 
induced during normal adult physiology promotes the abnormal accumulation of 
CD25+FoxP3+ Tregs in the periphery, leading to a pronounced bias in the T cell 
compartment toward immunosuppressive cells.   
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Figure 5.  Induction of SHIP-deficiency expands the CD25+FoxP3+ Treg 
compartment in peripheral lymphoid organs.   
(A) Representative CD4 vs. CD25 staining in SPL and LN from MxCreSHIPflox/flox (Cre+) 
and SHIPflox/flox (Cre-) mice after poly(I/C) administration.  (B) Percentage frequency of 
CD4+CD25+FoxP3+ Tregs after gating on CD3+ T cells, and total absolute 
CD3+CD4+CD25+FoxP3+ Treg numbers in the SPL and LN of the indicated genotype.  
For MxCreSHIPflox/flox (Cre+): n = 6 and SHIPflox/flox (Cre−): n = 9.  (*P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001)  
 
 
SHIP-Deficiency Alters the Expression of Key Receptors in the CD4+ T Cell 
Compartment.  The expression of specific receptors by Tregs, such as CD103, GITR, 
and OX40, has been associated with their regulatory function, activation status, 
trafficking, and retention in specific organs.  We find that the percentage of CD103+ cells 
in CD25− and CD25+ T cell subsets is significantly increased in the SPL and LN of 
SHIPΔIP/ΔIP mice compared with WT littermates (Figure 6A).  Examination of GITR 
expression on CD25+ Tregs from SHIPΔIP/ΔIP mice shows that the surface density, as 
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determined by mean fluorescent intensity (MFI) obtained from flow cytometric analysis, 
is also significantly greater than that seen on WT CD25+ Tregs in the SPL and LN.  In 
addition, SHIPΔIP/ΔIP mice exhibit a significantly larger representation of CD25−GITRhi T 
cells in the SPL and LN compared with WT littermates (Figure 6B).  Similar to GITR, in 
SHIPΔIP/ΔIP mice, there is an increased surface density of OX40 on CD25+ Tregs.  In 
addition, the frequency of OX40+ cells among CD25− T cells is significantly higher in the 
SPL and LN of SHIPΔIP/ΔIP mice compared with WT littermates (Figure 6C). 
 
 
 
 
 
Figure 6.  SHIP-deficiency promotes altered expression of surface markers, 
CD103, GITR and OX40 in the CD4+ T cell compartment.   
(A) Representative histogram of CD103 expression levels on viable CD3+CD4+CD25+ 
(CD25+) or CD3+CD4+CD25- (CD25-) T cells from SPL and LN of the indicated genotype.  
Bar graphs representing percentage frequency of CD103+ T cells among viable CD25+ 
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or CD25- T cells from the SPL and LN of the indicated genotype.  (B) Representative 
histograms of GITR expression on viable T cells as in panel A.  Bar graphs representing 
MFI of GITR expression on viable CD25+ T cells from SPL and LN of the indicated 
genotype.  Bar graph representing percentage frequency of GITRhi (as determined by 
depicted gate in histogram) T cells among viable CD25- T cells.  (C) Same as in panel B, 
but for OX40 expression.  For SHIPΔIP/ΔIP: n = 6, and for WT littermates: n = 6.  (*P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001)   
 
 
Recent studies attempting to define surface markers that improve purification of 
viable Tregs showed that Tregs express lower levels of the IL-7 receptor α chain, 
CD127, than do activated effector T cells499.  Although IL-7R signaling, like IL-2R and IL-
15R signaling, is required for Treg development.  In SHIPΔIP/ΔIP mice, we observed that 
CD25+ Tregs in SPL and LN express higher levels of CD127 (~2-fold higher MFI value) 
compared with WT littermates (Figure 7A).   
Furthermore, we examined the expression levels of these markers (CD103, 
GITR, OX40, and IL7R) among CD4+CD8−CD25− and CD4+CD8−CD25+ T cells in the 
thymus.  We found no significant difference comparing SHIPΔIP/ΔIP thymocytes to WT 
thymocytes (data not shown), suggesting that the increased expression of these markers 
is acquired in the periphery.   
As seen in other cell lineages, such as NK cells, receptors that recruit SHIP and 
whose activity is regulated by SHIP may be deregulated in SHIP-deficient T cells.  For 
example, T cells are thought to not express Fcγ receptors, such as FcγRIIb (CD32b) and 
FcγRIIIa (CD16), which are regulated by SHIP and expressed by most other 
hematopoietic cells500.  When examining the expression levels of FcγRIIb (CD32b) and 
FcγRIIIa (CD16) by flow cytometry using an antibody that recognizes both, we find that 
WT CD25− T cells and CD25+ Tregs express these FcγRs at low levels compared with 
appropriate isotype controls (Figure 7B).  Interestingly, in SPL and LN of SHIP-deficient 
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mice, we observed that both CD25− T cells and CD25+ Tregs express significantly 
elevated levels of FcγRIIb/FcγRIIIa compared to WT controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  SHIP-deficiency promotes altered expression of surface markers, CD127 
and FcgRII/III in the CD4+ T cell compartment.   
(A) Representative histogram of CD127 (IL-7R) expression on viable T cells as in panels 
A to C from Figure 6.  Bar graphs representing MFI of CD127 expression on viable 
CD25+ or CD25− T cells from SPL and LN of the indicated genotype.  (B) Same as in 
panel A, but for FcγRII/FcγRIII expression.  For SHIPΔIP/ΔIP: n = 6, and for WT littermates: 
n = 6.  (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001)   
 
 
 
SHIP-Deficiency Promotes the Accumulation of CD4+CD25− “Naive” T Cells 
that Express FoxP3 and have Suppressive Function.  Researchers have shown that 
analysis of surface marker expression, such as CD103, GITR, and of intracellular FoxP3 
identifies an immunosuppressive subpopulation within the CD25− T cell compartment.  
Consistent with the increase in CD25+FoxP3+ Treg numbers, we find a significant 
expansion of CD25−FoxP3+ T cells in the periphery of SHIP−/−, SHIPΔIP/ΔIP, and polyI/C-
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treated MxCreSHIPflox/flox mice, as detected by flow cytometry and Western blot analysis 
(Figure 8).  As shown in Figure 6, when analyzing the expression of surface markers 
associated with Tregs, such as CD103, GITR, and OX40, we found an enrichment of 
CD25− T cells that expressed these markers in SHIP−/− SPL and LNs compared with WT 
littermates.  The majority of these cells also coexpressed FoxP3 (data not shown).  
Thus, these CD25−FoxP3+ T cells may represent an immunoregulatory subset that 
contributes to the immunosuppressive environment in SHIP−/− mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  SHIP-deficiency promotes the expansion of a FoxP3+ subset amongst 
CD4+CD25- “naïve” T cells. 
(A) Representative histograms of FoxP3 expression levels in fixed CD25+ T cells from 
SPL and LN of the indicated genotype.  (B) Western blot analysis of FoxP3 protein 
expression in FACS-purified CD25- T cells from the indicated SHIP-deficient strain and 
WT counterpart.  (C) Bar graphs representing the percentage frequency of FoxP3+ T 
cells among CD25- T cells and absolute numbers of CD25-FoxP3+ T cells in the SPL and 
LN of the indicated genotype.  (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001) 
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Consistent with their increased FoxP3 expression, CD25− T cells from either 
SHIP-deficient strain are unresponsive to MHC-mismatched stimulators, and also 
demonstrate significant suppressive capacity on other CD4+ T cells (Figure 9).  When 
placed in an MLR with WT effector CD25− T cells at a 1:1 ratio, the suppressive capacity 
of SHIP-deficient CD25− T cells was comparable with that of conventional CD25+ Tregs 
placed in an MLR with WT effector CD25− T cells at a 1:8 ratio (Figure 9B).  This 
coincides with the fact that 15% to 20% of SHIP-deficient CD25− T cells are FoxP3+.   
Thus, the FoxP3+ cells in the SHIPΔIP/ΔIP CD25− T cell population are at approximately a 
1:8 ratio with WT effector CD25− T cells, suggesting that SHIPΔIP/ΔIP CD25−FoxP3+ T 
cells have suppressive capacity comparable with that of conventional WT Tregs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  SHIP-deficient CD4+CD25- and CD4+CD25+ T cells are suppressive in 
vitro.   
(A) In the first two bars, C57BL/6J WT (WT CD25-) or SHIP-deficient CD4+CD25- T cells 
(∆IP/∆IP CD25-) were mixed with irradiated Balb/cJ splenocytes in a one-way MLR.  
Subsequent bars are as described in (B).  (B) C57BL/6J WT CD4+CD25+ Tregs (WT 
CD25+, red), SHIP-deficient CD4+CD25+ Tregs (∆IP/∆IP CD25+, blue) or CD4+CD25- T 
cells (∆IP/∆IP CD25-, white) were mixed with C57BL/6J WT CD4+CD25- T cells at the 
indicated ratios (suppressors:effectors) and with irradiated Balb/cJ splenocytes in a 
MLR.  (*P ≤ 0.05) 
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SHIP-Deficient CD4+CD25+ Tregs are as Suppressive as WT Tregs.  The 
altered phenotype described herein suggests that SHIPΔIP/ΔIP Tregs may be more 
suppressive than WT Tregs.  To test this hypothesis in vitro, we directly compared the 
suppressive capacity of conventional SHIP-deficient and WT CD25+ Tregs at different 
ratios.  Multiple comparisons indicated SHIP-deficient Tregs are equally potent at 
suppressing an MLR compared with WT Tregs on a per-cell basis (Figure 9).  To confirm 
that SHIP-deficient Tregs are as suppressive as WT Tregs, we used the in vivo 
syngeneic colitis model, which assesses the ability of Tregs to control autoreactive T 
cells.  We found that SHIPΔIP/ΔIP CD25+ Tregs can protect C57BL/6J SCID hosts from 
WT CD25- T cell–induced colitis just as well as WT CD25+ Tregs, as assessed by weight 
change and colon histopathology (Figure 10).  Weight change analysis showed hosts 
receiving either WT or SHIPΔIP/ΔIP Tregs, along with the WT effector CD25- T cells, 
gained approximately 35% more of their initial weight by the end of the study, similar to 
the control group that received PBS only (Figure 10A).  Hosts receiving WT effector 
CD25- T cells gained approximately 10% of their initial weight, significantly less than the 
hosts receiving PBS or SHIPΔIP/ΔIP or WT Tregs.  Comparison of the colon histopathology 
for hosts in each cohort further supports that those hosts receiving either SHIPΔIP/ΔIP or 
WT Tregs were equally protected from colitis (Figure 10B).  The appearance and health 
of the colon in these hosts were very similar to that observed for hosts injected with PBS 
(Figure 10C).  The colon histopathology of hosts injected with WT effector CD25- T cells 
only was the most severe compared with the hosts of the other cohorts (Figure 10B, C).  
Thus, SHIPΔIP/ΔIP Tregs appear to have comparable regulatory capacity to their WT 
counterparts.   
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Figure 10.  SHIP-deficient CD4+CD25+ Tregs exhibit normal immunoregulatory 
capacity in vivo.   
C57BL/6J SCID hosts received 4x105 CD3+CD4+CD25− T cells from WT C57BL/6J 
donors by intraperitoneal injection on day 1 [n = 7].  Where indicated, the WT effector 
CD3+CD4+CD25− T cells were coinjected with 7x104 CD3+CD4+CD25+ Tregs from WT or 
SHIP−/− C57BL/6J donors into C57BL/6J SCID hosts [n = 9].  In parallel, a control group 
of C57BL/6J SCID hosts received a PBS injection [n = 5].  Disease and weight were 
monitored every other day.  (A) Analysis of the rate of weight change over the course of 
the study (3 months) in the cohorts that received WT effector CD3+CD4+CD25− T cells 
only (labeled WT CD25−), or effector WT CD3+CD4+CD25− T cells with WT or 
SHIP−/−CD3+CD4+CD25+ Tregs (labeled WT CD25− & WT CD25+ or WT CD25− & -/- 
CD25+, respectively), or PBS.  The weight change was determined by converting each 
actual weight to a percentage of that mouse's initial weight.  Each line depicts the 
average weight change for the specified cohort (P ≤ 0.001, WT CD25− vs. WT CD25− & 
WT CD25+, WT CD25− vs. WT CD25− & -/- CD25+, and for WT CD25− vs. PBS; P > 0.1 
for WT CD25− & WT CD25+ vs. WT CD25− & -/- CD25+, WT CD25− & WT CD25+ vs. 
PBS, and for WT CD25− & -/- CD25+ vs. PBS).  (B) Representative histological 
appearance of the colon (hematoxylin and eosin, X200) from a mouse in the WT CD25− 
(top left; HPS = 3), WT CD25− & WT CD25+ (top right; HPS = 1), WT CD25− & -/- CD25+ 
(bottom right; HPS = 1), and PBS (bottom left; HPS = 0) cohorts.  (C) Box and whisker 
plots and table summarizing the histopathology scores (HPS) given to the hosts within 
each cohort.  The HPS was determined by scoring the most affected area of the 
proximal colon on a scale of 0 to 4 according to the degree of inflammatory cell 
infiltration, goblet cell depletion, reactive mucosal epithelial hyperplasia, and thickness of 
the colon wall, as described further in Materials and Methods.  (P ≤ 0.001, WT CD25− vs. 
WT CD25− & WT CD25+, WT CD25− vs. WT CD25− & -/- CD25+, and for WT CD25− vs. 
PBS; P > 0.5 for WT CD25− & WT CD25+ vs. WT CD25− & -/- CD25+) 
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Evidence for Enhanced T Lymphoid Immune Regulation of Allogeneic 
Responses In Vivo.  SHIP-deficient CD25− T cells exhibited reduced allogeneic T cell 
responses in vitro and approximately 15% of them express FoxP3 (Figure 8-9).  Thus, 
we assessed their capacity to mediate allogeneic responses in an in vivo model of 
GvHD-induced colitis using MHC-mismatched (H2d) Rag2−/−γc−/− hosts480.  As expected, 
WT CD25− T cells mediate robust colitis and lethal GvHD in MHC-mismatched hosts, 
resulting in only 30% survival, whereas 70% of Rag2−/−γc−/− hosts survived that received 
an equivalent number of SHIP-deficient CD25− T cells.  This indicates that SHIP-
deficient CD25− T cells have significantly less capacity for lethal GvHD (Figure 11A), 
consistent with their reduced response in the one-way MLR assay (Figure 9).  Mice 
receiving SHIP-deficient CD25− T cells also have less evidence of colitis based on both 
the assessment of clinical symptoms (CAS) and histopathology (HPS) in the colon 
summarized in the DAI (Figure 11C).  Specifically, the severity of colitis was 
approximately 2-fold less in mice receiving SHIP-deficient CD4+ T cells (average DAI, 
2.5) than mice receiving WT CD4+ T cells (average DAI, 4.6).  Thus, SHIP-deficiency 
reduces allogeneic CD4+ T cell responses that can mediate colitis, GvHD, BM graft 
rejection, and organ graft rejection. 
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Figure 11.  Reduced alloreactivity of SHIP-deficient CD4+CD25− effector T cells in 
vivo.   
Rag2−/−γc−/− hosts on an H2d background received 4x105 CD3+CD4+CD25− T cells from 
SHIP−/− or WT C57BL/6J (H2b) donors by retro-orbital injection on day 1.  In parallel, a 
control group of Rag2−/−γc−/− hosts received a PBS injection.  Disease was monitored on 
a daily basis.  Data represent 2 separate studies that were combined, each with an n = 5 
per treatment group, resulting in an n = 10 per each treatment group.  (A) Kaplan-Meier 
step functions that show survival for the indicated Rag2−/−γc−/− cohorts [n = 10].  P ≤ 0.01 
for SHIP−/− (labeled -/- CD4) vs. WT CD25− (labeled +/+ CD4) T cell injected cohorts.  (B) 
Histopathologic appearance (hematoxylin and eosin, x200) of the proximal colon of 
Rag2−/−γc−/− mice after transfer of SHIP−/− or WT CD4+CD25− T cells.  These are 
representative examples that show grading to determine the HPS, using the criteria 
described in Figure 10.  Histology micrographs were taken as described in Figure 10.  
(C) Table summarizing the assessment of disease in Rag2−/−γc−/− mice cohorts receiving 
CD25− T cells from the indicated genotype or sterile PBS control based on the clinical 
assessment score (CAS), the HPS and the disease activity index (DAI = CAS + HPS).  
The CAS score is determined on a scale from 0 to 4 according to the occurrence of 
bristled fur, hunched posture, reduced activity, change in stool consistency, and rectal 
prolapse as described in Materials and Methods. 
 
 
To further assess immunoregulatory T cell function in vivo in SHIP-deficient 
hosts, we tested whether induction of SHIP-deficiency in adults could delay or prevent 
rejection of allogeneic organ grafts, a known function of Tregs501.  We induced SHIP-
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deficiency in MxCreSHIPflox/flox recipients by polyI/C injection.  Fourteen days after the 
first polyI/C injection, vascularized heart grafts from Balb/cJ donors were placed in 
MxCreSHIPflox/flox and SHIP+/+ C57BL/6J cohorts that received the same polyI/C regimen 
and unmanipulated SHIPflox/flox controls (Figure 12A).  As expected with such cardiac 
allografts481, the SHIPflox/flox and C57BL/6J control cohorts both rejected the Balb/cJ 
grafts within 7 days (Figure 12B).  However, most MxCreSHIPflox/flox recipients 
demonstrated a significant delay in rejection, specifically within 9 days (P < 0.01; Figure 
12B).  These findings suggest that SHIP-deficiency induced in the adult transplantation 
host can delay allogeneic organ graft rejection consistent with the expanded number and 
function of immunoregulatory T cells in SHIP-deficient hosts. 
 
 
 
 
 
Figure 12.  Induced SHIP-deficiency delays rejection of MHC-mismatched, 
vascularized heart allografts. 
(A) Example of an anastomosed heart early after reperfusion.  The heart was located in 
the right lower abdomen of the recipient mouse, and contractions could be palpated 
through the abdominal wall after closure.  (B) Kaplan-Meier step-functions for graft 
survival in MxCreSHIPflox/flox mice after induction of SHIP-deficiency (red), SHIPflox/flox 
controls (dashed black) and C57BL/6J mice (blue).  The latter group was treated with an 
identical polyI/C (labeled pI/C) regimen as that given to MxCreSHIPflox/flox mice.  P < 0.01 
for MxCreSHIPflox/flox vs. SHIPflox/flox graft survival.  P < 0.05 for MxCreSHIPflox/flox vs. 
C57BL/6J graft survival. 
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Discussion 
Here we provide evidence that germline or induced systemic SHIP-deficiency 
promotes an increased frequency of CD25+FoxP3+ T cells and CD25−FoxP3+ Tregs in 
secondary lymphoid tissues.  Furthermore, we find that SHIP-deficiency promotes a 
significant increased expression or representation of CD103, GITR, and OX40, markers 
associated with Tregs, and FcγRII/III among CD25+ Tregs and CD25− T cells.  SHIP-
deficiency does not compromise Treg function because SHIP-deficient Tregs are as 
suppressive as WT Tregs.  Finally, SHIP-deficient CD25− T cells are unresponsive to 
allogeneic stimulus in vitro and in vivo and suppress allogeneic T cell responses in vitro.  
Because FoxP3 expression in murine T cells confers suppressive capacity60, it is 
probable that the FoxP3+ subset among SHIP-deficient CD25− T cells is responsible for 
the observed immunosuppressive capacity of SHIP-deficient CD25− T cells in vitro and 
reduced GvHD in vivo.   
The increased representation of FoxP3+ Treg populations within CD25+ and 
CD25− T cell compartments could be due to by several extrinsic or intrinsic effects 
caused by SHIP-deficiency.  SHIP-deficiency in T-lineage cells could alter intracellular 
signaling pathways important in thymic selection or peripheral differentiation or survival.  
Alternatively, SHIP-deficiency could promote an immunosuppressive environment that 
preferentially promotes the generation, expansion, and/or survival of Tregs.  Tarasenko 
et al339 found that T cell–specific SHIP-deficiency does not promote the increased 
development or representation of FoxP3+ Tregs in the thymus or in peripheral lymphoid 
tissues.  Furthermore, they showed that SHIP does not regulate signaling through the 
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TCR.  These results, when paired with our findings, suggest that SHIP-deficiency 
promotes Treg expansion via a mechanism that is extrinsic to CD4+ T cells, although the 
possibility exists that both a SHIP-deficient environment and a SHIP-deficient T cell are 
required for the increased accumulation of Tregs that we observe.   
Here we show that the SHIP-deficient environment promotes the expression of 
receptors, CD103, GITR, and OX40, which have been associated with Treg function as 
well as with activated T cells.  Because of this, others have concluded that T cells exist 
in an activated state in SHIP-deficient mice354.  The data presented in this study further 
characterize T cells in SHIP-deficient mice, suggesting that expression of these 
receptors may be representative of an activated/effector T cell that also has 
immunosuppressive behavior.  Although Tregs can suppress in an antigen nonspecific 
manner, Tregs must undergo antigen-specific activation to suppress502.  Thus, SHIP-
deficient Tregs in both CD25+ and CD25− compartments may have an increased 
probability of suppressing other T cells because they exist in larger numbers and a 
larger proportion of them exist in an activated state.  Although we found that SHIP-
deficient Tregs are as equally potent at suppressing effector CD4+ T cells as are WT 
Tregs, SHIP-deficient Tregs may still have more potent suppressive activity when in a 
SHIP-deficient environment.  In addition, as done by Lehmann et al491, the number of 
Tregs coinjected along with WT effector CD25− T cells can be titrated to compare the 
smallest ratio of either SHIP-deficient or WT Tregs to effector T cells at which protection 
from colitis is compromised or lost.  Regardless, we show that SHIP-deficient Tregs are 
at least as suppressive as WT Tregs as assayed in vitro and in vivo.   
In WT mice, GITR expression in the CD25− and CD25+ T cell compartments 
represents immunoregulatory T cells capable of preventing autoimmune myocarditis, 
multiorgan inflammation, and murine inflammatory bowel disease.497 These studies 
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propose that GITR expression may be a better Treg surface marker than CD25.  
Similarly, in WT mice, CD25− and CD25+ T cells that express CD103 also represent a 
Treg subset capable of protecting mice from colitis in the SCID model in vivo491.  
Coincidentally, most GITR+ and CD103+ T cells within CD25+ and CD25− CD4+ T cell 
compartments in SHIP-deficient mice also coexpress FoxP3.  When using GITR or 
CD103 in addition to FoxP3, instead of CD25 and FoxP3, as the markers to determine 
the frequency of Tregs, there is a more pronounced increase in the representation of 
CD4+GITR+FoxP3+ Tregs or CD4+CD103+FoxP3+ Tregs than of CD4+CD25+FoxP3+ 
Tregs in the peripheral lymphoid organs of SHIP-deficient mice compared with that in 
WT mice (data not shown).   
As mentioned, both GITR and CD103 expression identifies a immunoregulatory T 
cell subset within the CD25− T cell compartment, although OX40 has not been shown to 
do so.  Streeter et al demonstrated that CD4+CD25−OX40+ T cells are proliferative on 
alloantigen stimulation whereas CD4+CD25+OX40+ T cells are suppressive.503 In SHIP-
deficient mice, even though there is approximately a 6-fold increase in the 
representation of CD25−OX40+ T cells compared with WT littermates, the SHIP-deficient 
CD25− T cell compartment as a whole was not more proliferative on alloantigen 
stimulation as demonstrated in vitro and in vivo.  Indeed, almost half of the CD25−OX40+ 
T cells in SHIP-deficient mice are also FoxP3+, whereas only approximately one-fourth 
of WT CD25−OX40+ T cells are FoxP3+ (data not shown).  Thus, in SHIP-deficient mice, 
the expression of OX40 among CD25− T cells is more closely associated with T cells 
with immunoregulatory capacity instead of T cells capable of alloantigen-induced 
proliferation.   
Engagement of costimulatory and cytokine receptors, such as OX40, GITR, 
CD103, IL-2R, and IL-7R, has been shown to confer survival and proliferative signals.494, 
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504-506 The increased density and expression levels of these markers on CD25− and 
CD25+ Tregs in SHIP-deficient mice may thus provide a survival advantage.  SHIP is 
known to oppose the activation of the PI3K pathway that can be activated by IL-2R, IL-
7R, or OX40 signaling504, 507.  Indeed, inhibition of PI3K signaling prevents IL-2 and other 
common gamma chain cytokines, IL-7 and IL-15, from supporting maximal suppression 
by Tregs507.  Thus, the survival and proliferative signals emanating from these receptors 
may be stronger when SHIP is not present to oppose PI3K.  The possibility of enhanced 
signaling from these receptors in combination with their increased surface expression 
could contribute to the increased representation of Tregs in peripheral lymphoid organs 
of SHIP-deficient mice.   
SHIP is also known to regulate signals emanating from both FcγRIIb, an 
inhibitory receptor, and FcγRIIIa, an activating receptor280, 508.  FcγR family members 
recognize the immunoglobulin Fc portion of antibodies, allowing free antibodies, immune 
complexes, and/or opsonized cells to fine-tune decisions between activation and 
suppression of an immune response.  FcγRs are expressed by almost all types of 
hematopoietic cells.  Previous studies examining whether T cells express FcγRs or not 
have been contradictory500.  Here we show that T cells in WT mice do express low levels 
of FcγRIIb/FcγRIIIa.  Intriguingly, SHIP-deficient CD25− T cells and CD25+ Tregs 
express FcγRIIb/FcγRIIIa at significantly higher levels than their WT counterparts.  This 
suggests that SHIP-deficient CD4+ T cells may be responsive to antibody, immune 
complexes and/or opsonized cells as SHIP is known to limit signals from both of these 
FcγRs280, 508.  Further analysis is needed to distinguish whether unopposed signals from 
these FcγRs occur in SHIP-deficient T cells and promote the preferable expansion of 
CD25−FoxP3+ T cells and CD25+FoxP3+ Tregs.  Consistently, serum levels of certain 
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IgG isotypes are increased in SHIP−/− mice, providing increased ligands for deregulated 
FcγRs present on SHIP−/− CD4+ T cells509. 
In addition to the increased expression of costimulatory molecules on Tregs, a 
SHIP-deficient environment promotes other immunologic changes that promote the 
accumulation of Tregs as well as protect against GvHD, specifically increased MDSC 
numbers,341, 345 and increased granulocyte colony-stimulating factor (G-CSF) 
expression356.  G-CSF promotes an immunosuppressive environment and thus protects 
against GvHD via many mechanisms.  Importantly, one study showed that in vivo G-CSF 
exposure promotes the acquisition of Treg properties by naive CD4+ T cells after T cell 
receptor ligation in vitro510.  Consistently, donors treated with pegylated G-CSF exhibited 
an increased generation of IL-10 producing Tregs and transplantation tolerance511.  
Furthermore, MacDonald et al showed that G-CSF and derivatives protected against 
GvHD by promoting the expansion of a CD11b+Gr1+ subset, similar to MDSC, that 
mediate the expansion of IL-10 secreting Tregs487.  This mechanism is plausible in a 
SHIP-deficient host, which is protected from GvHD, where increased G-CSF levels 
promote the expansion of MDSC that in turn mediate expansion of the peripheral Treg 
compartment.  Thus, SHIP may play both intrinsic and extrinsic roles to limit the 
accumulation of Tregs.   
The in vivo models described here provide further support that targeting SHIP 
could facilitate transplantation across MHC barriers.  We show that, in addition to the 
MDSC expansion, SHIP-deficiency promotes the accumulation of Tregs, which are 
known to play a pivotal role in transplantation immunology159, 512.  In a model of GvHD-
induced colitis, we show that isolated SHIP-deficient CD25− T cells inefficiently mount an 
immune response to cause colitis.  This outcome can be mediated by one of the 
following mechanisms.  First, because SHIP-deficient CD25− T cells could not cause 
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colitis in a Rag2−/−γc−/− mouse, which is not SHIP deficient, SHIP may play an intrinsic 
role in T cells that allows robust participation in allogeneic responses.  Alternatively, the 
SHIP-deficient environment could have led to the irreversible differentiation of some or 
all of the SHIP-deficient CD25− T cells into an unresponsive and/or immunosuppressive 
cell.  Consistently, two important observations can also be made from the vascularized 
heart transplantation model.  First, a significant increase in Treg and MDSC 
accumulation is observed in adult mice after only 8 days of induced SHIP-deficiency 
(data not shown).  Second, induced SHIP-deficiency in adulthood promotes a significant 
delay in graft rejection.  This study further characterizes the cells that make up the 
immunosuppressive environment promoted by SHIP-deficiency, providing further 
support for targeting of SHIP to improve allogeneic transplantation procedures.  
When considering cancer treatment, BMT can be employed to treat patients with 
certain forms of cancer, such as leukemia, lymphoma and multiple myeloma. In addition, 
BMT can be used after chemotherapy and radiation, which can effectively kill cancer 
cells but also destroy the patient’s bone marrow. Though, BMT exhibit significant clinical 
disadvantages, which can be fatal, primarily mediated by host versus graft and graft 
versus host immune responses.  Thus, improving its efficacy, especially across MHC 
barriers, would greatly impact the applicability and feasibility of BMT in cancer treatment.  
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Chapter 4.  SHIP has Lineage Extrinsic and Intrinsic Control on the Accumulation 
of Immunoregulatory Cells 
 
Introduction 
A role for SHIP in limiting immunoregulatory processes was initially revealed 
when it was found that a SHIP-competent, T cell replete BM graft failed to mount a 
robust GvH response in MHC-mismatched, SHIP-deficient hosts resulting in improved 
transplant survival325.  We subsequently found that the number of MDSC341, 345 and 
Tregs482 were profoundly increased in secondary lymphoid tissues of SHIP-/- mice and 
after ablation of SHIP expression in adult MxCreSHIPflox/flox mice.  GvHD and organ graft 
rejection are primed by host APC present in secondary lymphoid organs513-516.  MDSC 
and Tregs can antagonize this process resulting in reduced GvHD158, 341, 345, 517 or 
acceptance of allogeneic organ grafts484.  Thus, a more complete understanding of how 
SHIP limits the numbers of these two key immunoregulatory cells in vivo might have 
important implications for clinical transplantation. 
Several different hematolymphoid defects have been reported in SHIP-deficient 
mice325, 338, 340, 343, 344, 518-520.  In several cases these genetic phenotypes have been 
shown to result from a cell autonomous role for SHIP in the affected cell type336, 485, 519-
521.  However, instances have been documented where altered function on the part of a 
SHIP-deficient cell type impairs the function or development of a different cell type or 
lineage356, 522.  This appears to be due in large part to the altered production of key 
cytokines, growth factors or chemokines that occurs in SHIP-deficient mice.  SHIP-/- mice 
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exhibit profoundly increased production of IL-6519 and G-CSF356 and greatly diminished 
SDF1/CXCL12 production356, all of which can contribute to altered function or 
localization of other cells, as seen specifically with HSC356, 523, 524. The cellular and 
molecular basis of over- or under-production of soluble factors in SHIP-/- mice remains to 
be undefined, although studies with SHIP-/- mast cells, for example, indicate hyper-
activation of NF-κB contributes to their increased production of IL-6519. 
Studies have revealed that as anticipated, the primary role of SHIP in cell 
signaling is recruitment to receptor-signaling complexes where it can then oppose 
activation of PI3K effector kinases such as Akt by hydrolysis of the PI3K substrate, 
PI(3,4,5)P3325, 343, 525.  However, SHIP can also, in certain signaling contexts, ‘mask’ 
cytoplasmic motifs on certain receptors and in so doing prevent the inappropriate 
recruitment of other phosphatases (for example SHP1) or PI3K336.  This non-enzymatic 
role should be considered when attempting to decipher the role SHIP plays in signaling 
by a given receptor.  Also, although SHIP is largely considered to only exert a negative 
impact on cell function, survival or proliferation, in some contexts, SHIP can also 
promote cellular functions. For example, analysis of NK cells in SHIP-/- mice indicated 
that SHIP is essential for these cells to perform efficient target cytolysis and secretion of 
γ-IFN325, 336, 485, 526, the two major NK effector functions.  Consistently, recent reports have 
found that SHIP promotes macrophage effector function301 and cancer cell survival527 by 
synthesis of its product, PI(3,4)P2, which is known to recruit GTPase Irgm1301and 
activate Akt527-529. 
We have shown that in SHIP-deficient hosts, a significant number of T cells of 
the naïve phenotype CD4+CD25- express FoxP3 and are suppressive, suggesting T-
lineage intrinsic control of FoxP3 expression and suppressive function by SHIP.  
Uncertainty remains as to how SHIP-deficiency promotes the expansion of these 
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CD4+CD25-FoxP3+ T cells, as well as of conventional CD4+CD25+FoxP3+ Tregs, and 
MDSC numbers.  In the present study, we examine this question further and find 
evidence for lineage intrinsic control of MDSC numbers and function and that SHIP’s 
control of G-CSF production plays a role in this regulation.  However, SHIP exerts 
control over CD4+CD25-FoxP3+ T cells and conventional CD4+CD25+FoxP3+ Treg 
numbers through both lineage extrinsic and intrinsic mechanisms. 
 
 
Results 
 
Myeloid-Restricted Ablation of SHIP Expression Increases the Frequency of 
MDSC and Tregs in Peripheral Lymphoid Tissues.  Several groups have used the 
LysCre transgenic mouse to create myeloid-restricted deletion of floxed gene loci347.  We 
generated LysCreSHIPflox/flox mice to determine if myeloid-restricted deletion of SHIP 
would lead to increased numbers of MDSC in peripheral lymphoid tissues and, in turn, 
promote the expansion of Tregs.  LysCreSHIPflox/flox mice appeared to have an 
essentially normal life span as they typically live well over a year with no apparent health 
complications as opposed to germline SHIP-/- mice that typically succumb within 6-10 
weeks of life344, 345.  LysCreSHIPflox/flox mice also failed to develop the myeloproliferative 
disease (MPD) reported in germline SHIP-/- and MxCreSHIPflox/flox mice341, 344 as MPD-
associated splenomegaly in LysCreSHIPflox/flox mice was not observed (data not shown).   
Analysis of SPL and LN showed that the frequency of MDSC was significantly 
increased in both tissues in LysCreSHIPflox/flox mice relative to SHIPflox/flox controls (Figure 
13A).  This increase was not pan-lineage, as developing myeloid cells that possess the 
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same CD11b+Gr1+ phenotype as MDSC in the periphery, were not significantly 
increased in the BM of LysCreSHIPflox/flox relative to SHIPflox/flox littermates (Figure 13B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  The frequency of myeloid immunoregulatory cells is increased in mice 
with myeloid-restricted ablation of SHIP expression. 
(A) Representative contour plots of CD11b vs. Gr1 staining of viable SPL and LN cells 
from LysCreSHIPflox/flox (labeled as Cre+) and SHIPflox/flox controls (labeled as Cre-).  The 
percentage of CD11b+Gr1+ MDSCs in spleen and LN from LysCreSHIPflox/flox  (Cre+) and 
SHIPflox/flox controls (Cre-) are shown as box-and-whisker plots representing median with 
the maximum and minimum value range of n=12/genotype. (B) Representative FACS 
contour plots for CD11b vs. Gr1 staining of BM cells from Cre+ and Cre-.  Quantitation of 
immature CD11b+Gr1+ myeloid in the BM of Cre+ and Cre- controls.  Data are shown as 
a bar graph representing the mean + SEM of n=4/genotype. (*P ≤ 0.05, **P ≤ 0.01, ***P 
≤ 0.001) 
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In addition, a significant decrease in the frequency of CD3+ T lymphocytes in SPL 
and LN (Figure 14A) was observed, although the absolute number of CD3+ T cells did 
not change (Figure 14B).  In change, the frequency and absolute number of Tregs was 
significantly increased in both tissues (Figure 14D-F).  We confirmed that the T cell 
compartment in LysCreSHIPflox/flox mice expressed normal levels of SHIP protein (Figure 
14C).  Thus, the Treg increase cannot be attributed to lineage-inappropriate ablation of 
SHIP expression in LysCreSHIPflox/flox mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  The frequency of T lymphoid immunoregulatory cells is increased in 
mice with myeloid-restricted ablation of SHIP expression. 
(A, B) The percentage (A) and absolute number (B) of CD3+ T cells in spleen and LN 
from Cre+ and Cre- as indicated are shown as box-and-whisker plots representing the 
median with the maximum and minimum value range of n=8/genotype. (C) Western blot 
analysis of SHIP expression in CD3+ T cells sorted from Cre+ mice and Cre- controls.  (D) 
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Representative contour plots of CD4 vs. CD25 staining of viable CD3+ splenocytes and 
LN cells from Cre+ and Cre- controls.  (E, F) The percentage (E) and absolute number 
(F) of CD4+CD25+FoxP3+ Treg cells in spleen and LN as indicated are shown as box-
and-whisker plots representing the median with the maximum and minimum value range 
of n=8/genotype. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001) 
 
 
The increase in frequency in both myeloid and T lymphoid immunoregulatory cell 
numbers observed was physiologically relevant, as both LysCreSHIPflox/flox splenocytes 
(Figure 15A) and LN cells (Figure 15B) exhibited significantly reduced capacity for 
priming of allogeneic T cell responses by MHC-mismatched responder cells relative to 
SHIP-competent SHIPflox/flox controls.  A similar increase in the immunoregulatory 
capacity of peripheral lymphoid organs was also observed in germline SHIP-/- mice345, 
MxCreSHIPflox/flox mice after genetic ablation341 and following treatment with a SHIP1 
inhibitor527.  As anticipated, myeloid-restricted ablation of SHIP expression in 
LysCreSHIPflox/flox mice promoted an expansion of the MDSC compartment in secondary 
lymphoid tissues demonstrating that lineage intrinsic control of the production and/or 
survival of MDSC is regulated by SHIP.  The increased Treg frequency also observed in 
these tissues indicates that a myeloid cell that expresses SHIP limits the frequency of 
Tregs in peripheral lymphoid tissues in a lineage extrinsic fashion.  Following cytokine 
administration or tumor formation, others have previously reported MDSC can induce a 
significant increase in peripheral Treg numbers233, 487.  Our findings demonstrate SHIP 
also limits this function of the myeloid compartment. 
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Figure 15.  Peripheral lymphoid cells from mice with myeloid-restricted SHIP-
deficiency exhibit reduced capacity for priming allogeneic T cell responses.   
(A,B) One-way MLR analysis of allogeneic T cell (BALB/c) priming by irradiated Cre+ or 
Cre- splenocytes (A) and LN (B) cells.  Data are shown as mean + SEM of n=4. These 
results are representative of two independent experiments for both tissues.  (*P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001) 
 
 
MDSC Isolated from Naïve or Tumor-Bearing Mice Lack Detectable 
Expression of SHIP Protein.  The expansion of MDSC observed in LysCreSHIPflox/flox 
mice suggests that SHIP expression in these cells might oppose signals in these cells 
that limit their proliferation and/or survival in vivo.  As an initial test of this hypothesis, 
sorted MDSC from SHIP+/+ SPL were analyzed for SHIP expression by Western blot 
(Figure 16A).  Surprisingly, SHIP protein expression was essentially undetectable in 
naïve MDSC purified from SPL.  In addition, conventional MDSC purified from the SPLs 
and from the tumors of mice bearing MC-38 tumors (Figure 16A) were analyzed. MC-38 
tumors are known to harbor large numbers of potent MDSC530.  As with naive MDSC, 
these tumor-promoted MDSC also lacked detectable expression of SHIP.  These 
findings indicate that MDSC expansion in LysCreSHIPflox/flox mice is unlikely to be the 
result of cell-autonomous signaling by SHIP in MDSC since they lack expression of 
SHIP.  Thus, control of MDSC formation and/or survival by SHIP must be mediated by 
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another cell type within the myeloid lineage that expresses SHIP.  SHIP protein levels in 
immature CD11b+Gr1+ cells present in BM, as well as naïve T cells, Tregs and CD8+ T 
cells from normal mice were further examined (Figure 16B).   Although all T cell lineages 
express SHIP, the immature myeloid cells in BM also lacked detectable expression of 
SHIP. 
 
 
 
Figure 16.  MDSC purified from either naïve or tumor-bearing mice do not express 
SHIP.    
(A) Western blot analysis of SHIP and β-Actin expression in whole cell lysates prepared 
from sorted CD11b+Gr1+ cells from SPL of naïve mice, SPL of mice bearing MC-38 
tumors or directly from MC-38 tumors harvested from C57BL/6J hosts.  (B) Western blot 
analysis of SHIP and β-Actin expression in whole cell lysates prepared from the 
indicated FACS sorted cell populations prepared from the SPL or BM of naive C57BL/6J 
mice. Note: SHIP protein products commonly exhibit size variations with the longest 
isoform being SHIPα (145kDa), followed by SHIPβ (135kDa), SHIPγ (125kDa), and 
SHIPδ (110kDa)310  
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T Cell-Restricted Mutation of SHIP Leads to Expansion of Treg Numbers, 
but not MDSC.  Efficient ablation of floxed loci in a T-lineage restricted fashion can be 
achieved with a Cre recombinase transgene driven by the Lck proximal promoter531-534.  
LckCreSHIPflox/flox mice were thus developed to assess whether T-lineage restricted 
ablation of SHIP expression also promotes expansion of Tregs and whether these Tregs 
might in turn facilitate an increase in the frequency of MDSC in peripheral lymphoid 
tissues.  As anticipated, the T cell compartment in LckCreSHIPflox/flox mice exhibited 
significantly reduced expression of SHIP expression in T-lineage cells (Figure 17A).  We 
found a significant reduction in the frequency of splenic CD3+ T cells (Figure 17B) and of 
CD4+ and CD8+ T cells in the peripheral blood of LckCreSHIPflox/flox mice relative to 
SHIPflox/flox controls (Figure 17D).  The frequency of CD3+ T cells in LN was unchanged 
relative to SHIPflox/flox littermates (Figure 17B).  Additionally, the absolute number of CD3+ 
T cells does not change in the SPL and LN of LckCreSHIPflox/flox mice relative to 
SHIPflox/flox controls (Figure 17C).  In spite of this decrease in total splenic and circulating 
T cells in both the CD4 and CD8 lineages, a significant increase in the frequency and 
absolute number of Tregs in both the SPL and LN of LckCreSHIPflox/flox mice relative to 
SHIPflox/flox controls was observed (Figure 17E).   
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Figure 17.  T cell-specific SHIP-deficiency promotes increased Treg numbers in 
peripheral lymphoid tissues.   
(A) Western blot analysis of SHIP expression in CD3+ T cells sorted from the indicated 
genotypes.  (B,C) The percentage (B) and absolute number (C) of CD3+ T cells in spleen 
and LN from LckCreSHIPflox/flox (Cre+) and SHIPflox/flox (Cre-) controls  are shown as box-
and-whisker plots representing the median with the maximum and minimum value range 
of n=6/genotype. (D) Representative contour plots for CD4 vs. CD8 staining of viable 
PBMC for the indicated genotypes (E) Representative contour plots for CD4 vs. CD25 
staining of viable SPL and LN cells for the indicated genotypes.  The percentage and 
absolute number of CD4+CD25+FoxP3+ Treg cells in spleen and LN of the indicated 
genotype are shown as box-and-whisker plots representing the median with the 
maximum and minimum value range of n=6/genotype. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001) 
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In addition, there was a significant increase in the number of T cells of the naïve 
CD4+CD25- phenotype that expressed FoxP3 (Figure 18).  These results indicate SHIP 
limits the expression of FoxP3 by CD4+CD25- T cells and formation of CD4+CD25+ Tregs 
in a T-lineage intrinsic fashion.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  T cell-specific SHIP-deficiency promotes increased numbers of 
CD4+CD25-FoxP3+ T cells in peripheral lymphoid tissues.   
(A) Representative contour plots of intracellular FoxP3 vs. CD25 staining for splenic 
CD4+ T cells of LysCreSHIPflox/flox (Lys Cre+) or LckCreSHIPflox/flox (Lck Cre+) and their 
respective littermate SHIPflox/flox controls (Cre-) (B) The percentage of CD4+CD25-FoxP3+ 
cells among splenic CD4+ T cells for the indicated genotype are shown as box-and-
whisker plots representing the median with the maximum and minimum value range of 
n=8 for LysCre+, n=6 for LckCre+ and n=14 for Cre-. (*P ≤ 0.05) 
 
 
To determine if SHIP expression by a myeloid lineage cell might also limit 
expression of FoxP3 expression by CD4+CD25- T cells, the same analysis in 
LysCreSHIPflox/flox mice and SHIPflox/flox littermate controls were performed, which showed 
that myeloid-restricted SHIP-deficiency also promoted FoxP3 expression by CD4+CD25- 
T cells (Figure 18).  This suggests that SHIP limits conversion of naïve T cells to FoxP3+ 
Tregs or FoxP3 expression in both a T-lineage intrinsic and extrinsic fashion, with the 
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latter regulation pathway mediated by SHIP-expressing myeloid cell.  However, this 
increased frequency of FoxP3+ CD4+25- T cells and CD4+CD25+ Tregs in 
LckCreSHIPflox/flox mice did not promote a corresponding increase in MDSC frequency in 
peripheral lymphoid tissues (Figure 19).  Thus, the ability of SHIP-deficient 
immunoregulatory myeloid and T lymphoid cells to influence each other’s homeostasis 
and formation is unidirectional, with only SHIP-deficient myeloid lineage cells capable of 
trans-lineage control of immunoregulatory cell numbers in another lineage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  T cell-specific SHIP-deficiency does not affect MDSC numbers in 
peripheral lymphoid tissues.   
(A) Representative contour plots of CD11b vs. Gr1 staining of viable SPL and LN cells 
from mice of the indicated genotype.  (B) The percentage of CD11b+Gr1+ MDSCs in 
spleen and LN of the indicated genotype are shown as box-and-whisker plots 
representing the median with the maximum and minimum value range of n=6/genotype. 
 
 
G-CSF Promotes Expansion of MDSC in Mice Rendered SHIP-Deficient.  We 
previously showed that there is a profound increase in production of the myelopoietic 
growth factor G-CSF in SHIP-/- mice356.   This myelopoietic growth factor might promote 
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the MDSC expansion and consequently expansion of Treg numbers.  To test this, mice 
were treated with neutralizing anti-G-CSF antibodies for one week after ablating SHIP 
expression using the MxCreSHIPflox/flox mouse model341.  Consistent with this hypothesis, 
anti-GCSF treatment prevented the expansion of splenic MDSC after induction of SHIP-
deficiency (Figure 20A, B).  However, the splenic Treg expansion was still observed 
(Figure 20C, D).  Thus, expansion of MDSC in the SPL, but not in the LN of SHIP-
deficient mice (data not shown) is dependent upon increased G-CSF production.  
However, the Treg expansion that occurs in peripheral lymphoid tissues following 
induction of SHIP-deficiency in adults482 is not prevented by G-CSF neutralization and 
thus is not dependent upon increased G-CSF production or expanded numbers of 
MDSC.  In MxCreSHIPflox/flox mice where SHIP-deficiency is systemic, the Treg 
expansion likely results from the T-lineage intrinsic effects of SHIP-deficiency, increased 
production of another soluble or cell-bound ligand expressed by SHIP-deficient myeloid 
cells that is required for Treg expansion, but which does not impact MDSC numbers. 
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Figure 20.  G-CSF is required for the expansion of splenic MDSC numbers, and not 
of Treg numbers, in SHIP-deficient hosts. 
(A) Representative contour plots of CD11b vs. Gr1 staining of viable splenocytes from 
poly-I/C treated MxCreSHIPflox/flox and SHIPflox/flox mice after administration of anti-G-CSF 
or PBS as indicated.  (B) Bar graphs indicating the absolute number of CD11b+Gr1+ 
MDSC in SPL of mice of the indicated genotype and treatment.  (C) Representative 
contour plots of CD4 vs. CD25 staining of viable splenocytes from mice as in (A).  (D) 
Bar graphs indicating the absolute number of Tregs in SPL of mice of the indicated 
genotype and treatment. All data are shown as mean + SEM of n=8 and are pooled from 
2 experiments.  (*P ≤ 0.05) 
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G-CSF can also suppress SDF-1/CXCL12 production by osteoblasts, which is 
critical for their support of quiescent HSC in the endosteal BM niche535-537.  We 
previously found that BM niche expression and plasma levels of SDF1/CXCL12 are 
substantially diminished in SHIP-/- mice and MxCreSHIPflox/flox mice following ablation of 
SHIP expression356.  G-CSF neutralization might then prevent suppression of SDF-
1/CXCL12 production following induction of SHIP-deficiency.  However, suppression of 
SDF-1/CXCL12 following induction was not prevented by G-CSF neutralization (Figure 
21).  These results indicate suppression of SDF-1/CXCL12 production following SHIP-
deficiency is not a result from increased G-CSF production and may reflect a direct role 
for SHIP in promoting expression of SDF1/CXCL12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.  G-CSF neutralization does not reverse down-modulation of SDF-
1/CXCL12 production in SHIP-deficient hosts. 
Plasma concentration of SDF-1/CXCL12 measured by ELISA in MxCreSHIPflox/flox and 
SHIPflox/flox mice after deletion of SHIP and administration of anti-G-CSF or PBS as 
indicated. Data are shown as mean + SEM of n=8 and are pooled from 2 experiments.   
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Discussion 
 
By selectively ablating SHIP expression in either myeloid or T lymphoid lineage 
cells, we show here that SHIP exerts both lineage intrinsic and extrinsic control over the 
peripheral immunoregulatory cell compartment.  Myeloid-restricted ablation of SHIP 
expression causes a significant expansion of MDSC and SHIP-competent FoxP3+ T 
cells in both spleen and LN.  Consistently, priming of allogeneic T cells responses by 
these tissues is significantly compromised.  However, we failed to find evidence for 
reciprocal regulation of MDSC numbers by SHIP-deficient T cells despite a significant 
increase in Treg and CD4+CD25-FoxP3+ T cell frequency in LckCreSHIPflox/flox mice.  
Thus, SHIP possesses both lineage intrinsic and extrinsic control over peripheral Treg 
accumulation; and lineage-intrinsic control over MDSC accumulation when specifically 
manipulating SHIP in the T cell and myeloid compartments (see model, Figure 22).   
Surprisingly, we found that MDSC from naïve mice or tumor-bearing mice lack 
detectable levels of SHIP protein expression.  This suggests that regulation of MDSC 
formation occurs via a lineage-intrinsic mechanism mediated by another SHIP-
expressing myeloid cell that perhaps produces a soluble factor that promotes peripheral 
MDSC expansion.  Consistently, neutralization of G-CSF, which is significantly increased 
in SHIP-deficient mice, blocked splenic MDSC expansion of mice with induced SHIP-
deficiency.  Furthermore, immature CD11b+Gr1+ myeloid progenitors in the BM lack 
SHIP expression, suggested that the myeloid cell that limits MDSC accumulation is a 
differentiated myeloid cell in the periphery.  In addition, as seen with tissue MΦ301, 
activation of SHIP expression may be required for myeloid cell differentiation and 
acquisition of effector function.  Inability to activate SHIP expression may cause SHIP-
deficient myeloid cells to default to cells that possess immunoregulatory rather than 
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effector function.  Conversely, inappropriate activity, such as increased production of G-
CSF, by other SHIP-deficient myeloid cells may also promote MDSC accumulation.  
Previous studies have indicated a potential role for MDSC in promoting 
expansion of Tregs341, 345, 482 233.  Although, our G-CSF neutralization studies suggest 
otherwise, MDSC-mediated Treg expansion cannot be conclusively dismissed as a 
potential mechanism at play in our model of induced SHIP-deficiency.  Specifically, only 
splenic MDSC expansion, and not MDSC expansion in the LN, was prevented after G-
CSF neutralization.  Possibly, MDSC in the LN mediated Treg expansion in these mice.  
Otherwise, another myeloid cell population may also be responsible for this effect on the 
Treg compartment via a soluble factor or cell bound ligand other than G-CSF, since G-
CSF neutralization only prevented splenic MDSC expansion, and not Treg compartment 
expansion (see model, Figure 22).  Also, the unaffected increase in peripheral Tregs 
may have been due to their ineffective recruitment to their BM reservoir by SDF-
1/CXCL12, which is suppressed in the BM of SHIP-deficient mice and was not reversed 
by G-CSF neutralization.  Treg migration to tissue sites, including the BM reservoir, is 
controlled by SDF-1/CXCL12538, 539.  
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Figure 22. Proposed model of the lineage intrinsic and extrinsic effects SHIP-
deficiency has on immune regulatory cells. (A) The combination of intrinsic and 
extrinsic effects mediated by total SHIP-deficiency promotes the highest increase in 
MDSC and Treg numbers. Extrinsic factors such as increased production of G-CSF and 
perhaps the effect of another unknown myeloid cell, promote the expansion of MDSC in 
peripheral lymphoid organs. Extrinsic factors that promote the increase in Treg numbers 
include MDSC-mediated Treg expansion, decreased levels of SDF-1 and perhaps 
another unknown factor produced by an unknown myeloid cell. (B) With myeloid-
restricted SHIP-deficiency, a significant increase in MDSC and Treg is also observed. 
Due to the lack of SHIP expression by MDSC, another unknown SHIP-expressing 
myeloid cell may instead promote their expansion. Alternatively, perhaps myeloid 
differentiation is affected by myeloid-specific SHIP-deficiency such that myeloid cells 
default to cells with suppressive capacity capable of also promoting the expansion of 
Tregs. Again, Treg expansion may also be promoted by another unknown factor 
produced by an unknown myeloid cell. (C) T cell-specific SHIP-deficiency only affects 
the size of the Treg compartment suggesting that SHIP also plays an intrinsic role in 
Treg development independent of its extrinsic role as exhibited in the context of full 
SHIP-deficiency and myeloid-restricted SHIP- deficiency. 
 
 
Tarasenko et al also examined SHIP’s intrinsic role on the T cell compartment 
and reported contradictory results.  Specifically, using CD4CreSHIPflox/flox mice, they 
found that T cell-specific deletion of SHIP had no affect on T cell development, activation 
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state, or Treg numbers339.  The discrepancy may be because deletion of SHIP in 
CD4CreSHIPflox/flox mice may occur at a different time point during T cell development 
compared to SHIP deletion in LckCreSHIPflox/flox mice.  Nonetheless, the only supporting 
data provided was a table depicting the percentage of splenic FoxP3+ cells without 
distinguishing CD4 and CD25 expression, thus not being an accurate representation of 
the Treg compartment.  Furthermore, it was reported that 19-21% of splenocytes in 
CD4CreSHIPflox/flox mice were FoxP3+ which is an abnormally high percentage for splenic 
Tregs.  The more precise Treg phenotype analysis presented here indicates that SHIP 
does indeed intrinsically limit the size of the Treg compartment in vivo.  In addition, 
experiments performed by Locke et al further support SHIP’s intrinsic role in Treg 
development. Specifically, they showed that a significantly higher proportion of SHIP-
deficient CD4+FoxP3- T cells acquired FoxP3 expression compared to WT T cells in an 
in vivo adoptive transfer experiment355. 
Because of SHIP’s potential to influence many PI3K-mediated signaling 
pathways during the lifespan of a T cell, SHIP may control the Treg compartment size by 
limiting, for example, the acquisition of FoxP3 expression by peripheral T cells (Treg 
induction) and/or limiting the survival or proliferation of existing Tregs in the periphery 
(Treg homeostasis).  Consistently, NF-κB and NFAT,  transcription factors whose activity 
can be limited by SHIP520, 540, have recently been identified as critical for promoting 
FoxP3 expression during T cell development541.  CD28 engagement activates the 
PI3K/Akt pathway, which SHIP opposes542, to promote FoxP3 expression in peripheral T 
cells.  In addition, others have found that Akt can promote iTreg formation independent 
of CD28 signals543.  Furthermore, Treg numbers and function are compromised in 
p110delta PI3K mutant mice544 and increased in mice with enforced expression of 
Akt/PKB543.  Although, it must be noted that Tregs show reduced Akt phosphorylation355 
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and specifically require limited Akt activation to induce, but not maintain, FoxP3 
expression545, 546.  Furthermore, SHIP’s function in T cells may be more than just 
negative regulation of PI3K and instead also include activation of qualitatively different 
PI3K effector pathways.  Specifically, it has been shown that the catalytic product of 
SHIP, PI(3,4)P2, recruits different signaling proteins from those recruited by PIP3 and the 
PTEN product, PI(4,5)P2547.   
The findings presented here and our previous studies of MDSC, Tregs and  NK 
cell in SHIP-deficient mouse models 325, 336, 341, 345, 482, 485, 548 indicate that SHIP-deficiency 
promotes an immunosuppressive environment that preferentially impairs cell-mediated 
immunity, particularly those involving MHC-mismatched responses.  Recently, a SHIP-1 
selective inhibitor that also increases MDSC numbers in vivo and fosters a potent 
immunosuppressive environment in peripheral lymphoid tissues was identified527.  Thus, 
pharmacological targeting of SHIP1 activity in vivo could be used to improve the efficacy 
and utility of allogeneic organ and bone marrow transplantation.  We propose that down-
regulation of SHIP expression serves as a molecular switch to promote an 
immunosuppressive state in peripheral lymphoid organs549.  Such a “SHIP switch” is 
certainly plausible as SHIP expression is readily modulated post-transcriptionally by 
miR155317 and post-translationally by ubiquination550.  Indeed, SHIP expression varies 
significantly within both the myeloid (data not shown) and NK cell lineages 315 suggesting 
that SHIP regulation occurs during normal fluctuations in immune status and 
differentiation.  Rather than acting as a global immune suppressor, the increased MDSC 
and Treg numbers promoted by a “SHIP switch” may act to dampen low affinity T cells 
responses or self-reactive T cell response during intense immune responses allowing 
more focused, and thus more effective, immune responses to major pathogen 
challenges.  Intriguingly, tumor-bearing mice, similar to SHIP-deficient mice, exhibit an 
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increase in Tregs and MDSC.  Perhaps, tumors may also exploit this “SHIP switch” to 
their advantage in order to promote tumor progression. This would require further 
studies. 
A recent study performed by Kerr et al describing an interesting phenotype in 
SHIP-deficient mice provides further argument that SHIP does not simply act as a global 
immune suppressor. In addition, it shows that SHIP-deficiency has diverse effects in 
different anatomical compartments. Specifically, this study showed that SHIP-deficient 
mice exhibited ileitis similar to the enteric pathology seen in Crohn’s disease. Within the 
small intestine of SHIP-deficient mice, both CD4+ and CD8+ T cells were scarce while 
neutrophils were significantly increased in numbers compared to WT controls. 
Furthermore, this phenotype was mediated specifically by the hematopoietic 
compartment since reconstitution of SHIP-deficient mice with WT bone marrow 
corrected ileitis and reconstitution of WT mice with SHIP-deficient splenocytes did not 
transfer ileitis551.  This occurs as a paradox, where total SHIP-deficiency promotes an 
immune suppressive environment mediated by the accumulation of Tregs and MDSC in 
the periphery while also promoting immune hyper-activation in the small intestine 
mediated most likely by the over-abundance of neutrophils and lack of T cells. How a 
SHIP- deficient compartment promotes this phenotype is still unknown. Due to the lack 
of T cells in the intestine, perhaps T cells, including Tregs, are required to control the 
over-active neutrophilic response. SHIP-deficiency may have an effect on T cell homing 
and/or survival. Importantly, Tregs are also known to control IBD. If SHIP-deficiency 
does affect T cell homing, perhaps SHIP-deficient Tregs, regardless of their increased 
abundance, cannot properly home to the small intestine and protect the mice from CD. 
Unfortunately, the presence of ileitis was not investigated when performing the studies 
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presented above using the myeloid-specific SHIP-deficient mouse model. Clearly, these 
studies and others are required to fully clarify this paradox. 
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Chapter 5.  Rb1 Controls the Differentiation of Myeloid Derived Suppressor Cells 
Subsets 
 
Introduction  
MDSC are a heterogeneous myeloid population of immature precursors and 
pathologically activated cells that accumulate significantly in several pathological 
settings, such as cancer and chronic infection, inflammation, and stress.  The main 
defining characteristic of MDSC is that they effectively suppress several facets of the 
resulting immune response in these various settings.  In particular, MDSC have been 
studied extensively in cancer where their suppressive function has been clearly 
appreciated to contribute significantly to cancer progression.  In virtually every tumor 
model and in every type of human cancer that has been examined for them, MDSC have 
been shown to be expanded242, 552.  Moreover, when MDSC are depleted in tumor-
bearing mice and in cancer patients, enhanced immune responses and in some cases, a 
direct anti-tumor response are achieved553.  Thus, understanding the mechanisms 
driving their accumulation can be translated into therapeutic application by directly 
targeting these mechanisms554, 555. 
Initially, MDSC in cancer were simply identified as Gr1+CD11b+ cells with potent 
suppressive capacity204.  Further characterization of their phenotype according to 
morphology, the expression of surface markers, and modes of suppression has led to 
the identification of two major subsets within the overall MDSC population219, 233-236.  One 
subset is granulocyte-like (CD11b+Ly6GhiLy6C-), thus called granulocytic MDSC (G-
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MDSC); and the other is monocyte-like (CD11b+Ly6G-Ly6C+), thus called monocytic 
MDSC (M-MDSC).  G-MDSC suppressive capacity is primarily reliant on significantly 
high productions of ROS and close cell-cell contact with T cells.  In turn, M-MDSC rely 
on the activity of iNOS, Arg-1 and several suppressive cytokines to effectively suppress 
T cell responses independent of antigen specificity240, 242.  In many tumor models 
examined, there is a preferential accumulation of G-MDSC over M-MDSC in peripheral 
lymphoid organs, thus G-MDSC represents the majority of MDSC241.  Consistently, these 
two subsets also differ in their differentiation and proliferative capacity244, 556.  In culture 
supplemented with GM-CSF, G-MDSC that remain, essentially preserve their phenotype 
and morphology.  Instead, M-MDSC differentiate further acquiring CD11c, F4/80 
markers, which are DC and macrophage specific markers.  Additionally, G-MDSC are 
non-proliferative while M-MDSC are highly proliferative both in vitro and in vivo.  
Conversely, M-MDSC preferentially acquired the phenotype of G-MDSC with decreased 
acquisition of DC and macrophage specific markers in culture with TES.  Furthermore, 
the majority of M-MDSC transferred into tumor-bearing mice acquired the phenotype of 
G-MDSC, suggesting that G-MDSC accumulation may be a result of the proliferation and 
preferential differentiation of M-MDSC to G-MDSC in cancer556.  Further studies are 
required to understand the molecular mechanisms driving this process.   
The retinoblastoma protein (Rb) is well known for its involvement in a variety of 
cellular processes such as the cell cycle, differentiation, apoptosis and DNA repair.  Its 
most well-documented form of regulation is through its association with E2F family 
transcription factors which leads to transcriptional inhibition of E2F response genes.  In 
addition, Rb-E2F complexes act as active repressors by associating with several other 
chromatin-modifying complexes including histone deacetylases and methylase, DNA 
methyltransferases and ATP-dependent chromatin-remodeling enzymes375. 
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Because hematopoietic cells are constantly proliferating, differentiating and 
dying, Rb activity within the hematopoietic compartment is critical.  In fact, Rb is known 
to interact with several hematopoietic transcription factors472.  Rb-mediated regulation is 
both extrinsic and intrinsic in hematopoietic cells.  For example, Rb indirectly controls 
erythropoiesis by interacting with Id2, a transcription factor that regulates differentiation 
in fetal liver MΦ474.  In change, under stress condition, Rb was intrinsically required for 
proper erythroblast expansion and red cell enucleation475.  In addition, Rb has been 
shown to regulate monocytic and neutrophilic lineage commitment.  When Rb 
expression is decreased using antisense Rb oligonucleotides in progenitor cells, they 
preferentially differentiate into neutrophilic cells even under monocytic-promoting culture 
conditions472.  Consistently, Rb expression is down-regulated during granulopoiesis in 
vivo, in which neutrophil precursor cells express high level of Rb while more mature 
polymorphonuclear neutrophils express much less Rb477.  Finally, when Rb is deleted 
conditionally during adulthood, as accomplished with MxCreRbflox/flox mice, 
myeloproliferative disease develops.  This phenotype was not achieved when Rb was 
deleted only in HSC.  In change, the deletion of Rb in myeloid cells and in the BM 
microenvironment was sufficient to promote myeloproliferative disease suggesting an 
extrinsic effect of Rb on HSC homeostasis and differentiation471.  Though, when all Rb 
family members are conditionally deleted in mice, myeloproliferation disease develops in 
a cell-intrinsic manner and reintroduction of a single p107 allele prevented this.  
Furthermore, hematopoietic progenitor cells with all Rb family proteins deleted exhibited 
a gene expression profile consistent with the preferential myeloid development 
observed479. 
 In this study, the role of Rb1 in the accumulation and differentiation of MDSC 
subsets in cancer was examined.  We found that M-MDSC and G-MDSC express 
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different levels of Rb1 at both the mRNA and protein level.  Specifically, M-MDSC 
expressed high levels whereas G-MDSC expressed undetectable levels.  In culture with 
GM-CSF, M-MDSC Rb1 expression levels stayed relatively the same while increasing in 
G-MDSC over time, which is accompanied by an increase in histone acetylation at the 
Rb1 promoter.  Further, when treated with an HDAC inhibitor (HDACi), the increase in 
Rb1 expression in G-MDSC was enhanced with increased acetylation at the Rb1 
promoter.  Treatment of M-MDSC with HDACi, which presumably promotes sustained 
Rb1 expression, abrogated their ability to differentiate into G-MDSC, even in the 
presence of TES.  Finally, analysis of these subsets in a model of induced Rb1-
deficiency exhibited a preferential expansion of myeloid cells with a phenotype similar to 
that of G-MDSC.  These results suggest that Rb1 indeed plays a role in the 
accumulation of MDSC, particularly G-MDSC in cancer.   
 
 
Results 
 
MDSC Express Low Levels of Rb1 Compared to Other Differentiated Cells.  
Several studies have suggested that Rb1 plays a role in the differentiation and/or 
accumulation of myeloid cells.  In cancer, there is a significant accumulation of MDSC, a 
heterogeneous population of pathologically activated myeloid precursors.  As an initial 
test to see if Rb1 may be playing a role in tumor-associated accumulation of MDSC, the 
expression of Rb1 mRNA and protein in MDSC compared to non-MDSC isolated from 
the same SPL of a tumor-bearing mouse were examined.  Surprisingly, Rb1 protein 
expression was essentially undetectable in MDSC.  Rb1 mRNA expression was about 
five times greater in non-MDSC compared to MDSC (Figure 23A).  Rb1 expression 
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levels in MDSC compared to other more differentiated myeloid cell types, such as 
dendritic cells (DC) and MΦ were further investigated.  Again, DCs and MΦ expressed 
much higher levels of Rb1 protein and mRNA than MDSC (Figure 23B).     
MDSC are known to survive and further differentiate in culture supplemented with 
GM-CSF209, 557.  Thus, we wanted to examine if Rb1 expression changed over time in 
vitro.  When placed in culture with GM-CSF, Rb1 mRNA and protein expression levels in 
MDSC increased with time.  The increase in Rb1 mRNA levels occurred quickly, within 
the first day in culture and remained high for the duration of the experiment (Figure 23C).  
The increase in Rb1 protein level did not peak until after 3 days in culture with GM-CSF.  
TES has been shown to delay MDSC differentiation into DCs and MΦ209, 557.  
Interestingly, when tumor explant supernatant (TES) was also added to the culture, the 
increase in Rb1 protein level seen over time with GM-CSF only was delayed (Figure 
23D).   
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Figure 23.  MDSC express low levels of Rb1 mRNA and non-detectable levels of 
Rb1 protein, which increases over time in culture.   
(A) Rb1 mRNA and protein expression levels in splenic MDSC obtained by magnetic 
isolation of Gr1+ cells compared to Gr1- cells were determined by RT-PCR and Western 
blot, respectively.  Bar graph represents Rb1 mRNA relative expression calculated by 
normalizing Rb1 quantitative values against the endogenous control, 18S.  (B) Same as 
in A, instead comparing MDSC Rb1 expression levels to MΦ obtained from the 
peritoneum after casein-induced mobilization, and DCs obtained from whole BM cells 
differentiated with GM-CSF and IL-4 for 5 days.  (C) Rb1 mRNA expression levels in 
magnetically isolated MDSC cultured over time with GM-CSF and compared to that in 
DCs.  (D) Rb1 and β-Actin protein level in magnetically isolated MDSC cultured for 5 
days with GM-CSF with or without TES. 
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MDSC Subsets Express Different Levels of Rb1 mRNA and Protein When 
Freshly Isolated and When Placed in Culture Over Time.  As mentioned, MDSC can 
be divided further into two distinct groups; M-MDSC, which are mononuclear 
CD11b+Ly6G-Ly6Chigh cells and G-MDSC, which are polymorphonuclear CD11b+Ly6G+ 
Ly6Clo cells.  Consistent with their phenotypic differences, M-MDSC and G-MDSC also 
differ in the expression of Rb1 mRNA and protein.  M-MDSC expressed very high levels 
of Rb1 mRNA and protein while G-MDSC expressed very low levels of mRNA and 
undetectable protein levels, even when loading five times more protein (Figure 24).  
Interestingly, the expression of Rb1 by M-MDSC from SPL and BM of tumor-bearing and 
from cells of the same phenotype in naïve BM is very similar.  The lack of Rb1 
expression is also shared by G-MDSC from of the same various sources.  E2F is a 
downstream target of Rb1, its protein expression down-regulated by Rb1 activity.  
Consistently, E2F protein expression correlated inversely with Rb1 expression, with high 
expression in G-MDSC and undetectable expression in M-MDSC (Figure 24A).   
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Figure 24.  Freshly isolated M-MDSC express high levels of Rb1 while G-MDSC 
express low levels of Rb1.   
(A) G-MDSC (CD11b+Ly6G+Ly6Clo) and M-MDSC (CD11b+Ly6G-Ly6Chi) were sorted 
from SPL and BM of tumor-bearing mice and from BM of naïve mice.  RNA and protein 
were extracted from each sample to perform RT-PCR and Western blot analysis, 
respectively.  Bar graph represents Rb1 mRNA expression normalized against the 
expression of endogenous control, 18s.  Western blot analysis depicting Rb1, 
phosphorylated Rb1 (pRb), E2F and β-Actin expression in the corresponding samples.  
(B) Western blot analysis of Rb1 and β-Actin expression in MDSC, G-MDSC and M-
MDSC sorted from SPL of tumor-bearing mice compared to T cells and B cells sorted 
from SPL of naïve mice.  For MDSC and G-MDSC, five times more protein was also 
loaded depicted as 5x MDSC and 5x G-MDSC. 
 
 
It has also been shown that M-MDSC survive and proliferate as seen in a 5 day 
culture with GM-CSF; while G-MDSC do not, with only 20% survival observed in a 3 day 
culture with GM-CSF556.  Thus, we examined the change in Rb1 expression in M-MDSC 
and G-MDSC over a 3 day culture.  When placed in culture supplemented with GM-CSF, 
the change in Rb1 expression level in M-MDSC and G-MDSC was very distinct (Figure 
25A).  In M-MDSC, Rb1 mRNA expression did not change significantly over time with 
GM-CSF regardless of the presence of TES (Figure 25B).  Conversely, G-MDSC 
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cultured with GM-CSF displayed a rapid increase in Rb1 mRNA expression, reaching its 
peak by day 2.  This was delayed by the presence of TES (Figure 25C).  When 
analyzing Rb1 protein levels in G-MDSC, a difference could easily be distinguished 
between freshly isolated G-MDSC and G-MDSC in culture for 2 days (Figure 25D) but 
no difference was visible between G-MDSC in culture for 2 days with GM-CSF only and 
G-MDSC cultured for 2 days with GM-CSF plus TES.  This can be due to the lack of 
sensitivity in the Western blot assay or that there indeed is no difference in protein 
expression.  Of particular interest, is the intense band representing Rb1 protein 
expression in neutrophils obtained from the peritoneum after casein-induced mobilization 
thus representing active neutrophils (Figure 25D).   
 
 
 
Figure 25.  Rb1 mRNA and protein levels increase in G-MDSC but not in M-MDSC 
in vitro over time. 
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(A) RT-PCR was performed on RNA extracted from sorted M-MDSC and G-MDSC 
cultured with GM-CSF on the indicated days for 3 days.  (B) RT-PCR was performed on 
RNA extracted on the indicated days from sorted M-MDSC that were cultured with GM-
CSF with or without TES for 5 days.  (C) RT-PCR was performed on RNA extracted on 
the indicated days from sorted G-MDSC that were cultured with GM-CSF with or without 
TES for 3 days.  (D) Western blot analysis of Rb1 and β-Actin protein expression in 
freshly isolated G-MDSC, G-MDSC cultured for 2 days in GM-CSF only, G-MDSC 
cultured for 2 days in GM-CSF plus TES, neutrophils isolated from the peritoneum after 
casein-induced mobilization and DCs obtained from whole BM cells differentiated with 
GM-CSF and IL-4 for 5 days. 
 
 
Rb1 Expression is Regulated by Histone Acetylation.  Protein expression can 
be regulated by many means employed at the transcriptional, translational and post 
translational level.  To regulate transcription, for example, modifications such as histone 
acetylation results in more relaxed chromatin associated with gene activation, while DNA 
methylation results in more compact, inactive chromatin associated with gene 
inactivation.  Acetylation of histones is primarily regulated by the competing activity of 
HATs, histone acetyltransferase, and HDACs, histone deacetyltransferases.  DNA 
methylation is mediated by DNMT, DNA methyltransferases558.  To study the role of 
histone acetylation and methylation in regulating gene expression, HDAC inhibitors 
(HDACi) such as trichostatin (TSA), valproic acid (VPA), suberoylanilide hydroxamic acid 
(SAHA) and MS275; and DNMT inhibitors (DNMTi) such as 5-aza-2’-deoxycytidine 
(AZD) are commonly used.  The effects of TSA, an HDACi and AZD, a DNMTi on Rb1 
mRNA expression were analyzed in BM cells enriched for hematopoietic progenitor cells 
(HPC).  HPC were cultured for two days with GM-CSF plus TES and then treated with 
TSA or AZD for 12 hours before harvesting for RNA extraction.  Surprisingly, TSA 
treatment resulted in a dose-dependent increase in Rb1 mRNA expression while AZD 
treatment had no effect (Figure 26A).  Furthermore, magnetically isolated G-MDSC 
cultured in GM-CSF plus TES treated overnight with SAHA, and more so with VPA, 
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exhibited an enhanced increase in Rb1 mRNA expression that lasted at least for 2 days 
compared to untreated G-MDSC (Figure 26B).  This data suggest that Rb1 expression is 
primarily regulated by changes in histone acetylation and not by DNA methylation.  To 
further confirm this, G-MDSC were treated overnight with and without MS275, a class I 
HDAC-selective inhibitor, to analyze the change in acetylation level on the Rb1 promoter 
using the CHIP assay and Acetyl-Histone H3 specific antibody.  When cultured overnight 
in GM-CSF plus TES, G-MDSC exhibit an increase in acetylation of the Rb1 promoter 
region which correlates with the observed increase in Rb1 mRNA levels.  When MS-275 
is added to this culture condition, the increase in acetylation at the Rb1 promoter region 
is enhanced compared to untreated cells (Figure 26C). 
 
 
 
 
Figure 26.  Effect of HDACi and DNA methylation inhibitors on Rb1 mRNA 
expression.   
(A) Bar graph representing Rb1 mRNA relative expression in BM cells that were 
magnetically enriched for HPC by lineage depletion, cultured for two days with GM-CSF 
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plus TES, then treated with the indicated amounts of TSA and AZD before harvesting 
RNA.  (B) Line graph depicting change in Rb1 mRNA expression over time in G-MDSC 
cultured with GM-CSF plus TES and treated overnight with VPA or SAHA.  (C) Bar 
graph representing relative acetylation levels at the Rb1 promoter analyzed after 
overnight treatment with and without MS275, an HDACi, compared to freshly isolated G-
MDSC. 
 
 
Rb1 Expression Regulates MDSC Subset Accumulation and Differentiation.  
M-MDSC and G-MDSC differ not only in their phenotype, morphology, suppressive 
mechanism and Rb1 expression, as shown here; they also differ in their proliferative and 
differentiation capacity.  M-MDSC, when in culture with GM-CSF, are capable of 
differentiating into DCs, MΦ and importantly into G-MDSC.  Furthermore, in the 
presence of GM-CSF plus TES, there was a much higher frequency of G-MDSC that 
differentiate from M-MDSC than that seen with GM-CSF alone (Figure 27).  When M-
MDSC were transferred into a tumor-bearing mouse, the majority of M-MDSC 
differentiated into G-MDSC, thus suggesting that G-MDSC in tumor-bearing mice are 
mainly sourced by M-MDSC556.   
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Figure 27.  M-MDSC differentiate preferentially to G-MDSC in the presence of GM-
CSF plus TES compared to GM-CSF alone.   
Sorted M-MDSC from tumor-bearing mice were cultured with GM-CSF with or without 
TES for the indicated amount of time and then analyzed.  (A) Flow plots depicting cells 
expressing Ly6C vs. Ly6G, first gated on viable CD11b+ cells.  (B) Wright-Giemsa 
staining showing the presence of polymorphonuclear cells derived from M-MDSC in 
culture for the indicated amount of time.   
 
 
Next, we wanted to explore if changes in Rb1 expression serves as the switch 
that drives this preferential differentiation which may also be promoted by the tumor 
microenvironment. Otherwise, Rb1 expression is simply a consequence and 
unconnected to the process.  Because HDACi treatment increased Rb1 mRNA 
expression in HPCs and in G-MDSC, M-MDSC were treated with VPA to see if this 
would affect their preferential differentiation to G-MDSC and even perhaps push them to 
differentiate into DCs or MΦ.  When treated with VPA in the presence of GM-CSF plus 
TES, M-MDSC differentiation to G-MDSC was nearly abolished as well as to 
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differentiation to DCs and MΦ.  Interestingly, when analyzing proliferation with BrdU 
incorporation, VPA caused a massive increase in proliferation in M-MDSC (Figure 28).   
 
 
 
 
Figure 28.  HDACi treatment prevents M-MDSC from differentiating into G-MDSC. 
(A) Splenic Ly6C+ from EL-4 tumor-bearing mice were sorted and cultured for three days 
supplemented with GM-CSF plus TES to allow for differentiation to G-MDSC and other 
myeloid lineages.  BrdU was added during the last four hours in culture to analyze BrdU 
incorporation by flow in remaining M-MDSC and differentiated G-MDSC in culture.  (B) 
Same as in A, except that VPA was added after resting cells overnight and removed 
after 18hrs of treatment.   
 
  
  Other studies have shown that Rb1-deficiency induced in adulthood results in a 
myeloproliferative-like disease with myeloid hyperplasia in the BM and increased 
extramedullary hematopoiesis with a significant expansion of myeloid cells, CD11b+Gr1+ 
in the SPL471.  In tumor mouse models, a similar expansion of MDSC occurs with 
increased myeloid cell cellularity in the BM and in the SPL241.  Thus, the inducible Rb1-
deficiency model was further analyzed to see if the expansion of myeloid cells was 
primarily monocytic or granulocytic in nature.  After induction of Rb1 deficiency in MxCre 
Rb1flox/flox, an increased accumulation of CD11b+Ly6G+Ly6Clo in the SPL both in 
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frequency and in absolute number of cells was observed (Figure 29), suggesting that 
lack of Rb1 expression indeed promotes the preferential expansion of myeloid cells with 
a granulocytic phenotype.   
 
 
Figure 29.  Induction of Rb1 deficiency promotes an expansion of splenic 
CD11b+Ly6G+Ly6Clo cells.   
(A) Representative Ly6C vs. Ly6G staining after gating on viable CD11b+ cells in SPL 
from Rb1flox/flox and MxCreRb1flox/flox mice after poly(I/C) administration.  (B) Percentage 
frequency and total absolute number of CD11b+Ly6G+Ly6Clo cells in the SPL of the 
indicated genotype.  For MxCreRb1flox/flox: n = 4 and Rb1flox/flox: n = 4.  *P < 0.05.   
 
 
 
Discussion 
In this study, the role of Rb1 in the accumulation and differentiation of MDSC 
subsets was examined.  Freshly isolated splenic MDSC from tumor-bearing mice, 
without discriminating the G-MDSC and M-MDSC subsets, exhibited very low or 
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undetectable Rb1 expression levels at the mRNA and protein level, respectively, 
compared to more differentiated cells, such as DCs and MΦ.  Interestingly, when 
discriminating between M-MDSC and G-MDSC, different levels of Rb1 expression at 
both the mRNA and protein level were seen.  M-MDSC expressed high levels while G-
MDSC expressed undetectable levels.  As shown by Youn et al, in most of the tumor 
models observed, particularly in the tumor model used throughout this study, EL-4 
thymoma, MDSC were primarily composed of G-MDSC, while M-MDSC only made up 
about 10-15% of MDSC241.  Additionally, when using Gr1 antibody and magnetic 
isolation, the majority of Gr1+ cells isolated are those that express high levels of Gr1 
which are mainly G-MDSC.  This may explain why when examining MDSC as a whole, 
they seemed to express low or undetectable levels of Rb1 since the majority of isolated 
cells were G-MDSC.   
MDSC subsets differ in their morphology, phenotype, preferred mode of 
suppression and, as shown here, expression of Rb1 mRNA and protein when freshly 
isolated, as well as when measured over time in culture.  In culture with GM-CSF, M-
MDSC Rb1 expression levels stayed relatively the same while increasing in G-MDSC 
over time, which was slightly hindered in the presence of TES at the mRNA level.  
Although very different, M-MDSC and G-MDSC do share an important relationship.  M-
MDSC have been shown to preferentially differentiate into G-MDSC in the presence of 
tumor-derived factors556.  We hypothesize that M-MDSC in tumor-bearing mice are 
promoted to differentiate preferentially into G-MDSC, which is mediated by the tumor 
microenvironment.  Recent studies performed by Youn et al have shown that when 
placed in culture with GM-CSF, G-MDSC are capable of differentiation further, acquiring 
characteristics common to neutrophils, such as increased expression of a lysosomal 
enzyme, decreased expression of specific surface markers and increased phagocytic 
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activity556.  To add to this list, G-MDSC also acquired Rb1 protein expression.  Thus, it 
seems that in tumor-bearing mice, G-MDSC do not further differentiate to neutrophils 
and instead remain as pathologically activated precursors, capable of immune 
suppression.  Rb1 expression seems to play a role in this differentiation, but up to now 
with the results presented here, it can only be said that Rb1 expression correlates with 
differentiation stage, where it is high in M-MDSC, low in G-MDSC and high in 
neutrophils, as well as any other differentiated cell such as DCs, MΦ, T cells and B cells.   
One way we attempted to investigate this further was by altering Rb1 expression 
levels in MDSC subsets.  Notably, the increase of Rb1 expression observed over time in 
G-MDSC correlated with increased histone acetylation at the Rb1 promoter.  This 
prompted us to examine the control of Rb1 expression at the transcriptional level by 
using HDACi and DNA methylation inhibitors.  Initially, HPC were used since they have 
been shown to be capable of differentiating into MDSC in culture559 and thus represent 
potential precursors of MDSC in vivo.  When treated with HDACi in culture, HPCs 
exhibited an increase in Rb1 mRNA expression in a dose-dependent manner.  This was 
not observed when using the DNMTi.  Furthermore, when treating G-MDSC with HDACi, 
the increase in Rb1 expression was enhanced with increased acetylation at the Rb1 
promoter region.  Specifically the HDACi used in this case was MS-275, a class 1 
specific HDACi.  This suggests that in MDSC subsets, Rb1 expression is controlled by 
histone modifications mediated by class 1 HDACs.   
To take it a step further, the differentiation capacity of M-MDSC to G-MDSC was 
analyzed in the presence of HDACi.  Interestingly, treatment of M-MDSC with HDACi 
abrogated their ability to differentiate into G-MDSC, even in the presence of TES.  We 
have shown here that HDACi treatment causes increased Rb1 expression and thus may 
cause Rb1 expression to maintain itself in M-MDSC, preventing them from further 
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differentiating.  In other words, HDACi treatment presumably prevented the 
downregulation of Rb1 expression required to drive further differentiation of M-MDSC to 
G-MDSC by sustaining or enhancing histone acetylation at the Rb1 promoter region.  
Though, this did not push M-MDSC to differentiate into DCs and MΦ which would 
probably require more than just sustained Rb1 expression.   
Also, HDACs are well known for controlling the transcription of an enormous 
variety of genes.  Thus, it cannot be concluded that the effect on M-MDSC differentiation 
capacity seen is solely due to the affect of HDACi treatment on Rb1 expression.  The 
alteration of various other genes may have contributed to the observed phenotype.  It is 
also notable that when treated with HDACi, M-MDSC proliferation is enhanced.  This is 
contradictory to other studies which have shown that HDACi treatment instead induces 
cell cycle arrest in normal and transformed cells and induces terminal cell 
differentiation560, 561.  In addition, of all the genes known to be controlled by Rb1, when in 
complex with HDAC1, Rb1 represses a specific subset of promoters and transcription 
factors562.  Perhaps the HDACi treatment also affected the interaction between Rb1 and 
HDAC1 and subsequently inhibited their selective repressive activity while maintaining 
Rb1 expression.  This may have also contributed to the observed increase in 
proliferation and lack of differentiation.   
Finally, a mouse model of inducible Rb1-deficiency was used to explore the 
effect of Rb1 in the development and accumulation of myeloid cells.  Analysis of the 
myeloid compartment using the same phenotypic markers used to distinguish G-MDSC 
and M-MDSC subsets showed that there is a preferential expansion of myeloid cells with 
a phenotype similar to that of G-MDSC.  Further studies are required to elucidate if the 
accumulation of these G-MDSC-like cells is due to the affect that Rb1-deficiency has on 
the differentiation capacity of M-MDSC-like cells; or due to other possible reasons, such 
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as the affect that Rb1-deficiency has on the proliferation and survival of G-MDSC-like 
cells.   
Although not fully demonstrated, this data does allow one to speculate that a 
tumor-derived factor or factors, or a specific aspect of tumor progression promotes this 
preferential G-MDSC expansion via down-regulation of Rb1 expression.  If so, further 
experiments would be aimed at elucidating this as well as examining where along the 
differentiation process from HSCs to G-MDSC does this regulation occur.  Furthermore, 
it remains possible that Rb1 expression serves as a switch that promotes the 
differentiation of MDSC subsets from M-MDSC to G-MDSC to neutrophils where the 
transition from M-MDSC to G-MDSC is promoted and the transition from G-MDSC to 
neutrophils is impeded by tumor-derived factors.  Regardless, these results do suggest 
that Rb1 plays a role in the accumulation and differentiation of cells of the myeloid 
compartment such as MDSC and particularly G-MDSC in cancer. Furthermore, if Rb1 
indeed plays a role in MDSC accumulation in cancer by dictating their differentiation, this 
can have clinical implication. As mentioned before, the expansion of MDSC and their 
potent suppression of anti-tumor responses contribute significantly to tumor progression. 
Thus, if MDSC differentiation is controlled by Rb1, manipulation of Rb1 expression in the 
myeloid compartment by pharmacological means in vivo may in turn prevent MDSC 
accumulation and thereby suppressive hold that MDSC have on anti-tumor immune 
responses. In addition, if a tumor-derived factor(s) is responsible for the down-regulation 
of Rb1 expression in the myeloid compartment and resulting differentiation block and 
accumulation of G-MDSC, then this factor(s) can also be targeted.  
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